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One of the main functions of the kidney is the excretion of low molecular weight 
water-soluble waste products into the urine, whereas plasma proteins of the size of albumin 
and larger are retained. This filtration occurs in the glomeruli of the kidney.  
 
 
The normal glomerulus 
 
The glomerulus is a network of capillaries. It receives its blood supply from an 
afferent arteriole of the renal circulation, and empties into an efferent arteriole. The 
relative resistance of the arterioles results in high intrglomerular pressure leading to the 
process of ultrafiltration where fluids and soluble materials in the blood are forced out of the 
capillaries and into the lumen of Bowman’s space. Morphologically the glomerular filter 
consists of three layers: (1) the fenestrated endothelial cell layer, (2) the glomerular 
basement membrane (GBM) and (3) the glomerular visceral epithelial cell (podocyte) layer 

























Figure 1. The glomerulus: The afferent arteriole forms a network of capillaries, the glomerular tuft, which is
surrounded by Bowman’s capsule. The depicted cross-section of a capillary shows the filtration barrier, which consists
of the fenestrated endothelium, the GBM and the interdigitating podocyt foot processes. Once plasma leaves the
glomerular capillaries this “ultrafiltrate” enters the lumen of Bowman’s capsule (Bowman’s space). Bowman’s capsule is
covered by the parietal epithelial cells and forms a barrier between the ultrafiltrate and the periglomerular interstitium. 
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For many years the GBM was considered the primary filtration barrier for the plasma 
proteins. In the last decade studies have disclosed that also the podocytes and particularly 
the slit diaphragms have a central role in retaining plasma proteins in the circulation. The 
GBM is a meshwork consisting of the extracellular matrix molecules type IV collagen, laminin 
and nidogen and proteoglycans 1. It is believed that the anionic moieties, such as heparan- 
and chondroitin sulfates side chains of GBM proteoglycans, form an electric barrier for 
negatively charged molecules. The outer aspect of the GBM is covered by the podocytes. 
Podocytes are highly specialized terminally differentiated epithelial cells with a complex 
cytoarchitecture. From the cell body arise long primary processes that at the end contain the 
foot processes. The foot processes are connected to the GBM via integrin α3β1 and the 
dystroglycan complex 2-4. The interdigitated foot processes of neighboring podocytes are 
connected which each other by the slit diaphragm (Figure 2). The slit diaphragm is composed 
of several recently discovered proteins (eg .Neph-1, Nephrin, Podocin, CD2AP, and FAT) and 
is connected to the contractile apparatus of the podocyte 5-9.  
The discovery of disease causing mutations in these proteins has emphasized the 
importance of the slit diaphragm for the maintenance of the filtration barrier 5;9-12. The 
glomerular tuft is surrounded by Bowman’s capsule, which is covered by the parietal 
epithelial cells (PECs). PECs are flattened inconspicuous cells that appear “pressed against” 
Bowman’s capsule and form a barrier between the ultrafiltrate and the periglomerular 
interstitium. In comparison to the other glomerular cells, relatively little is known about the 
role of PECs in glomerular disease. Several studies on crescentic glomerulonephritis have 
demonstrated that PECs are involved in extracapillary proliferation and can become highly 









Figure 2. Trasmission electron micrograph illustrating 
podocyte foot processes (FP) on the GBM. The 
interdigitating foot processes are connected with each 
other by the slit diaphragm (SD). CL; Capillary lumen,  




Podocyte injury and proteinuria 
 
Podocyte injury is clinically characterized by proteinuria and morphologically by 
retraction of podocyte foot processes (foot process effacement; FPE). FPE is the result of the 
retraction and even total disappearance of the interdigitating foot processes, with the 
formation of a diffuse cytoplasmic sheet 20;21. Although FPE and proteinuria nearly always co-
exist in nephrotic syndrome, it is unknown whether FPE and albuminuria are causally related. 
FPE may be the cause or consequence of proteinuria or even occur independently of 
proteinuria. 
Several causes of FPE and associated proteinuria have been identified; Interference 
with the GBM or the podocyte-GBM interaction 3;22-24, direct interference with the 
cytoskeleton 25;26, interference with the negative surface charge of podocytes 27-29, or 
interference with the proteins of the slit diaphragm and its lipid rafts 10;11;30;31. In addition, 
there is evidence that exposure of the podocytes to high protein load or an increased 
intraglomerular pressure causes podocyte injury 32-35.  
Podocyte are highly dynamic cells and can recover from injury. This has been shown 
in experimental studies demonstrating that FPE induced by protamine sulfate is rapidly 
restored after infusion of heparin 27;36;37. Recently, Asanuma et al showed that podocyte 
plasticity is dependent on synaptopodin 38. Impaired podocyte plasticity, as observed in 
synaptopodin knock-out mice, predisposed to increased and prolonged proteinuria after 
injection of LPS. Persistent FPE and associated proteinuria, may lead to prolonged proteinuria 
and eventually development of nephrotic syndrome and glomerular focal segmental 
glomerulosclerosis (FSGS).  
 
 
Focal segmental glomerulosclerosis 
 
FSGS is the hallmark of the glomerular lesion that is characteristically observed in 
failing kidneys, independently of the cause or activity of the underlying disease. FSGS is one 
of the leading causes of renal insufficiency 39. FSGS is characterized by the focal and 
segmental occurrence of lesions with adhesions between the glomerular tuft and Bowman’s 
capsule, podocyte hypertrophy, mesangial sclerosis, obliteration of glomerular capillaries 
with hyalinosis and intracapillary foam cells 40. FSGS is not a disease entity, but rather a 
pattern of injury with a quite diverse clinical behavior, morphology, and possibly also 
pathogenesis 41. FSGS occurs as a primary glomerular disease with unknown cause (idiopathic 
FSGS) and secondary to a variety of pathological processes that induces structural and 
functional adaptations, resulting in segmental glomerular scars. Secondary FSGS has also been 
associated with viral infections of the kidney (eg. HIV 42 and B19 parvovirus 43) and with drug 
toxicity (heroin 44, pamidronate 45). The pathogenesis of FSGS has been the subject of 
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numerous studies. Many investigators have focused on the podocytes. Normal podocytes are 
considered terminally differentiated, post-mitotic cells, which are unable to proliferate and 
to compensate for damaged neighboring podocytes. Studies by Kriz and co-workers in various 
rat models of FSGS suggested loss of podocytes and adherence of the parietal epithelial cell 
(PEC) to the naked GBM as the critical event in the formation of FSGS lesions 46-52 (Figure 3A). 
Additionally, recent studies have demonstrated a causal relationship between podocyte 
depletion and development of FSGS 53;54.  
A different pathomechanism has been proposed for FSGS lesions that are associated 
with collapse of the glomerular tuft and epithelial hyperplasia. These so called collapsing 
FSGS lesions are generally considered to be the result of proliferation of dysregulated 
podocytes 55-57. Dysregulated podocytes are characterized by loss of podocyte markers, are no 
longer growth restricted and have regained the ability to proliferate (Figure 3B). 
 
A B
Figure 3. Pathways to FSGS: (A) Degenerative pathway; Progressive loss of podocytes leads to the fixation of PECs to
denuded segments of the GBM resulting in the formation of a tuft adhesion (A, arrowhead). Perfused capillaries
contained in a tuft adhesion may deliver a filtrate to the interstitium (arrow). Eventually this lesion will progress to global
sclerosis and local interstitial fibrosis. (B) Dysregulative pathway; In the glomerulus, dysregulation of podocytes leads
to loss of the specific cell shape and to uncontrolled proliferation. The now cuboidal podocytes (B, arrowhead) may fill
Bowman’s space and form “pseudocrescents”. The dysregulative pathway is associated with collapse of the glomerular




Proteinuria may play an important role in the development of FSGS. As stated above 
persistent proteinuria is closely related to progressive renal disease. There is increasing 
evidence of harmful secondary effects of proteinuria. Numerous studies have shown a 
relationship between the magnitude of progressive proteinuria and the rate of decline of 
renal function 58-61. In addition, the majority of studies on treatments modalities for patients 
with nephrosis have demonstrated an unequivocal correlation between the reduction of 
proteinuria and the slowing of the progression of renal failure. Although reduction of 
proteinuria is beneficial in FSGS patients, the direct relation between proteinuria and the 
development of FSGS is not well characterized.  
 
 
Angiotensin II blockade 
 
In daily clinical practice a reduction of proteinuria can be achieved by blocking 
angiotensin II either by using inhibitors of angiotensin converting enzyme and/or angiotensin I 
(AT1) receptor antagonists. During the last two decades, the renoprotective effects of 
angiotensin converting enzyme inhibitors (ACEi) are increasingly appreciated. ACEi inhibit the 
progressive renal failure in patients with secondary forms of FSGS associated with 
hypertension and hyperfiltration. Although studied to a lesser extent, the salutary effects of 
ACEi have also been shown in patients with idiopatic FSGS. Guidelines for the treatment of 
nephrotic and non-nephrotic patients with primary FSGS include good blood pressure control 
and the use of ACEi (and/or angiotensin II type I receptor antagonists) 62;63. Recent studies 
have provided evidence that the effects of ACE inhibitors cannot simply be explained by their 
effects on blood pressure and subsequent reduction of proteinuria, since other 
antihypertensive drugs have not been equally effective 64. In this regard, it has been 
suggested that angiotensin II (ANGII) is not merely a vasoactive agent but also is a true 
profibrotic cytokine capable of inducing extracellular matrix (ECM) production, inhibition of 
ECM degradation and induction of cellular growth by either proliferation or hypertrophy 65;66. 
In addition, it has been suggested that ACE inhibitors have specific effects on the size 
selective filtration barrier of the slit diaphragm 67;68. 
 
 
Thy-1.1 transgenic mouse model 
 
In order to obtain more insight in the pathogenesis of albuminuria and FSGS animal 
models are needed, since the decisive events are difficult to study in man. Notably, most 
patients with FSGS are biopsied long after onset of proteinuria. Consequently, such biopsies 
cannot disclose the earliest changes that occur during development of proteinuria and FSGS. 
FSGS is a disease with variable histological and clinical presentation leading to renal failure, 
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probably reflecting differences in pathogenesis. To address this diversity numerous animal 
models have been established in mouse and rat that aim to reflect specific elements of 
human FSGS. Well-established models are those that reflect FSGS as a result of hyperfiltration 
due to induced or spontaneous hypertension or to renal ablation. The discovery of disease-
causing mutations in podocyte specific genes has led to new transgenic or gene knock-out 
mouse models. Other models are based on the induction of podocyte injury. The most widely 
used models are the adriamycin nephropathy and the puromycin aminonucleoside 
nephropathy (PAN). These agents cause podocytic injury leading to necrosis and detachment 
of the podocytes from the GBM. In both models the level of proteinuria correlates with the 
degree of podocyte detachment 69.  
In an attempt to study the interspecies distribution of Thy-1, Kollias et al generated a 
transgenic mouse that carried a mouse-human chimaeric transgene (Figure 4), and were 
characterized by the ectopic expression of the mouse Thy-1.1 antigen on podocytes 70. The 
wild-type littermates and other mice strains did not express the Thy-1.1 antigen in the 
kidney. The aberrant expression of the Thy-1.1 antigen on podocytes resulted in the slow and 
spontaneous development of proteinuria and focal glomerulosclerosis. Injection of monoclonal 
antibodies directed at the Thy-1.1 protein in Thy-1.1 transgenic mice induced an acute 
massive albuminuria and the development of focal glomerulosclerosis within 3 weeks after 
the induction of the albuminuria. We have shown that the development of albuminuria was 
independent of complement and leukocytes 71. We proposed that these characteristics made 
the Thy-1.1 model an ideal model for further studies of the relation between podocytic 
injury, albuminuria and FGS development. 
 
 
Figure 4. The mouse Thy-1.1-human Thy-1 recobinant gene. The gene was constructed from the 5’ half of murine
Thy-1.1 gene containing the first 3 exons and the coding part of exon IV. The murine DNA was linked to the 3’ half of
the human Thy-1 gene containing only the remaining noncoding part of exon IV plus the 3’ human UTR. The
transgenic mice were generated by injection of this hybrid gene into proneuclei of mouse zygotes. The expressed
Thy-1.1 protein is completely translated from the mouse sequence. The 3’ UTR sequence of the human Thy-1 gene
contains an enhancer sequence that directs expression of the Thy-1.1 gene in the podocytes. 




Scope of the thesis 
 
The studies that are presented in this thesis were aimed at the evaluation of the Thy-
1.1 transgenic mouse as a model for podocyte injury associated proteinuria and FSGS and at 
identification of possible mechanisms involved in the development of acute albuminuria and 
accelerated FSGS after injection of monoclonal anti-Thy-1.1 antibodies.  
Specifically, we examined the phenotype of the Thy-1.1 mouse, including the time 
course of proteinuria and the dose-dependency of proteinuria and FSGS. In addition, we 
questioned the relationship between the albuminuria and development of FSGS and studied 
the ultrastructural and molecular changes of the podocytes during the development of the 
acute albuminuria (Chapter 2). 
Although FSGS may result from a decrease in podocyte number we lack information on 
the decisive molecular processes that occur in the early development of FSGS. Analysis of the 
glomerular proteome of glomeruli with early FSGS lesions may reveal “novel” proteins that 
are crucially involved in the development of FSGS. To this purpose we optimized and 
evaluated the application of 2D electrophoresis (2DE) to study the glomerular protein 
expression and to identify differentially expressed proteins during early development of FSGS 
(Chapter 3). To further address the pathogenesis of FSGS in the Thy-1.1 transgenic mice we 
studied the histopathological changes that occur in the early stages of FSGS development, 
with emphasis on the specific roles of podocytes and PECs (Chapter 4). We observed that the 
scar lesions, observed three weeks after the anti-Thy-1.1 mAb injection, were preceded by an 
“active” hypercellular FSGS lesion, which resembled the human collapsing FSGS lesions. The 
proliferating epithelial cells originated from the parietal epithelium. In addition, the data 
indicated that the extracellular matrix that is present in the scar is derived from the parietal 
epithelium. To document the relevance of this finding we performed studies in human FSGS. 
We have summarized these studies and discuss the current information on PECs in Chapter 5.  
As described earlier, the renoprotective effects of ACE inhibition are well established 
in secondary forms of FSGS. In contrast, much less is known about the effects of ACE 
inhibition on the development and progression of the “active” hypercellular lesion that can 
be encountered in idiopathic and collapsing FSGS. To address this issue, we studied the 
effects of treatment with the ACE-inhibitor captopril, compared to ANG II independent 
antihypertensive therapy, on the development of collapsing FSGS lesions in Thy-1.1 transgenic 
mice (Chapter 6).  
Thy-1.1 transgenic mice spontaneously develop proteinuria and FSGS, which can be 
accelerated by anti-Thy-1.1 mAb injection. The molecular mechanisms leading to the 
podocyte injury and subsequent FSGS in the Thy-1.1 mouse model are unknown. As noted 
above, it has been shown that impaired podocyte plasticity, as observed in synaptopodin 
knockout mice, may predispose to increased and prolonged proteinuria after podocyte injury 
38. Prolonged proteinuria may eventually lead to development of FSGS. Impaired podocyte 
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plasticity may thus explain the development of the spontaneous and antibody-mediated FSGS 
in the Thy-1.1 transgenic mouse model. We have studied podocyte plasticity in the Thy-1.1 
transgenic mouse (Chapter 7). Additionally, we examined if podocyte foot process 
effacement induced by anti-Thy-1.1 mAb binding is dependent on proteinuria.  
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Thy-1.1 transgenic mice, characterized by ectopic expression of the Thy-1.1 protein 
on podocytes, spontaneously develop proteinuria and FSGS. Injection of a monoclonal 
antibody (mAb) directed against the Thy-1.1 protein in young transgenic mice induces a 
massive albuminuria that is followed by an accelerated FSGS within 3 weeks. This albuminuria 
is complement and leukocyte independent. The time course of proteinuria, the pathogenesis 
of the acute proteinuria and the dose-dependency of FSGS are unknown.  
Albuminuria was measured in Thy-1.1 transgenic mice after injection of different 
doses of anti-Thy-1.1 mAb and at different time points within the first 24 hrs after injection. 
Podocytic foot processes and slit pore diameter were quantitated by electron microscopy. 
Changes in expression of slit pore constituents (podocin, CD2AP, nephrin, ZO-1). cytoskeleton 
associated proteins (actin, α-actinin, ezrin, synaptopodin), and podocytic adhesion molecules 
(α3-integrin, heparan sulfate) were studied by immunofluorescence. FSGS was scored by light 
microscopy at 3 weeks after induction of albuminuria. 
Albuminuria in Thy-1.1 transgenic mice was observed within 10 min after anti-Thy-1.1 
mAb injection. This rapid development of albuminuria was accompanied by a reduction in 
number of podocytic foot processes from 20.0 ± 0.7/10 µm GBM in saline-treated transgenic 
mice to 8.0 ± 0.5 and 2.2 ± 0.2 in anti-Thy-1.1 treated mice, at 10 min and 8 hrs after 
treatment, respectively. In addition, we observed a significant decrease in width of remaining 
slit pores, from 32.7 ± 1.1 to 26.8 ± 1.4 nm at 10 min after mAb injection. By 
immunofluorescence, we did not observe major changes in the expression pattern of any of 
the proteins studied. There was no correlation between the injected dose of the anti-Thy-1.1 
mAb and the acute albuminuria. In contrast, the percentage of FSGS at 3 weeks correlated 
with the dose, and a significant correlation between the percentage of FSGS and the time-
averaged albuminuria over the 3 week study period (P < 0.001) was found.  
In conclusion, injection of mAb directed against the Thy-1.1 protein, in young non-
albuminuric Thy-1.1 transgenic mice induced an acute albuminuria within 10 min, which was 
accompanied by foot process effacement. Notably, we observed a decrease in slit pore width 
although the expression of slit pore proteins was unchanged. Also, the acute albuminuria 
could not be related to alterations in cytoskeleton associated proteins, the GBM adhesion 
molecule α3-integrin or heparan sulfate in the GBM. The dose dependent development of 
FSGS, and the correlation between the percentage FSGS and time-averaged albuminuria 
suggest that, in our model, FSGS is a consequence of podocyte injury. However, the data 
leave open the possibility that albuminuria itself contributes to FSGS development. The Thy-
1.1 transgenic mouse model is an excellent model to further study the relation between 




Proteinuria is a hallmark of glomerular renal diseases. In patients with renal diseases 
proteinuria is an important predictor of progressive renal failure 1. Proteinuria is generally 
attributed to a defect in the permselectivity of the glomerular filter. In recent years many 
studies have focussed on the role of the glomerular epithelial cells, the so called podocytes, 
in the induction of proteinuria as well as in the development of focal segmental 
glomerulosclerosis (FSGS) 2. Podocytes are terminally differentiated, specialized epithelial 
cells, which are anchored to the GBM and cover the GBM surface. The podocytes have a 
characteristic structure with interdigitating foot processes. The space between adjacent foot 
processes is called the slit pore. This slit pore is bridged by a slit diaphragm, which by many 
investigators is considered important for maintenance of glomerular permselectivity 3;4. 
Recent studies have greatly enhanced our knowledge of the slit pore structure at the 
molecular level. Nephrin and podocin are important membrane proteins localized in the slit 
pore and anchored to the actin cytoskeleton through CD2AP and α-actinin-4. Despite these 
major advances in our knowledge of the molecular structure of the podocyte it remains 
unknown which molecular alterations occur during and are responsible for the development of 
proteinuria.   
Many models have been used to study proteinuria. We recently have reported detailed 
studies of acute proteinuria in a mouse model, the so called Thy-1.1 transgenic mouse. The 
mouse-human chimaeric transgene causes ectopic expression of the mouse Thy-1.1 antigen on 
podocytes. Injection of mAb directed against the Thy-1.1 antigen causes albuminuria within 
24 hrs 5. Also, induction of proteinuria, either by injecting anti-Thy-1.1 mAb or by injecting a 
combination of mAb directed against aminopeptidase A (APA) causes accelerated 
development of FSGS in Thy-1.1 transgenic mice 5. FSGS is the characteristic lesion in 
progressive renal injury, and may be the consequence of longstanding proteinuria 6. However, 
the relation between proteinuria and FSGS needs further study. 
In the present study, we have evaluated the time course of proteinuria in the Thy-1.1 
transgenic mouse. Next, we specifically have studied alterations in podocyte morphology, in 
slit pore geometry, and expression of proteins involved in podocyte-GBM adhesion that occur 
upon onset of proteinuria. In addition, we have questioned if the acute proteinuria and the 










Heterozygous Thy-1.1 transgenic mice were kindly provided by Dr. D.J. Evans (T6, T-
construct mice 7). These mice were generated by injecting a hybrid human-mouse Thy-1.1 
gene into pronuclei of zygotes of Thy-1.2 CBA x C57BL/10 mice 7. These mice express the Thy-
1.1 gene abnormally in podocytes, resulting in the presence of the Thy-1.1 antigen on the 
podocytes. All mice were bred in our animal facility. Breading pairs consisted of a 
heterozygous (+/-) transgenic mouse and its non-transgenic (-/-) counterpart. The presence of 
the transgene was examined by PCR on genomic DNA from the tail, with a forward primer: 5’-
CGCCTGAGTCCTGATCTCC-3’ and a reverse primer: 5’-AACCTGCATCTTCACTGGGT-3’. The 
presence of the transgene resulted in a specific 834-bp amplicon. As a positive control for the 
presence of amplifiable genomic DNA a primerset for aminopeptidase A (APA; EC 3.4.11.7), 
consisting of the forward primer: 5’-ACACAACCCCAGCTCCTTCC-3’ and reverse primer 5’-
TCTTCTGCAGCCTGGATCAC-3’, was used. The amplification of the APA gene with these 





For in vivo experiments a mouse anti-mouse Thy-1.1 mAb (19XE5: subclass IgG3) was 
used. 19XE5 was generated in vitro, by hollow fibre culture, purified by protein A column 
affinity chromatography and concentrated (Nematology Department, Agriculture University 
Wageningen, The Netherlands). The mAb was decomplemented at 56°C for 45 min and 
sterilized by passage through a sterile 0.2 µm filter, and stored at –80°C. For 
immunohistological detection of glomerular localized antigens and injected antibodies we 





To evaluate the dose-dependency of albuminuria and the development of FSGS 5 
week old transgenic mice (at this time point urinary albumin excretion is still normal 5) 
received an intravenous injection of different doses of 0, 0.1, 1, 10, 100, 500, 1000, and 2000 
µg anti-Thy-1.1 mAb, respectively. The mice were studied for 3 weeks after anti-Thy-1.1 mAb 
administration. Urine samples were collected at day 1, 7, 14, and 21 after anti-Thy-1.1 mAb 
injection.  
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Urine samples were obtained by placing the animals in individual metabolic cages during 18 
hrs 8. During their confinement in the cages they had only access to tap water. At day 22 the 
mice were killed and kidneys were removed to be processed for histology.  
Based on the obtained data (see results section) a dose of 1000 µg anti-Thy-1.1 mAb 
in 0.9% saline solution (total volume 0.1 ml) was used in further experiments. To determine 
the time course of the acute proteinuria, urine samples were collected by bladder punctures 
at different time-points (10 min, 1, 4, 8, and 24 hrs). After bladder puncture mice were killed 
and kidneys were removed to be processed for histology. Transgenic mice injected with 0.9% 
saline solution alone were used as controls.  
 
Table 1: Antibodies used for detection of glomerular antigens 
antigens Primary antibody Dilution supplier/ 
reference 
Secondary antibody Dilution Supplier/ 
reference 
Thy-1.1 Mouse anti-Thy-1.1 (19XE5) 1 AUW Goat anti-mouse IgG3-FITC 25 Nordic 
Nephrin Rabbit anti-Nephrin 50 H. Holthöfer Swine anti-rabbit Ig - FITC 40 Dako 
ZO-1 Rat anti-ZO-1 200 Chemicon Rabbit anti-rat Ig - FITC 100 Dako 
Podocin Rabbit anti-Podocin 40 C. Antignac Swine anti-rabbit Ig - FITC 40 Dako 
CD2AP Rabbit anti-CD2AP 200 Santa-Cruz Swine anti-rabbit Ig - FITC 40 Dako 
Heparan sulfate Mouse anti-Heparan sulfate  (JM403)    






Goat anti-mouse IgM - FITC 





α3–integrin Mouse anti α3-integrin 1 A. Sonneberg  Sheep anti-mouse Ig - FITC 100 Cappel 
Ezrin  Rabbit anti-Ezrin 200 P. Mangeat Swine anti-rabbit Ig - FITC 40 Dako 
Synaptopodin Mouse-anti-Synaptopodin (P44) 1 Progen Sheep anti-mouse Ig - FITC 100 Cappel 
α-actinin Rabbit anti-α-actinin 200 Sigma Swine anti-rabbit Ig - FITC 40 Dako 
Actin Phalloidine-FITC 20 Sigma    
 
Suppliers:  
AUW = Agriculture University Wageningen, Department Nematology, The Netherlands 
Chemicon, Temecula, Canada 
Santa-Cruz, Santa-Cruz, USA 
Progen, Heidelberg, Germany 
Sigma, Sigma-Aldrich, Zwijndrecht, The Netherlands 
Dako, Glostrup, Denmark 
Nordic, Tilburg, The Netherlands 
Cappel, Organon Teknica, The Netherlands 
Dr. C. Antignac, Inserm U423, Tour Lavoisier, Hopital Necker, Paris, France 
Dr. P. Mangeat, Dynamique Moleculaire des Interactions Membranaires, University Montpellier II, Montpellier, France 
Dr. H. Holthöfer, Haartman Institute, Department of Bacteriology and Immunology, University of Helsinki, Finland  




Urine albumin measurement 
 
Urine albumin was measured by radial immunodiffusion using a goat antiserum against 
mouse albumin 8. The normal physiological albuminuria was determined in wild type (Thy-1.1 
negative) mice (27 ± 2 µg/ml). 
 
 
Light microscopy, Immunofluorescence  
 
For light microscopy, kidney fragments were fixed in Bouin’s solution, dehydrated, 
and embedded in paraplast (Amstelstad, Amsterdam, The Netherlands) and 4 µm sections 
were stained with periodic acid-Schiff and methenamine silver 8. To obtain the FSGS-score at 
least 100 glomeruli were evaluated for the presence of podocytic hypertrophy, synechiae, 
sclerosis or hyalinosis, and the percentage of abnormal glomeruli was calculated. 
For immunofluorescence (IF) kidney fragments were snap-frozen in liquid nitrogen, 
and 2 µm acetone fixed cryostat sections were used. The expression of Thy-1.1 was studied by 
indirect IF by using the primary antibodies followed by FITC-labeled secondary antibodies as 
listed in table 1. The expression of important constituents of the podocyte and the GBM were 
examined at different time points (10 min, 1, and 24 hrs) using unlabeled primary monoclonal 
antibodies and FITC-labeled secondary antibodies as listed in table 1. The slides were 
examined with a confocal microscope (Leica Lasertechnik GmbH, Heidelberg, Germany). 
For electron microscopy small fragments of the kidney were fixed in 2.5% 
glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer, pH 7.4 overnight at 4°C and 
washed in the same buffer. The tissue fragments were postfixed in cacodylate-buffered 1% 
OsO4 for 2 hrs, dehydrated, and embedded in Epon812 (Merck, Darmstadt, Germany). 
Ultrathin sections were used and contrasted with 4% uranyl acetate for 45 min and 
subsequently with lead citrate for 4 min at room temperature. Sections were examined in a 





The localization of the Thy-1.1 antigen on podocytes was examined by indirect 
immunoelectron microscopy (IEM), using immunoperoxidase labelling on 20 µm frozen 
sections. A Thy-1.1 transgenic mouse was first perfused retrogradely via the aorta with PBS 
for 5 min and subsequently with a mixture of 10 mM peroidate, 75 mM lysine, and 2% 
paraformaldehyde, pH 6.2 (PLP) for 10 min. The kidneys were removed and small pieces were 
further fixed by immersion for 3 hrs in PLP. After rinsing several times in PBS, the fragments 
were cryoprotected by immersion in 2,3 M sucrose, pH 7.2, for 1 hr and then frozen in liquid 
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nitrogen. 20 µm thick sections were rinsed in PBS for 1 hr, then incubated with the anti-Thy-
1.1 mAb diluted in PBS containing 1% BSA for 18 hrs at 4°C, followed, after several washes 
with PBS, by incubation with a peroxidase labeled rabbit anti-mouse IgG (Dako Glostrup, 
Denmark) diluted in PBS containing 1% BSA. After three washes in PBS, the sections were 
incubated in PBS, pH 7,4 containing diaminobenzidine (DAB) medium for 10 min, followed by 
DAB with addition of 0.003% H2O2 for 7 min. The sections were washed in distilled water, 
postfixed in palade buffer containing 1% OsO4 for 30 min at 4°C, dehydrated, and embedded 
in Epon812 (Merck, Darmstadt, Germany). Ultrathin sections were examined in a JEOL 1200 
EX2 electron microscope (JEOL, Tokyo, Japan).  
 
 
Measurement of foot processes, GBM and slitpores 
 
Negatives of electron micrographs (magnification x6000) were scanned at 600 dpi 
resolution using a scanner (Epson Perfection 1200 Photo, Epson Europe, Amsterdam), resulting 
in a specimen-level pixel size of approximately 7x7 nm2. Measurement of resulting images was 
performed using Leica QWin Pro V2.4 (Leica Imaging Systems Ltd, Cambridge, UK) under 
Microsoft Windows NT 4.0. The system was callibrated using the marker bar on the electron 
micrographs. For five open random capillary loops in each of five randomly selected glomeruli 
per specimen, the GBM was selected using a graphic tablet. The image analysis software was 
used to measure the length and width of the GBM of each loop. Also, for each loop the 
number of podocytic foot processes was manually counted and expressed as the number of 
foot processes per 10 µm GBM length. Results of the measurement of 25 capillary loops were 
averaged. For each specimen the width of approximately 100 individual slit pores was 
measured using the same set of digitized electron micrographs. To obtain the slit pore width, 
the diameter of the narrowest region of the pore between two adjacent foot processes was 





Time-averaged albuminuria was calculated after log-transformation. For multiple 
comparisons, ANOVA was used and post hoc analyses were done with Tukey’s. To test the 
homogeneity of variances, Levene statistic was used. P < 0.05 was considered significant. For 
correlations Pearsons r was calculated. All values are expressed as means ± SEM unless 







Different dosages (0.1, 1, 10, 100, 500, 1000, and 2000 µg) of anti-Thy-1.1 mAb were 
injected in Thy-1.1 transgenic mice and the albumin excretion was measured at days 1, 7, 14 
and 21 (Figure 1A). The highest level of albuminuria at day 1 was already reached with a dose 
of 500 µg. The data show a lesser albuminuria at day 1 in the mice injected with the highest 
dose (2000 µg anti-Thy-1.1 mAb). However, urine volumes of these mice were very low, 













































































Figure 1. (A) Albuminuria induced by different dosages anti-Thy-1.1 mAb in Thy-1.1 transgenic mouse (n = 3-5).
(B) Light microscopic image of the kidney of a Thy-1.1 transgenic mouse, at day 22 after injection with 1000 µg anti-
Thy-1.1 mAb. Typical focal segmental glomerulosclerotic lesions are present such as adhesions of the capillary tuft to
Bowman’s capsule (arrows), increase in mesangial matrix and cells, and accumulation of hyaline material. Unaffected
glomerulus (asterisks) (methenamine silver staining). Bar = 25 µm. (C) Percentage of glomerulosclerosis detected in
Thy-1.1 transgenic mice mice treated with different doses anti-Thy-1.1. Values are given as means ± SD, n = 3-5. Note
that the percentage of glomerulosclerosis increased in a dose dependent manner. * P < 0.05 versus 100 µg,
** P < 0.001 versus 100 µg, *** P < 0.001 versus 1000 µg anti-Thy-1.1 mAb. 
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From Figure 1A it is evident that the persistence of the albuminuria was dose dependent. The 
albuminuria induced with 100 µg anti-Thy-1.1 mAb dropped rapidly and reached baseline 
levels within 7 days, whereas the albuminuria induced by the higher dosages persisted during 
the whole 3 week study period. At day 22, the extent of FSGS was evaluated by light 
microscopy. We observed a dose dependent FSGS (Figure 1B, C). We found no correlation 
between the percentage of glomeruli with FSGS lesions at day 22 and the initial albuminuria 
at day 1. However, there was a significant correlation (r = 0.93, P < 0.001) between the 
percentage FSGS and the time-averaged albuminuria over the 3-week study period.  
Based on the above mentioned experiments we have used a dose of 1000 µg anti-Thy-
1.1 mAb for following experiments. Results of albuminuria measured at 10 min, 1, 4, 8, and 
24 hrs after anti-Thy-1.1 mAb administration are presented in Figure 2. Saline injected 
transgenic mice showed no noteworthy 
albuminuria (93 ± 4 µg/ml). Injection of 
anti-Thy-1.1 mAb resulted in an acute 
albuminuria, which was observed 
already at 10 min after intravenous anti-
Thy-1.1 mAb administration, and peaked 
after 4 hrs. Injection of anti-Thy-1.1 
mAb into non-transgenic mice did not 
affect the normal physiological 
albuminuria (data not shown). 
By light microscopy we observed 
dilated tubuli and protein casts in distal 
tubuli and collecting ducts, already in 
kidneys of mice killed at 10 min after 
anti-Thy-1.1 mAb administration (Figure 
3A). These findings clearly confirm the 
data of the time-response course of 
albuminuria. At 8 hrs after anti-Thy-1.1 mAb administration, these protein casts were more 
densely colored and could be seen in all types of tubuli and in glomeruli. Furthermore, a large 
number of resorption vacuoles and damaged cells were observed in proximal tubuli. Glomeruli 
became increasingly ischemic, leading to an enlarged Bowman’s space due to the collapse of 
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Figure 2. Time course of albuminuria in Thy-1.1 transgenic
mice after injection of 1000 µg of anti-Thy-1.1 mAb. Albumin
was measured in urine samples obtained by bladder puncture
at the indicated time points. Dotted line: 10 min after antiThy-




Utrastructural analysis (IEM) of the Thy-1.1 protein expression, in a non-treated 
kidney of a Thy-1.1 transgenic mice, showed a homogeneous staining of the basal and apical 
cell membrane of the podocytes (Figure 4A). IF showed that anti-Thy-1.1 mAb injected in 
Thy-1.1 transgenic mice bound in a homogeneous pattern to the podocytes already at 10 min 
after the mAb administration (Figure 4B). Injected anti-Thy-1.1 mAb did not, as expected, 









Figure 3. (A) Light microscopy of Thy-1.1 mice kidney sections at 10 min and 8h after mAb injection. Deposits of
proteins (asterisks) are already observed 10 min after mAb injection. (B) At 8hrs after mAb injection massive deposits
(dense casts) are observed. There is a high rate of protein resorption in proximal tubuli (arrow). The glomerulus is







Figure 4. (A) Indirect immunoelectron microscopy of a Thy-1.1 transgenic mouse kidney incubated with the anti-Thy-1.1
mAb. Linear staining of the Thy-1.1 protein along the apical and basal cell membrane of the podocyte (Insert) Closer
view on the foot-processes. (P) podocyte cell body, (CL) capillary lumen, (US) urinary space. Bar = 2µm.  (B)
Immunofluorescence pictures of kidneys of Thy-1.1 transgenic mice injected with 1000 µg of anti-Thy-1.1 mAb. Strong
homogeneous binding of the injected anti-Thy-1.1 mAb to podocytes, already at 10 min after mAb injection. (C) No
binding of the anti-thy-1.1 mAb in a non-transgenic mouse. Bars B, C = 25 µm. For color figure see appendix 
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To evaluate the relation between the acute albuminuria and podocyte foot process 
effacement, detachment or GBM denudation, we studied by electron microscopy and 
morphometric measurements the changes that occurred after anti-Thy-1.1 mAb 
administration (Figure 5).  
 
In glomeruli of Thy-1.1 transgenic mice injected with anti-Thy-1.1 mAb, the number 
of foot processes per 10 µm GBM decreased from 20.0 ± 0.7 in saline-treated transgenic mice 
to 8.0 ± 0.5 and 2.2 ± 0.2 in anti-Thy-1.1 mAb treated transgenic mice, at 10 min and 8 hrs 
after anti-Thy-1.1 mAb treatment, respectively. In addition, we observed a significant 
decrease in diameter of remaining slit pores, from 32.7 ± 1.1 to 26.8 ± 1.4 nm at 10 min after 
mAb injection. We found no evidence for podocyte detachment or denudation of the GBM and 
there were no alterations in the thickness of the GBM. 
Next we studied by IF changes in the expression pattern of slit pore constituents 
(podocin, CD2AP, nephrin, ZO-1), cytoskeleton associated proteins (actin, α-actinin, ezrin, 
synaptopodin), GBM/podocyte adhesion molecule (α3-integrin) and heparan sulfate. For most 
of these proteins we did not observe any changes in expression pattern upon anti-Thy-1.1 
mAb injection. However, the homogeneous binding pattern of antibodies to podocin changed 
into a fine granular binding at 1h after anti-Thy-1.1 mAb injection. At 24 hrs after mAb 
injection, binding was more granular and there was a slight reduction in signal intensity 
(Figure 6). We did not observe any difference in the expression of the slit pore constituents, 
cytoskeleton associated proteins, and adhesion molecules at the early time point of 10 min 









Figure 5. Electron micrographs showing podocytic foot-process retraction (bold arrows). (A)Partial foot-process retraction
is observed 10 min after mAb injection and (B) gradually develops to more extensive retraction, seen at 8 hrs.











Figure 6. The immunologic localization of the slit diaphragm associated protein podocin in
(A) saline injected mouse  and at 10 min, 1 hr, and 24 h after injection of the anti-Thy-1.1 mAb
in Thy-1.1 transgenic mice (B,C,D, respectively). The prominent homogeneous staining for
podocin along the capillary wall (A, B) gradually became more granular and less intense from




A single injection of a mAb directed against the Thy-1.1 antigen on podocytes of Thy-1.1 
transgenic mice induced an acute and massive albuminuria, and accelerated the development 
of FSGS as previously published. In the present manuscript we focused on the alterations in 
podocyte morphology and the expression pattern of several podocyte specific markers in 
relation to the time course of the early albuminuria (10 min – 24 hrs). In addition we describe 
the dose dependency of the albuminuria and FSGS development. Our present data 
unequivocally demonstrate the rapid onset of albuminuria, within 10 min after anti-Thy-1.1 
mAb injection, as confirmed by bladder puncture and histology. This very rapid onset of the 
albuminuria indicates that the process(es) leading to albuminuria must be independent of 
gene regulation since the molecular processes of transcription, translation of the transcripts 
and targeting of the newly made proteins will require more time. To elucidate the processes 
leading to albuminuria, we have to focus on changes in podocyte morphology or alterations in 
the expression or activity of proteins involved in maintaining glomerular permselectivity. The 
GBM was for long considered the main size and charge selective filter 9. Recent studies 
provide evidence that the podocyte and especially the slit diaphragm are important in 
maintaining permselectivity 3;10. Changes in foot process morphology with attendant protein 
loss are hallmarks of glomerular diseases, including minimal change nephropathy, and 
diabetic nephropathy. Possibly, albuminuria is a consequence of changes in podocyte integrity 
due to cytoskeletal rearrangement causing alterations of slit diaphragm geometry, or 
functional abnormalities of the slit pore complex. 
Therefore, in addition to podocyte morphology we have in the present study focused on the 
expression of proteins involved in maintaining the cytoskeleton of the podocyte, in 
constituents of the slit pore and in molecules involved in podocyte-GBM adhesion.  
We have performed detailed electron microscopical measurements of podocytic foot 
processes and slit pore width. We did not observe large gaps between podocytes nor podocyte 
detachment. In this respect our mouse model closely resembles human nephropathies such as 
minimal change disease or FSGS. Our model contrasts with two other widely used models of 
podocyte injury, proteinuria and progressive glomerulosclerosis using the chemotherapeutic 
agents, puromycin aminonucleoside and adriamycin. These agents cause severe podocytic 
injury leading to necrosis and detachment of the podocytes from the GBM. In both models the 
level of proteinuria correlates best with the degree of podocyte detachment 11. Thus, in our 
model the podocyte injury is relatively small, with no detachment detectable in the first 24 
hrs after mAb injection, despite massive proteinuria.  
We noted that already at 10 min after mAb injection albuminuria was accompanied by 
a major decrease in the number of foot processes. We feel that this finding suggests that foot 




the albuminuria. Admittedly, because of the abrupt onset of albuminuria in this model we 
cannot discern the precise relationship in time between foot process effacement and 
albuminuria. We have previously studied the relationship between foot process effacement 
and albuminuria in a different mouse model. In the latter model, albuminuria is induced by a 
single injection of a combination of two mAb directed against APA, a protein expressed in the 
cell membrane of podocytes and of the brush border of proximal tubuli 12.  After 
administration of the anti-APA mAbs the first sign of proteinuria was detected at 6 hrs, 
whereas the morphometric measurements showed already after 4 hrs a reduction in number 
of foot processes. These findings suggest that foot process effacement is a marker of 
podocyte injury or activation and not a consequence of albuminuria. This latter conclusion is 
supported by the observation that reactive oxygen metabolites can cause massive proteinuria, 
which is not accompanied by ultrastructural abnormalities 13. A cause-effect relation between 
foot process effacement and albuminuria remains to be proved. In fact, in the APA model, 
maximal effacement was measured at 24 hrs after anti-APA mAb injection while at this time 
point albuminuria had almost returned to baseline level. Thus, both foot process effacement 
and albuminuria may be consequences of podocyte injury and are not necessarily causally 
related.  
We noted a significant reduction in slit pore width already at 10 min after anti-Thy-
1.1 mAb injection. The reduction of slit pore width may be explained by the collapse of the 
glomerular tuft after injection of the mAb. However, ischemic changes of the glomeruli were 
not observed at the earliest time points. Alternatively, this reduction in slit pore diameter 
may point to the presence of intrinsic injury with alterations in the interactions of slit 
diaphragm proteins like podocin, nephrin, and CD2AP. However, we were unable to 
demonstrate major changes in the expression pattern of these slit diaphragm proteins as 
observed in IF studies. Admittedly, these studies cannot exclude that structural changes in 
these proteins might have occurred.  
We have studied several GBM characteristics in more detail. We did not observe a 
reduced expression of α3-integrin, a molecule involved in podocyte-GBM adhesion. This 
finding seems in accordance with the fact that we never observed podocyte detachment in 
electron microscopy. There was also no evidence of loss of GBM negative charge, an 
important mechanism of proteinuria in other models, ascribed to destruction of 
glycosaminoglycans by reactive oxygen species. In our model the expression of JM403 and 
HS4C3, antibodies against heparan sulfate which are used to characterize GBM negative 
charge 14;15, remained normal indicating that the acute albuminuria is not related to a defect 
or reduction of GBM negative charge. We did not test the possible role of vasodilatory and 
permeability-promoting factors such as VEGF, PAF and TNFα, which can be produced by 
podocytes 16;17, Thus, we cannot exclude these factors as mediators of proteinuria. 
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In our model, the development of FSGS was dose dependent. This finding fits with the 
recently proposed role of podocyte injury in FSGS. FSGS is considered to be the consequence 
of loss of podocytes due to podocyte injury 18. Since podocytes are terminally differentiated 
cells and unable to replicate, lost podocytes cannot be replaced. The naked GBM will be 
covered by parietal cells and Bowman´s membrane giving rise to adhesions, the first step in 
the formation of a sclerotic lesion. In our model, higher doses of antibodies will lead to more 
extensive podocyte injury, thus explaining the dose dependency of the FSGS. One could argue 
that there was no clear relationship between the antibody dose and the level of the acute 
albuminuria. However, our data indicate that the acute albuminuria might not be the best 
reflection of podocyte injury. Even with a relatively low dose massive acute albuminuria 
occurred, which plateaued, most likely as a consequence of altered glomerular 
hemodynamics as indicated by the development of oliguria. We observed a strong correlation 
between time-averaged albuminuria and the number of FSGS lesions. Most likely the 
persistence of albuminuria is a better reflection of the severity of podocyte injury than the 
acute albuminuria. Although we feel that in our model FSGS is linked to podocyte injury, the 
data leave open the possibility that albuminuria itself is detrimental to podocytes and 
contributes to FSGS development. This however needs to be further investigated. 
The mechanisms that induce the podocyte alterations upon mAb injection are still 
unknown. Thy-1.1 is a 17 kDa cell-surface glycoprotein, anchored to the cell membrane via a 
GPI-anchor 19. Recent studies provided evidence that GPI-anchored proteins including Thy-1.1 
are partitioned in lipid rafts 20. These lipid rafts are proposed to be involved in membrane 
trafficking of GPI-anchored proteins and in signal transduction via src-family kinases 21. Lipid 
raft components can be crosslinked with antibodies or lectins in living cells, resulting in 
coalescence of individual rafts to form raft clusters. Several studies showed that antibody-
mediated cross-linking of Thy-1 and other GPI-anchored proteins can induce cell activation 
thru activation of src-familiy kinases 22. Antibody-mediated crosslinking of gangliosides, which 
together with cholesterol form lipid rafts, can mimic GPI-anchored protein signaling, 
illustrating the importance of the raft structure 23. Interestingly, Reivinen et al. described a 
podocytic specific ganglioside in rat kidney, O-acetylated GD3 24. In vivo binding of antibodies 
directed against this ganglioside induced rapid morphological changes in the foot processes 25. 
Recent studies showed that lipid raft domains are also involved in the spatial organization and 
the signaling events of the glomerular slit diaphragm 26. Furthermore, Fyn a member of the 
src-kinase family, binds to and phosphorylates nephrin 27. This phosphorylation might be a 
part of the nephrin-dependent signaling, which is believed to be essential for the podocyte 
integrity 27;28. It is tempting to speculate that co-localization of the Thy-1.1 protein and slit 
diaphragm proteins in raft domains, plays a role in the podocyte alterations observed in the 




Besides activating a specific signaling cascade the podocytic alterations in the Thy-1.1 
mouse can also be caused by non-specific injury due to antibody binding. Clustering of rafts 
carrying the Thy-1.1 protein might influence for instance the location and behaviour of other 
surface proteins, influencing podocyte and slit diaphragm geometry, without protein 
signaling. Furthermore, the net negative charge is thought to be necessary for maintaining 
the integrity of the slit pores 29. Lowering the high negative charge by injecting protamine 
sulfate induces a rapid (15 min) effacement of the foot processes 30. Isoelectric focusing 
revealed that the anti-Thy-1.1 mAb has a pI of approximately 8. This pI results, in a 
physiological environment, in a net positive charge. Binding of a large amount of this antibody 
can neutralize the podocytic negative charge resulting in the foot process effacement.  
In conclusion, a single injection of the anti-Thy-1.1 mAb in Thy-1.1 transgenic mice 
induces an acute and massive albuminuria, which is followed by an accelerated FSGS. The 
early albuminuria is already accompanied by foot process effacement and narrowing of the 
slit pore. Although we did not observe changes in the expression of important podocyte- and 
cytoskeleton associated molecules, it is possible that structural changes in such molecules are 
involved. In the Thy-1.1 model, FSGS lesions developed within 3 weeks in a dose dependent 
process. The immediate onset of the albuminuria together with the fast development of FSGS 
makes the Thy-1.1 model an ideal model for further studies of the relation between podocytic 
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Focal segmental glomerulosclerosis (FSGS) is a hallmark of progressive renal disease. 
We have used the Thy-1.1 transgenic (tg) mouse as a model for FSGS. Thy-1.1 tg mice express 
the Thy-1.1 antigen on podocytes. Injection of anti-Thy-1.1 mAb results in the development 
of FSGS lesions within 7 days.  
In the present study we have evaluated the potential of 2D gel-electrophoresis (2DE) 
to study alterations in the glomerular protein profile in the early development of FSGS. 
First we optimized the procedure for the isolation of glomeruli and the preparation of 
the samples to obtain reproducible glomerular protein profiles. Subsequently, we compared 
the protein profiles of saline injected Thy-1.1 tg mice (control n=3) with the profiles of Thy-
1.1 tg mice at day 6 after anti-Thy-1.1 mAb injection (n=3). In addition, we analyzed all 
detectable protein spots by matrix-assisted laser desorption/ionisation-time of flight mass 
spectrometry (MALDI-TOF MS) for protein identification.  
We have constructed reproducible glomerular profiles consisting of approximately 600 
protein spots of which 47 spots were identified. Most identified proteins were cytoskeleton- 
and mitochondrial-associated proteins or other high abundant “housekeeping” proteins. By 
comparison of the protein profiles of controls and anti-Thy-1.1 injected mice, we detected 4 
protein spots that showed a difference in staining intensity or location on the 2D gel. One of 
these spots represented α-actin, which was up-regulated in FSGS as verified by mRNA In situ 
hybridization.  
In conclusion, by optimizing the 2DE we were able to produce reproducible mouse 
glomerular protein profiles. Since only high abundant “house keeping” proteins were 
identified we question the applicability of 2DE for the identification of (low abundant) 




FSGS is one of the most common glomerular diseases 1. FSGS is characterized by the 
focal and segmental occurrence of lesions with mesangial sclerosis, obliteration of glomerular 
capillaries with hyalinosis and intracapillary foam cells, adhesions between the glomerular 
tuft and Bowman’s capsule, and podocyte hypertrophy 2. FSGS is not a disease entity, but 
rather a pattern of injury with quite diverse clinical behavior, morphology, and possibly also 
pathogenesis 3. The pathogenesis of FSGS has been the subject of many studies. The discovery 
of mutations in podocytic proteins, such as nephrin, podocin and α-actinin-4 in familial FSGS 
4-7, has pointed to the podocyte as the culprit in FSGS. Specifically, podocyte loss is 
considered the mechanism underlying the initial step in the development of 
glomerulosclerosis 8-10. Thus far however, the decisive molecular processes that are involved 
in the early development of FSGS are unknown. 
Analysis of the glomerular proteome in FSGS lesions may reveal “novel” proteins that 
are crucially involved in the development of FSGS. Proteomic analysis is suitable for large-
scale studies and biomarker screening to examine overall protein expression profiles in cell, 
tissue, or organ. The most widely used proteomic technology for quantitative comparison of 
proteomes is 2D electrophoresis (2DE).  
Recently, we have proposed the Thy-1.1 transgenic (tg) mice as a mouse model to 
study proteinuria and FSGS 11;12. Thy-1.1 transgenic mice carry a mouse-human chimaeric 
transgene that causes ectopic expression of the mouse Thy-1.1 antigen on podocytes. 
Injection of mAb directed against the Thy-1.1 antigen induces an acute albuminuria within 10 
min and the first FSGS lesions were observed within 7 days 13.   
In the present study we have optimized 2DE for the analysis of mouse glomerular 
proteins and have evaluated the application of 2DE to study the glomerular protein expression 








Heterozygous Thy-1.1 transgenic mice (T6, T-construct mice were generated by 
injecting a hybrid human-mouse Thy-1.1 gene into pronuclei of zygotes of Thy-1.2 CBA x 
C57BL/10 mice 14. These mice express abnormally the Thy-1.1 gene in podocytes, resulting in 




Anti-Thy-1.1 monoclonal antibody 
 
For in vivo experiments a mouse anti-mouse Thy-1.1 mAb (19XE5: subclass IgG3) was 
used. 19XE5 was generated in vitro, by hollow fiber culture, purified by protein-A column 
affinity chromatography and concentrated (Nematology Department, Agriculture University 
Wageningen, The Netherlands). 
 
 
Animal experiment and sample preparation 
 
Six-week-old Thy-1.1 tg mice received an intravenous injection with 1 mg anti-Thy-
1.1 mAb (19XE5) in 0.1 ml 0.9% saline solution. As control, transgenic mice received only 0.1 
ml 0.9% saline solution. At day six the mice were anaesthetized with a mixture of isofluorane 
and oxygen. After anaesthetization, the abdomen was opened. A 19 mm 24 gauge NeoflonTM 
catheter (Becton Dickinson, Helsingborg, Sweden) was inserted in the aorta just above the 
aortic bifurcation. After removal of the inner needle the cannula was connected to an 
infusion system placed 1.2 m above working level and an incision was made in the vena cava. 
Subsequently, both kidneys were rinsed for 1 min with ice-cold Ringer’s solution containing 
1.0 mM sodium fluoride and 2.0 mM sodium orthovanadate. When the kidneys were 
completely blanched and free of blood the kidneys were perfused with 10 ml ice-cold iron 
oxide solution (1% magnetic iron oxide solution in Ringer’s solution), containing 1.0 mM 
sodium fluoride and 2.0 mM sodium orthovanadate. Subsequently, the kidneys were removed 
and gently pressed through a 75-µm cell strainer. The cell strainer was then washed with 50 
ml phosphate-buffered saline (PBS) solution containing 0.05% Tween-20, 1.0 mM sodium 
fluoride and 2.0 mM sodium orthovanadate to collect the filtrate. The filtered tissues were 
put on ice for 20 min to settle. The supernatant was discarded and the formed sediment was 
diluted in 50 ml PBS containing 0.05% Tween-20, 1.0 mM sodium fluoride and 2.0 mM sodium 
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orthovanadate. This procedure was repeated twice. The iron oxide containing glomeruli were 
collected using a magnetic particle concentrator and transferred to 50 ml of isotonic sucrose 
buffer (290 mM sucrose, 10 mM Tris-HCl pH 7,5, 1.0 mM sodium fluoride, 2.0 mM sodium 
orthovanadate and 0.05% Tween-20). This procedure was repeated for three times to remove 
residual salts of the phosphate-buffered saline that disturb the first dimension 
electrophoresis. All solutions used in above described procedure were 0°C. 
Finally, after centrifugation at 420x g for 5 min the supernatant was discarded and 
the isolated glomeruli were homogenized in 350 µl lysis buffer (7.0 M urea, 2.0 M thiourea, 
1.0% ASB-14, 2.0% CHAPS and 50 mM Tris-HCl pH 7.8). The glomerular lysates were pressed 
repeatedly through a 19G needle. The suspension was dialysed using the mini dialysis kit (GE 
health care, Life Sciences, The Netherlands) against a buffer containing 7.0 M urea, 2.0 M 
thiourea, 1.0% ASB-14, 2.0% CHAPS and 10 mM Tris-HCl pH 7.8.  The protein concentration of 
the glomeruli lysates were determined with the 2D Quant™ Kit (GE health care, Life Sciences, 





Immobiline™ DryStrips (IPG strips) containing a fixed pH gradient (pH3 - pH10 NL, GE 
health care, Life Sciences, The Netherlands) were used for the isoelectric focusing (IEF) of 
the glomerular proteins. IPG strips were loaded with 160 µg of protein in 350 µl rehydration 
buffer containing 7.0 M urea, 2.0 M thiourea, 1.0% ASB-14, 2.0% CHAPS, 25 mM DTT and 1.75 
µl IPG-buffer (pH3 - pH10 NL, GE health care, Life Sciences, The Netherlands). The IPG strips 
were hydrated for 14 hrsours under low voltage (20V) and IEF was performed under increasing 
voltages (500 V for 1 hr, followed by 1000 V for 1hr and 8000 V for 4 hrs) on the IPGphor™ 
system (GE health care, Life Sciences, The Netherlands). The IPG strips were equilibrated for 
15 min in 6.0 M urea, 50 mM Tris-HCl pH 6.8, 30% glycerol(87%), 2.0% SDS, 1.0% DTT and 
subsequently for 15 min in the same buffer containing 0,25% iodoacetate. The IPG strips were 
transferred on a 12% polyacrylamide gel and electrophoresis was performed by 40 mA/gel for 









The gel slabs were fixed for 1 hr in a fixative consisting of 30% ethanol and 5.0% 
acetic acid in deionized water and subsequently washed for 10 min in deionized water. The 
gel slabs were sensitized for 1 min in 0.02% sodium thiosulfate, and afterwards washed in 
deionized water for 3 min. Subsequently, the gel slabs were stained for 1 hr in a solution 
consisting of 6.25 ml 1.0N silver nitrate and 140 µl formaldehyde [37%] in deionized water in a 
total volume of 200 ml. The gel slabs were rinsed for 30 seconds with deionized water and 
subsequently developed in a solution consisting of 15 mg potassium carbonate, 125 µl 
formaldehyde [37%] and 62,5 µl sodium thiosulfate [10%] diluted in deionized water in a total 
volume of 500 ml). After the desired intensity of staining was achieved, the development was 
stopped by placing the gels in stop solution (2.0% acetic acid and 2.0% Tris in deionized water 
 
 
Colloidal Coomassie Brilliant Blue staining 
 
The gel slabs were fixed for 1 hr in 12% w/v Trichloroacetic acid in deionized water 
and rinsed for 10 min in deionized water. Next the gels were stained in colloidal staining 
solution (10% ammonium sulfate, 2.0% phosphoric acid, 0.1% Colloidal Coomassie Brilliant 
Blue-G250 (CBB) and 20% ethanol in deionized water).  Finally, the gel slabs were washed for 
4 hrs in deionized water. 
 
 
In gel digestion 
 
The protein spots of interest were isolated from CBB-stained gels and unstained in a 
solution containing 10% acetic acid and 40% methanol in deionized water. The gel pieces were 
washed for 30 min in 50 µl of 25 mM ammonium bicarbonate and subsequently incubated for 
15 min in 30% acetonitrile. Next, the gel pieces were washed in 25 mM ammonium 
bicarbonate in acetonitrile and subsequently dehydrated in 100% acetonitrile. The dehydrated 
gel pieces were completely dried in a vacuum centrifuge and afterwards rehydrated for 1 hr 
at 0°C in 5 µl digestion buffer containing 25 mM ammonium bicarbonate, 5 mM n-octyl β-d-
glucopyranoside and 3 ng trypsine. Next, the supernatant was removed and replaced with 5 µl 
of the same buffer, but without trypsin, followed by an overnight incubation at 37°C. The 
tryptic digest was extracted for 1 hr at room temperature in 1 µl extraction buffer (50% 
acetonitril, 0.5% trifluoroacetic acid (TFA) and 5 mM n-octyl β-d-glucopyranoside. The tryptic 
digests we stored at -20oC  
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MALDI-TOF MS Measurements and MASCOT Search Parameters 
For MS analysis, 0.25 µl of extracted peptides was pipetted on a MALDI-TOF sample 
plate and directly mixed with an equal volume of sample buffer containing 20 mg/ml α-cyano-
4-hydroxycinnamic acid in 0.05% (v/v) TFA, 50% (v/v) acetonitrile. MALDI-TOF MS 
measurements were performed in the mass range of 650–2,600 Da on a Bruker III mass 
spectrometer, set to reflectron mode, after calibration using a mixture of bradykinin 
fragment 1–7, angiotensin, synthetic peptide P14R, and adrenocorticotropic hormone 
fragment 18–39. Mass spectra were determined as the sum of 180 measurements. 
Monoisotopic peaks were manually selected, excluding background peaks. Peptide masses 
were exported to Biotools software and used to perform a MASCOT search in a database of the 
predicted M. musculus proteome. Search parameters allowed a mass deviation of ±0.3 Da, 
matching peptides containing one miscleavage, fixed modification of carbamidomethylated 
cysteines, and a variable modification of oxidized methionines. Probability based Mowse 
scores defined as (-10*log (P)), where P was the probability that the observed match is a 
random event were determined. Protein scores greater that 58 were considered as significant 
identifications (p<0.05).  
 
 
In situ hybridisation 
 
To analyze β-actin mRNA expression 4µm paraffin section of kidneys fixed in 4% 
buffered formaldehyde were subjected to in situ hybridization (ISH) using digoxigenin (DIG)-
labeled β-actin antisense RNA probe. The corresponding sense probe was used as a control. 
The hybridized probe was detected by an alkaline phosphatase-labeled sheep anti-DIG 







Optimizing 2DE and assessment of reproducibility 
 
We have optimized the 2DE for profiling of glomerular protein extracts. We have 
isolated glomeruli using the magnetic FeO isolation procedure 15. Using this approach we 
succeded to overcome serious practical problems, particularly high salt concentrations in the 
lysates, which interfered with iso-electric focussing of during 2DE. This was achieved by 
inclusion of different desalting steps, including the use of isotonic Tris-HCl buffered sucrose 
solution instead of PBS and dialyses of the lysates, minimized the interference of ions in the 
first dimension of 2DE. In addition, we compared (combinations of) different nonionic and 
zwitterionic detergents (NP-40, Triton X-100, CHAPS and ASB-14) for the lysis of the 
glomerular cells. The best protein focussing and the highest number of protein spots on the 
2D gel were obtained using a lysis buffer containing two zwitterioninc detergents, specifi-
cally 2% CHAPS and 1% ASB-14.  
Eventually, the optimized 2DE procedures resulted in the typical glomerular protein 
profile as depicted in Figure 1. The glomerular protein profile consisted of approximately 600 
visible silver stained protein spots. 
  





Figure 1. A typical silver-stained protein map, obtained by 2DE, of a
mouse glomerular lysate.  
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To assess the reproducibility of the sample preparation we examined the protein 
profiles of separate glomerular protein samples that were extracted from the same mice. The 
protein profiles of these samples were highly comparable (Figure 2), indicating that the 
sample preparation was reproducible. 
 
 
Differential protein expression in FSGS 
 
We compared glomerular proteome 
profiles of saline injected mice with profiles 
of mice with developing FSGS lesions at day 6 
after the anti-Thy-1.1 mAb injection. In the 
glomerular maps of anti-thy-1.1 injected 
mice 4 protein spots showed an altered 
location or expression level compared to the 
spots in the protein maps of saline injected 
mice. To identify proteins we performed 
MALDI-TOF peptide fingerprinting analysis. 
Since silver staining was not compatible with 
MALDI-TOF analysis separate gels were 
stained with colloidal Commassie Brilliant Blue (CBB) staining, which was compatible with 
MALDI-TOF analysis but proved to be less sensitive and only 150 spots could be visualized. 
Two of the differentially expressed protein spots were not detected on the CBB 
stained gels and therefore not identified by MALDI-TOF. A higher protein load (300 µg) did not 
result in a positive identification. Higher protein loads (1 mg) resulted in poor resolution due 
to disturbed focussing of the proteins in the first and second dimension. MALDI-TOF analysis 
of one of the differentially expressed proteins resulted in apparent monoisotopic peaks. 
Unfortunately, this spectrum did not yield a significant protein identification.  
The fourth differentially expressed protein spot was identified as β-actin. The staining 
intensity of identified spot was higher in the anti-Thy-1.1 injected mice (Figure 3A), 
indicating higher protein levels during development of FSGS. To verify possible increased β-
actin levels in development of FSGS we assessed the expression level of β-actin of mRNA level 
by in situ hybridisation (ISH). There was a marked increase in β-actin mRNA expression in 
glomeruli with FSGS lesions (Figure 3B). 
 Sample 1 Sample 2 Merge
 
Figure 2. To visualize the reproducibility of the sample
preparation two separate samples were prepared from
the same mouse kidneys. Two segments of the obtained
silver-stained protein profiles were digitally converted to
green (sample 1) and red (sample 2) signals and
merged (merge) (RGB signals were converted in
Adobe® Photoshop® 7.0). The two samples have an
almost identical protein profile resulting in a yellow signal
for all protein spots, as can be appreciated in the merge.
The small differences in localization of the proteins are






Evaluation of the application of 2DE 
 
Since approximately 150 separate protein spots were visible on the CBB stained 2D 
gels, we assumed that only the most abundant proteins were detectable and questioned 
whether the application of 2DE is useful for detecting the changes in the expression of 
regulatory proteins. To identify the visible proteins all 150 spots were picked and analyzed by 
MALDI-TOF analysis. 




































Figure 4. CBB stained protein map of a mouse glomerular lysate. All visible protein spots (n=150) were dissected and
processed for MALDI-TOF analysis. The encircled spots were identified and are listed in table 1.  
































Figure 3. (A) For the detection of differentially expressed proteins in total six gels were compared (n=3 per sample). One
of the differentially expressed protein spots (encircled) showed an elevated staining in the gels of the glomerular lysate
obtained from the anti-Thy-1.1 injected mice. This protein was identified as β-actin (Figure 4 and Tabel 1). 
(B) In situ hybridization analysis showed an elevated signal for β-actin mRNA in glomeruli of the anti-Thy-1.1 injected
mice compared to the saline injected control mice.  For color figure see appendix. 
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Forty-seven protein spots were identified and are listed in Table 1. Examination of 
the described cellular localization and function of the identified proteins indicated that the 
identified proteins represent mainly cytoskeleton-, and mitochondrial-associated proteins or 
other high abundant “housekeeping” proteins. 
 
  Table 1. Protein identification: The proteins are numbered according to the identification number in Figure 4. 
        Observed          Theoretical
No Protein pI Mw (kDa) pI Mw (kDa)      Biological process gi code
1 ATP synthase D chain 5.57 16 5.52 18,8 oxidative phosphorylation Gi 20913657
2 ATP synthase D chain 5.59 17 5.52 18,8 oxidative phosphorylation Gi 20913657
3 prohibitin 5.61 21 5.57 29,9 inhibitor of DNA synthesis Gi 6679299
4 NADH-ubiquinone oxidoreductase 5.68 19 6.40 30,4 oxidative phosphorylation Gi 23396786
5 Glutathione peroxidase 3 precursor 5.85 17 6.38 22,9 glutathione metabolism Gi 1170039
6 3-mercaptopyruvate sulfurtransferase 6.61 25 6.11 33,2 cysteine metabolism Gi 20149758
7 enoyl coenzyme A hydratase 1 6.48 26 7.60 36,4 fatty acid beta-oxidation Gi 7949037
8 lactamase, beta 2 6.33 25 5.89 33,0 antibiotic catabolism Gi 21703764
9 isocitrate dehydrogenase 3 5.66 36 6.27 40,1 citrate cycle (TCA cycle) Gi 18250284
10 isocitrate dehydrogenase 3 5.84 36 6.27 40,1 citrate cycle (TCA cycle) Gi 18250284
11 beta-actin 5.13 40 5.78 39,4 cytoskeleton Gi 49868
12 beta-actin 5.22 40 5.78 39,4 cytoskeleton Gi 49868
13 beta-actin 5.34 40 5.78 39,4 cytoskeleton Gi 49868
14 succinyl-CoA ligase [ADP] beta-chain 5.55 40 5.65 45,6 citrate cycle (TCA cycle) Gi 21263999
15 succinyl-CoA ligase [GDP] beta-chain 5.71 41 5.91 44,1 citrate cycle (TCA cycle) Gi 21263998
16 beta-actin 5.88 39 5.78 39,4 cytoskeleton Gi 49868
17 NADH dehydrogenase 1α complex 10 6.51 39 7.63 40,9 oxidative phosphorylation Gi 13195624
18 aldehyde dehydrogenase 2 6.77 51 7.53 57,0 carbohydrate metabolism Gi 6753036
19 aldehyde dehydrogenase 2 6.47 51 7.53 57,0 carbohydrate metabolism Gi 6753036
20 D-lactate dehydrogenase 6.26 50 5.71 52,2 pyruvate metabolism Gi 12852638
21 NADH dehydrogenase Fe-S protein 2 6.23 41 6.43 53,7 oxidative phosphorylation Gi 13278096
22 ornithine aminotransferase 6.15 43 6.19 48,7 amino acid metabolism Gi 8393866
23 protein disulfide isomerase A3 6.08 53 5.88 57,1 antigen presentation Gi 13096984
24 protein disulfide isomerase A3 5.97 53 5.75 56,9 antigen presentation Gi 6679687
25 vacuolar H+ATPase B2 5.83 51 5.75 56,5 oxidative phosphorylation Gi 1710537
26 vacuolar H+ATPase B2 5.69 51 5.75 56,5 oxidative phosphorylation Gi 1710537
27 ATP synthase, H+ F1 complex, beta unit 5.51 45 5.19 56,3 oxidative phosphorylation Gi 25052136
28 ubiquinol-cytochrome c reductase 5.57 45 5.75 53,4 oxidative phosphorylation Gi 13384794
29 gamma-actin 5.35 46 5.31 41,8 cytoskeleton Gi 809561
30 gamma-actin 5.20 46 5.31 41,8 cytoskeleton Gi 809561
31 ATP synthase, H+ F1 complex, beta unit 5.02 48 5.19 56,3 oxidative phosphorylation Gi 25052136
32 ATP synthase, H+ F1 complex, beta unit 5.09 48 5.19 56,3 oxidative phosphorylation Gi 25052136
33 ATP synthase, H+ F1 complex, beta unit 5.11 48 5.19 56,3 oxidative phosphorylation Gi 25052136
34 tubulin, beta 5.00 51 4.78 50,4 cytoskeleton Gi 21746161
35 protein disulfide-isomerase  ERp61 4.81 55 4.75 56,8 antigen presentation Gi 1083311
36 calreticulin 4.39 58 4.33 48,1 antigen presentation Gi 6680836
37 60 kDa heat shock protein 5.19 56 5.35 61,0 protein chaparone Gi 3219998
38 60 kDa heat shock protein 5.40 56 5.35 61,0 protein chaparone Gi 3219998
39 60 kDa heat shock protein 5.48 56 5.35 61,0 protein chaparone Gi 3219998
40 heat shock 70kD protein 9B 5.64 68 5.50 73,7 protein chaparone Gi 1072476
41 heat shock 70kD protein 9B 5.53 68 5.50 73,7 protein chaparone Gi 1072476
42 vacuolar H+ATP synthase A1 5.57 66 5.62 68,6 oxidative phosphorylation Gi 6680836
43 heat shock 70kD protein 8 5.45 66 5.32 70,9 protein chaparone Gi 13624307
44 heat shock 70kD protein 5 5.03 68 5.01 72,3 protein chaparone Gi 109893
45 endoplasmin precursor 4.75 90 4.72 92,7 protein chaparone Gi 6755863
46 heat shock protein 75 kDa 6.18 68 6.25 80,5 protein chaparone Gi 13385998






Numerous studies and reviews have described the successful application of 2DE in 
combination with Mass Spectrometry (MS) in nephrological research 16-20. Most of these studies 
involve studies on the urinary proteome during various physiological stimuli or pathological 
conditions or studies on renal cell lines. In addition, both Witzman et al and Arthur et al have 
used 2DE to identify proteins differentially expressed in rat kidney medulla and cortex 21;22. 
To our knowledge only few studies have examined changes in glomerular 2DE profiles in 
glomerular disease. Nazeer and co-workers identified differentially expressed proteins in the 
glomeruli isolated from a rat model of glomerulonephritis. They recognized 28 proteins that 
were differentially expressed 23. One of these proteins was up-regulated during 
glomerulonephritis and identified as tropomyosin 5. Yoshida et al. have constructed a 
proteome map of normal human glomeruli. From approximately 1.600 visualized protein 
spots, more than 212 proteins have been identified 24. 
In the present study we performed 2DE for analysis of the glomerular proteome 
associated with FSGS. We have been able to obtain reproducible samples. Proteomic analysis 
by 2DE revealed approximately 600 protein spots of which 47 spots were identified. 
Comparison between lysates of glomeruli isolated from normal kidneys and from kidneys with 
early FSGS lesions revealed 4 differentially expressed proteins. One of these proteins was 
identified as β-actin, which was present in higher abundancy in the FSGS glomeruli. We were 
able to confirm these findings by measuring mRNA expression. This β-actin up-regulation may 
be explained by the marked cellular hypertrophy of podocytes and parietal epithelial cells 
and by the increased proliferation rate of the glomerular parietal epithelial cells.  
Unfortunately, we were unable to identify the other three differentially expressed 
proteins. For two of these proteins the reason was low abundancy, as these were not 
detected by CBB staining. The third protein was not identified because the peptide masses 
generated by MALDI-TOF did not result in a positive identification. In case of the latter, 
although not performed in this study, sophisticated tandem MS instrumentation may facilitate 
the identification since it enables de novo sequencing of peptides. 
Almost all proteins that were identified by MALDI-TOF were abundantly expressed 
“house keeping” proteins, which are considered to have a relatively invariable expression. 
This observation may explain why we have found only a small number of proteins that are 
differentially expressed between the FSGS and control samples. Yet, the identified proteins 
represent only a part of the proteins visualized in the 2DE analysis. Gygi and co-workers also 
showed, using proteins extracted from yeast, that proteome analysis accomplished by the 
combination of 2DE and MS mainly found abundant and water-soluble proteins 25. In addition, 
we should realize that separation of large proteins (>100 kDa) and those with extreme pI, 
remain a problem. Admittedly, the technology of 2DE develops rapidly and 2DE procedures 
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that we have used can already be further improved. Comparisons were performed on silver 
stained gels, and it is well known that silver staining offers high sensitivity but low dynamic 
range. Therefore, subtle changes in protein expression levels will be missed using silver 
staining. In recent years novel methods based on fluorescent dyes have become available 
(e.g. Sypro Ruby staining) that are as sensitive as silver staining but show a greater dynamic 
range 26. In addition, in a typical 2DE experiment, the protein profiles of the samples are 
compared in parallel gels. Variations in protein focusing and staining between parallel gels 
will complicate the detection of differentially expressed proteins. Using so called Difference 
Gel Electrophoresis (DIGE) significant advances can be made in respect to the reproducibility 
of 2DE 27. In this method, the proteomes to be compared are labeled with fluorescent dyes 
that emit at different wavelengths. The labeled samples can be compared in a single gel 
eliminating gel-gel variances. Despite these advances not many groups have implemented this 
technology, mainly due to the high costs of the reagents and scanning equipment. In the 
present study a broad range pH gradient was used (pH3-pH10). Using broad gradient allows 
one to analyze most proteins in a sample with one gel, but may result in overlap of proteins 
that have a comparable molecular weight and pI. Using narrow gradients (eg. pH6-pH7) the 
overlap will be minimized but all proteins with a pI outside the gradient will be lost and 
multiple 2DE analysis have to be performed. 
Implementation of the above noted advances in 2DE technology, may improve the 
reproducibility of 2DE and the detection of differential expressed proteins. On the other 
hand, these advances may not improve the sensitivity of the 2DE and MALDI-TOF combined 
analysis, which is in our view the most crucial limitation of the 2DE analysis in the present 
study. 
As the limitations of gel-based approach become more recognized, new techniques 
are developed that can be used as an alternative or complementary technique to get around 
the limitations of 2DE. One of the latest advances in this regard, is 2D-LC-MS/MS. Using this 
technique, complex protein samples can be digested without initial separation circumventing 
the generally poor recovery of proteins from gel pieces, as is the case in gel-based 
approaches. The separation of the peptides is based on their hydrophobic characteristics.  LC-
MS/MS technology can be used when only very small amount of protein are available and for 
the identification of low abundant proteins 16. The drawbacks of this approach, when 
compared to 2DE are that quantitative estimates are not easy to make and that 2D-LC-based 
methods put enormous demand on the instrumentation and bioinformatics capabilities of the 
laboratory16;28.  
In conclusion: 2DE lacks sufficient sensitivity to identify low abundant proteins. 
Consequently, we question the applicability of 2DE for the identification of (low abundant) 
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Focal segmental glomerulosclerosis (FSGS) is a hallmark of progressive renal disease. 
Podocyte injury and loss have been proposed as the critical events that lead to FSGS. In the 
present study we have examined the development of FSGS in Thy-1.1 transgenic (tg) mice, 
with emphasis on the podocyte and parietal epithelial cell (PEC). Thy-1.1 tg mice express the 
Thy-1.1 antigen on podocytes. Injection of anti-Thy-1.1 mAb induces an acute albuminuria 
and development of FSGS lesions that resemble human collapsing FSGS. 
We studied FSGS lesions at days 1,3,6,7,10,14 and 21, in relation to changes in the 
expression of specific markers for normal podocytes (WT-1, synaptopodin, ASD33 and the Thy-
1.1 antigen), for mouse PECs (CD10), for activated podocytes (desmin), for macrophages 
(CD68), and for proliferation (Ki-67). The composition of the extracellular matrix (ECM), that 
forms tuft adhesions or scars, was studied using mAbs against collagen IV α2 and α4 chains 
and antibodies directed against different heparan sulfate species.  
The first change we observed was severe PEC injury at day 1, which increased in time 
and resulted in denuded segments of Bowman’s capsule at day 6 and 7. Podocytes showed 
foot process effacement and microvillous transformation. There was no evidence of podocyte 
loss or denudation of the GBM. Podocytes became hypertrophic at day 3, with decreased 
expression of ASD33 and synaptopodin, and normal expression of WT-1 and Thy-1.1. Podocyte 
bridges were formed by attachment of hypertrophic podocytes to PECs and podocyte 
apposition against denuded segments of Bowman's capsule. At day 6, there was a marked 
proliferation of epithelial cells in Bowman’s space. These proliferating cells were negative for 
desmin, and all podocyte markers, but stained for CD10, and thus appeared to be PEC. The 
staining properties of the early adhesions was identical to that of Bowman's capsule, 
suggesting that the ECM in the adhesions was produced by PECs.  
In conclusion, we propose the following sequence of events leading to FSGS lesions in 
the Thy1.1 tg mice 1) PEC damage and denudation of Bowman's capsule segments, 2) 




Focal segmental glomerulosclerosis (FSGS) is one of the most common patterns of 
glomerular injury encountered in human renal biopsies 1.  In its classical form, FSGS is 
characterized by mesangial sclerosis, obliteration of glomerular capillaries, formation of 
adhesions between the glomerular tuft and Bowman’s capsule, podocyte hypertrophy, 
hyalinosis and intracapillary foam cells. More recently, various morphological variants have 
been described 2. Notably, FSGS is merely a descriptive diagnosis, and not a disease entity. 
Clinically, presentation of the patients varies widely 3. 
FSGS was long considered to be the consequence of mesangial overload leading to 
mesangial cell proliferation, mesangial cell injury, and increased production of extracellular 
matrix (ECM) 4-7. More recently, focus has turned on the visceral epithelial cell, the so called 
podocyte. Seminal studies of Kriz and co-workers in various rat models of FSGS have proposed 
the following sequence of events that ultimately lead to FSGS: 1) podocyte injury resulting in 
podocyte loss with denudation of the GBM, 2)  adherence of the parietal epithelial cell (PEC) 
to the naked GBM, 3) formation of an adhesion of the GBM to Bowman's capsule, 4) 
misdirected filtration of proteins to the periglomerular and peritubular space 8-17. However, 
the studies by Kriz and co-workers were performed in animal models in which a common 
feature was glomerular hypertension with capillary ballooning and the development of hypo-
cellular FSGS lesions, which resemble lesions observed in human secondary FSGS. Their 
findings may therefore not apply to FSGS in general. Recently, we have proposed the Thy-1.1 
transgenic (tg) mice as a mouse model to study proteinuria and FSGS 18. Thy-1.1 transgenic 
mice carry a mouse-human chimaeric transgene that causes ectopic expression of the mouse 
Thy-1.1 antigen on podocytes. Injection of mAb directed against the Thy-1.1 antigen induces 
an acute albuminuria within 10 min and a dose dependent development of FSGS within 3 
weeks 19. FSGS lesions in this mouse model bear resemblance to the collapsing variant of 
human FSGS. 
In the present study we have examined the histopathological changes that occur in 
the early stages of FSGS development. We particularly focussed on the podocytes and PECs. 









Heterozygous Thy-1.1 transgenic (tg) mice were kindly provided by Dr. D.J. Evans (T6, 
T-construct mice 20). These mice were generated by injecting a hybrid human-mouse Thy-1.1 
gene into pronuclei of zygotes of Thy-1.2 CBA x C57BL/10 mice. These mice express the Thy-
1.1 gene abnormally in podocytes, resulting in the presence of the Thy-1.1 antigen on the 
podocytes. All mice were bred in our animal facility. Breading pairs consisted of a 
heterozygous (+/-) transgenic mouse and its non-transgenic (-/-) counterpart. The presence of 
the transgene was examined by PCR on genomic DNA from the tail, with a forward primer: 5’-
CGCCTGAGTCCTGATCTCC-3’ and a reverse primer: 5’-AACCTGCATCTTCACTGGGT-3’. The 
presence of the transgene resulted in a specific 834-bp amplicon. As a positive control for the 
presence of amplifiable genomic DNA a primerset for aminopeptidase A (APA; EC 3.4.11.7), 
consisting of the forward primer: 5’-ACACAACCCCAGCTCCTTCC-3’ and reverse primer 5’-
TCTTCTGCAGCCTGGATCAC-3’, was used. The amplification of the APA gene with these 





For in vivo experiments a mouse anti-mouse Thy-1.1 mAb (19XE5: subclass IgG3) was 
used. 19XE5 was generated in vitro, by hollow fibre culture, purified by protein-A column 
affinity chromatography and concentrated (Nematology Department, Agriculture University 
Wageningen, The Netherlands). The mAb was decomplemented at 56°C for 45 min and 





Five-week old Thy-1.1 transgenic mice received an intravenous injection with 1 mg 
anti-Thy-1.1 mAb (19XE5) in 0.1 ml 0.9% saline solution. Transgenic mice injected with 0.1 ml 
0.9% saline solution alone were used as controls. To evaluate the FSGS development, kidney 




Light microscopy and Transmission Electron Microscopy 
 
For light microscopy, kidney fragments were fixed in Bouin’s solution, dehydrated, 
and embedded in paraplast (Amstelstad, Amsterdam, The Netherlands). 4 µm sections were 
stained with periodic acid-Schiff, and 2 µm sections with silver methenamine 21. At least 60 
glomeruli per mouse were evaluated. We determined the percentage of glomeruli with a FSGS 
lesion (FSGS score). Only lesions with an adhesion (matrix continuity between the tuft and 
Bowman’s capsule in the silver stain) were counted. The number of nuclei in Bowman’s space 
was determined (expressed as nuclei/glomerular cross section) and served as an objective 
measure for hyperplasia of glomerular epithelial cells.  
For electron microscopy, we used immersion and perfusion fixed kidneys. For 
immersion fixation, small fragments of cortex were fixed in 2.5% glutaraldehyde dissolved in 
0.1 M sodium cacodylate buffer, pH 7.4, overnight at 4°C and washed in the same buffer. To 
obtain perfusion fixed kidneys, anti-Thy-1.1 injected mice were perfused retrogradely via the 
aorta. The animals were flushed for 30 seconds with a buffered saline solution and perfused 
with a 2,5% glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer, pH 7.4, for 10 min. 
Perfusion was performed at a pressure of 120 mm Hg. Small fragments of cortex were further 
fixed by immersion in the same fixative, overnight at 4°C and washed in 0.1 M sodium 
cacodylate buffer, pH 7.4. The tissue fragments were postfixed in palade-buffered 2% OsO4 
for 1 hr, dehydrated, and embedded in Epon812, Luft's procedure (Merck, Darmstadt, 
Germany). Ultrathin serial sections with 2 µm intervals were contrasted with 4% uranyl 
acetate for 45 min and subsequently with lead citrate for 5 min at room temperature. 





Immunohistochemical staining was performed on kidneys, fixed in 4% buffered 
formaldehyde for 24 hrs and embedded in paraffin. 4 µm sections were incubated with rat 
rabbit anti-mouse Ki-67 (Dianova Immundiagnostic, Hamburg, Germany), goat anti-CD10, and 
rabbit anti-WT-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). As secondary antibodies 
we used a biotinylated goat anti-rabbit antibody for Ki-67 and WT-1, and a horse anti-goat for 
CD10 (Vector laboratories Inc., Burlingame, CA, USA). Detection was carried out with 
vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) with the use of peroxidase as 
label and diaminobenzidine as substrate. Quantification of the WT-1 and Ki-67 positive cells 
was performed with the Zeiss KS 400 image analysis system (Carl Zeiss b.v., Weesp, The 
Netherlands). Images were acquired using AxioPlan2 imaging microscope and AxioCam MRc 




glomeruli and segments of interstitium were interactively drawn using a graphic tablet. 
Positive nuclei in the selected areas were interactively marked. A customized macro under 
KS400 software (KS400 3.0) determined the area (mm2) of the selected segments, and the 
number of positive nuclei within this area. Per mouse, approximately 30 glomeruli were 
counted in one cross-section. For staining of CD68 and desmin we used 2 µm acetone fixed 
cryosections. The sections were incubated with rat anti-mouse CD68 (clone FA-11, Serotec, 
Oxford, UK), and rabbit anti-desmin 22. As secondary antibodies we used biotinylated rabbit 
anti-rat for CD68, and biotinylated goat anti-rabbit antibody for desmin (Vector laboratories 
Inc., Burlingame, CA, USA). Detection was carried out with vectastain ABC kit for alkaline 





Kidney fragments were snap-frozen in liquid nitrogen, and 2 µm acetone fixed serial 
cryostat sections were used. Thy-1.1 was detected using a rat polyclonal anti-Thy-1 antibody 
(59AD2.2; IgG2a, 23). As secondary antibody we used a FITC labeled sheep anti-rat antibody 
(Serotec, Oxford, UK). A double-immunolabeling technique was performed to determine the 
co-localization of Thy-1.1 and Ki-67, and of Thy1.1 and desmin. Thy-1.1 was stained as 
described above. After washing with PBS, the sections were incubated with rabbit anti-mouse 
Ki-67 (Dianova Immundiganostic, Hamburg Germany), or with rabbit anti-desmin 22, and 
detected with a goat anti-rabbit AlexaTM 568 antibody (Molecular probes Inc, Leiden, The 
Netherlands). Synaptopodin was detected using an anti-synaptopodin mAb (Progen Biotechnik, 
Heidelberg, Germany), followed by a FITC labeled sheep anti-mouse IgG1 (Nordic 
Immunologicals, Tilburg, The Netherlands). For detection of the podocyte we also have used 
ASD33, a rat monoclonal antibody, generated in our laboratory, which only reacts with the 
podocyte cell membrane 24. The identity of the antigen is unknown. For the detection of 
ASD33 we have used a FITC-labeled rabbit anti-rat antibody (Dako A/S, Glostrup, Denmark). 
Type IV collagen α2 and α4 chains were detected with rat monoclonal antibodies directed 
against human collagen (IV) α2 (H22) and human collagen (IV) α4 (H43), a gift from Dr. 
Yoshikazu Sado (Shigei Medical Research Institute, Okayama, Japan). Detection was done 
using goat anti-rat AlexaTM 488/568 antibodies (Molecular probes Inc, Leiden, The 
Netherlands). Nuclei were stained with TO-PRO-3 (Molecular probes Inc, Leiden, The 
Netherlands), a monomeric cyanine nucleic acid stain. Different heparan sulfate species were 
detected with various single chain antibodies, HS4C3 25, HS4E4, and EV3C3 26. The single chain 
antibodies were detected with a Cy3-labeled rabbit antibody directed against the VSV-g 
epitope tag (Sigma-Aldrich, Zwijndrecht, The Netherlands). The sections were examined with 





For multiple comparisons, ANOVA was used and post hoc analyses were done with 





Histopathology of the kidney 
 
Thy-1.1 tg mice that received a single injection of 1 mg anti-Thy-1.1 mAb developed 
FSGS lesions within 3 weeks. The histopathology was examined by light microscopy at days 1, 
3, 6, 7, 10, and 21 (Figure 1). At day 1, we observed enlarged Bowman’s space due to 
collapse of the glomerular tuft, consistent with ischemia. No enlarged podocytes 
(hypertrophy) were observed. In contrast, PECs showed vacuolisation and detachment. In 
tubular lumens we observed many hyaline appearing protein casts. Proximal tubular epithelial 
cells showed damage similar to PECs (Figure 1A). At day 3, glomeruli were not ischemic 
anymore and the number of tubular protein casts 
had decreased. There was segmental hypertrophy 
of glomerular epithelial cells (Figure 1B). At day 6 
and 7, the first FSGS lesions with tuft adhesions 
to Bowman's capsule, were observed. Affected 
glomeruli showed segmental collapse of the 
capillary tuft and a marked increase of epithelial 
cells in Bowman’s space (Figure 1C, D). It was 
shown that there was a significant overall 
increase of the number of nuclei in bowman’s space at day 7 (Table 1).  
Adhesions (continuity of ECM between the capillary tuft and Bowman’s capsule) were 
formed by thin strands of ECM that were located between the epithelial cells in Bowman’s 
space. Sporadically (not quantified) we observed endocapillary foam cells, an endocapillary 
neutrophil or mononuclear cell, mild mesangial hypercellularity and mild hyalinosis (Figure 
1F). From a histological point of view the FSGS lesions closely resembled the collapsing 
variant of human FSGS 27. The percentage of glomeruli with FSGS lesions was scored at days 1, 
3, 6, 7, 10, and 21 by light microscopy (Figure 1G).  FSGS lesions, with tuft adhesions to 
Bowman's capsule, could be observed in 11 ± 1% and 26 ± 3% of the glomeruli at day 6 and 7, 
respectively. The percentage of glomeruli with FSGS lesions did not increase thereafter. 
However, at day 21, the lesions were more advanced, showing a high degree of ECM 
accumulation, which had culminated in the formation of segmental- or even global- scars 
(Figure 1E). 
Table 1. Number of nuclei in Bowman’s space. 
      group Number of nuclei n 
      Saline 15,7 ± 0,4 (4) 
      Day 1 14,7 ± 0,6 (3) 
      Day 7 19,5 ± 1,3a (4) 
   
Significant increase in number of nuclei at day 7 
after anti-Thy-1.1 injection versus the saline 
injected mice and mice at day 1 after anti-Thy-1.1 
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Figure 1. Histology of kidney sections of Thy-1.1 transgenic mice, at days 1, 3, 6, 7 and 21 after anti-Thy-1.1
mAb injection, (A-E, respectively). (A) At day 1, light microscopy revealed vacuolization and detachment of
PECs (arrow). In proximal tubules many protein resorption droplets were observed (*). (B) At day 3, a
pronounced hypertrophy of glomerular epithelial cells was observed (*). (C,D) At days 6 and 7, tuft adhesions
were observed (arrows). Glomeruli showed segmental collapse of capillaries and an increased number of
epithelial cells in Bowman’s space (*). (E) At day 21, glomeruli showed accumulation of ECM in Bowman's
space, with formation of segmental scars (arrow) Unaffected glomerulus (*). Methenamine silver staining.
Original magnification: X400. (F) Occasionally, mild hyalinosis (arrow) and a mitotic endocapillary cell
(arrowhead) was observed. PAS staining. Original magnification X400.  The percentage of glomeruli with FSGS
lesions at days 1, 3, 6, 7, and 21 is depicted in G. * P < 0.05, *** P < 0.001 versus day 1.  For color figure see
appendix. 
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EM analysis at day 1 and day 3, using immersion fixed tissue, showed global podocyte 
alterations with foot process effacement and microvillous transformation. However, we did 
not observe podocyte detachment nor areas of denuded GBM. In contrast to humans, mouse 
glomeruli frequently show prominent intraglomerular proximal tubular epithelial cells. These 
“glomerular proximal tubular cells” and PECs showed extensive nuclear activation, 
vacuolisation and widespread injury, especially at day 1 (Figure 2A). As most FSGS lesions 
develop around day 6 and day 7 we performed extensive EM analysis at this time point, using 
both immersion and perfusion fixed tissue. At day 6 and 7, in early lesions, PEC appeared 
activated with enlarged nuclei and prominent nucleoli. The number of PEC nuclei along 
Bowman’s capsule appeared increased and mitotic figures were occasionally encountered 
(Figure 2C,D). In these areas with increased cell number, we frequently observed electron 
dense bodies, probably cell remnants, suggesting PEC loss (Figure 2D). Detachment of PECs 
with naked Bowman’s capsule was occasionally observed (Figure 2B). In affected glomerular 
segments the podocytes were markedly hypertrophic showing extensive vacuolisation, 
resorption droplets and formation of pseudocysts (Figure 2D). In immersion fixed tissue 
Bowman’s space was absent and hypertrophic podocytes were positioned directly against 
PECs. In perfusion fixed tissue, we frequently observed cell bridges formed by a hypertrophic 
podocyte attached to a PEC (in our hands perfusion fixation, as compared to immersion leads 
to more shrinkage of the glomerular tuft and flattening of the PECs resulting in a prominent 
Bowman’s space). At the interface between hypertrophic podocytes and PECs occasionally 
junctional complexes were observed (Figure 2E). In immersion fixed tissue we did occasionally 
see podocytes positioned directly against denuded Bowman’s capsule (Figure 2B) but in the 
perfusion fixed tissue optically empty space was always present and true attachment could 
not be confirmed. In more advanced lesions Bowman’s space was filled with an increased 
number of epithelial cells (both fixation techniques) and pericellular accumulation of matrix 
was observed (Figure 2F). Serial sections of single glomeruli showed that FSGS lesions did not 
develop exclusively close to the urinary pole but were also encountered near the vascular 




     
Figure 2. Electron microscopy. Injured glomeruli (day 1, 6, and 7) analysed by transmission electron microscopy (TEM).
(A) At day 1, PECs show widespread injury (insert). Epithelia of Bowman’s capsule constituting proximal tubular
epithelial cells show extensive vacuolisation of the cytoplasm (*). Podocytes showed foot process effacement (arrow)
and microvillous transformation (arrowhead). (B) At day 6 and 7, segments of denuded Bowman's capsule were
observed (arrows). Podocytes positioned against the denuded capsule were observed, thus forming podocyte bridges
between the GBM and the bare Bowman's capsule (*). (C-E) At day 6 and 7, in early lesions, PEC appeared activated
with enlarged nuclei and prominent nucleoli. The number of PEC nuclei along Bowman’s capsule appeared increased
(star). The hyperplasia of epithelial cells in Bowman’s space was also encountered near the vascular pole (vp).
Podocytes were markedly hypertrophic showing extensive vacuolisation, resorption droplets (rd) and formation of
pseudocysts (*). In perfusion fixed tissue cell bridges formed by a hypertrophic podocyte attached to a PEC were
observed (arrows). At the site of attachment between hypertrophic podocytes and PECs occasionally junctional
complexes were observed (arrows in inserts 1 and 2). (F) Glomerular epithelial cells positioned in Bowman’s space
showed pericellular accumulation of ECM (m). (A, B, F, immersion fixed, C-E, perfusion fixed) Original magnifications: A




To assess changes in podocyte phenotype during the development of FSGS we studied 
the expression of podocyte specific markers, WT-1, synaptopodin, ASD33 (an unidentified cell 
membrane antigen, strongly expressed on mouse podocytes), the Thy-1.1 antigen, Ki-67 as a 
marker of proliferation, desmin (associated with podocyte dedifferentiation)28, and CD68 
(macrophage marker). At day 3, in the absence of sclerotic lesions, we already observed some 
decrease in the expression of ASD33 and synaptopodin (data not shown). At days 6 and 7, 
changes were even more prominent (Figure 3A). The decrease of ASD33 and synaptopodin 
expression was in particular observed in segments with a tuft adhesion or tuft collapse. 
During the first 7 days we did not observe a change in the number of WT-1 positive cells. At 
day 21, we did observe a significant decrease in number of WT-1 positive podocytes compared 
with days 1 and 6 (Table 2). At day 7, there was an increased expression of desmin in 
affected glomeruli. Desmin co-localized with the Thy-1,1 antigen and thus is expressed by 
podocytes (Figure 3B). There was no glomerular expression for CD68 (data not shown). 






























Figure 3. Podocyte phenotype. (A) IF for podocyte and an anti-heparan sulfate single chain antibody (HS4C3). 
Serial sections, from control- and anti-Thy-1.1 mAb injected- mice (day 7). HS4C3 stains GBM and mesangium, showing a
normal tuft architecture in the control and a segmental lesion in thy-1.1 injected mice (day 7, *). In control mice, ASD33,
synaptopodin, and Thy-1.1 showed a homogeneous staining pattern along the GBM. There is a decrease in expression of
ASD33 and synaptopodin in areas with a segmental lesion. There is still high expression of the Thy-1.1 antigen
surrounding the collapsed segment (arrow). 
(B) IF for desmin and Thy-1.1. Section from an anti-Thy-1.1 mAb injected- mouse (day 7). Thy-1.1 shows a normal
podocyte staining in the unaffected glomerulus (arrowhead) but an irregular pattern in an affected glomerulus (*). The





Characterization of the proliferating epithelial cells  
 
We have performed phenotypic analysis of proliferating epithelial cells in Bowman’s 
space in order to clarify their origin. Sections were stained for Ki-67. We observed an increase 
in the number of proliferating cells which peaked at day 3 for the interstitial compartment, 
and at day 7 for the glomerulus (approximately 5x baseline levels). Thereafter, the number of 
Ki-67 positive cells declined to baseline levels (Figure 4A). 
Approximately 50% of proliferating cells were located in Bowman's space, the rest was located 
within the glomerular tuft. Proliferating cells were often positioned along Bowman's capsule 
and appeared to be PECs (Figure 4B). In addition, proliferating cells were often located 
adjacent to adhesions (Figure 5B).  
   Table 2. Number of WT-1 positive cells per mm2 in Thy-1.1 tg mice 
   group WT-1 positive cells/mm2 n 
Saline 2388 ± 69 (4) 
Day 1 2518 ± 169 (5) 
Day 3 2497 ± 122 (4) 
Day 6 2728 ± 81 (4) 
Day 7 2332 ± 247 (4) 
Day 10 2137 ± 412 (3) 
Day 14 1974 ± 72 (4) 
Day 21 1694 ± 141a,b (4) 
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Figure 4. Cellular proliferation in the glomerulus and interstitial compartment. (A) The number of Ki-67 positive
proliferating cells in the glomerulus gradually increased and peaked at day 7. Thereafter, the number of Ki-67 positive
cells declined to baseline levels. Peak proliferation of cells within the interstitial compartment was observed at day 3. (B)
Immunohistochemistry for Ki-76. There is a high number of Ki-67 positive nuclei positioned along Bowman's capsule
(arrow) and within the glomerular tuft we observed Ki-67 positive nuclei (arrowhead). Original magnification: X400. (n=4)
** P < 0.01 versus saline, *** P < 0.001 versus saline. 
In the first seven days there is no significant 
decrease in WT-1 positive cells versus the saline 
injected mice. There is a significant decrease in 
number of WT-1 positive cells visible at day 21 
versus day 1 and 6.   
a: P < 0.05 vs. Day 1, b: P < 0.01 vs. Day 6 
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By double immunofluorescence, we never observed co-localization of Ki-67 and the 
podocyte specific Thy-1.1 antigen, arguing against the presence of proliferating podocytes. 
We did not observe Thy-1.1 expression in areas with accumulations of epithelial cells in 
Bowman's space (Figure 5A) however, in these areas, we did observe expression of the neutral 
endopeptidase CD10 (Figure 5D), a protein that, in glomeruli of control mice, is strongly 





Figure 5: Phenotype of proliferating cells. Panel A shows immunofluorescence in an anti-Thy-1.1 mAb injected mouse
(day 7), for Thy-1.1 (green) and HS4E4, an anti-heparan sulfate antibody (red). Nuclei are stained with TO-PRO-3 (blue
staining). Shown is a FSGS lesion with accumulation of cells in Bowman’s space (A, arrowhead). Thy-1.1 is present
along the glomerular tuft, but there is no staining for Thy-1.1 within the lesion. HS4E4 stains Bowman's capsule and tuft
adhesions (A, arrow). Panel B shows immunofluorescence for collagen α2 (IV) (red) and Ki-67 (green). Collagen α2 (IV)
is present in Bowman's capsule, mesangium and tuft adhesions (B, arrow) Ki-67 positive cells are located adjacent to
tuft adhesions. Magnifications: X500 in A and X600 in B. Panels C and D show immunohistochemistry for CD10.
Immunoreactive cells stain brown. In control mice CD10 is, within the glomerulus, strongly expressed on PECs (C). In a
FSGS lesion (day 7) epithelial cells in Bowman’s space strongly express CD10 (D). Original magnification: X400.  For




Characterization of extracellular matrix 
 
The composition of the ECM that is present in the adhesions was studied by staining 
serial sections with antibodies directed against the α2 and α4 chains of collagen IV. In 
addition, we have used different anti-HS single chain antibodies that in control mice 
predominantly stain Bowman's capsule and not the GBM. The ECM forming tuft adhesions 
stained for collagen α2 (IV) and the anti HS antibodies and was negative for collagen α4 (IV) 
and HS4C3, an anti-HS antibody that stains GBM and mesangium. Thus, the staining properties 
of the newly formed ECM were identical to those of Bowman's capsule, arguing that this 













Figure 6. Assessment of the composition of the ECM. Immunofluorescence for collagen IV α2 and α4 (green) and
HS4E4 (red), in serial sections of a glomerulus with adhesions (day 7). (A) Within the glomerulus, collagen α4 (IV) is
expressed specifically in the GBM. (B) Collagen α2 (IV) is expressed in Bowman's capsule, mesangium and in the tuft
adhesions. (C,D) HS4E4 stains Bowman's capsule and the accumulations of ECM, which form the tuft adhesions
(arrows). (E) There was no co-localisation of collagen α4 (IV) and heparan sulfate identified by HS4E4. (F) Collagen α2
(IV) shows co-localisation with the HS4E4 heparan sulfate in Bowman's capsule and the tuft adhesions. Original




Our study indicates that PECs play an important role in the development of FSGS in 
the Thy-1.1 transgenic mouse. Although we observed also distinct changes in the podocyte, 
we feel that the involvement of the PEC is more prominent. In the early time-points after 
induction of albuminuria, we observed PEC injury, which was accompanied by denudation of 
segments of the Bowman's capsule. Thereafter, a cellular lesion consisting of hypertrophic 
and hyperplastic glomerular epithelial cells developed. Although hypertrophic podocytes 
contributed to these lesions, most cells were proliferating PECs. Finally, the cellular lesions 
turned into the adhesive scar that is the hallmark of FSGS. We have evaluated the 
composition of the scar using antibodies against heparan sulfates and collagen (IV) α2 and α4, 
and the data indicated that the ECM that is present in the scar is derived from the parietal 
epithelium. 
Podocyte changes in our model consisted of podocyte hypertrophy and podocyte foot 
process effacement. Of note, we never observed detachment of the podocytes or areas of 
denuded GBM. Our findings are in contrast with the observations of Kriz and coworkers, who 
have postulated a final common pathway for the development of FSGS, on the basis of their 
studies in various rat models. Their proposed pathway toward FSGS emphasizes on the 
podocyte. Detailed histological analyses have pointed to the following sequence of events: 1) 
podocyte injury,  2) detachment of podocytes and/or loss of podocytes (podocytopenia) with 
denudation of the GBM, 3) adherence of the naked GBM to PECs which then loose intercellular 
contacts, and 4) the formation of an adhesion between the glomerular tuft and Bowman's 
capsule which allows "misdirected" filtration of plasma proteins to the periglomerular and 
peritubular space ultimately leading to global glomerulosclerosis and tubulo-interstitial 
fibrosis 13-17. 
In our model development of FSGS clearly follows other pathways, thus suggesting 
that the model proposed by Kriz et al. may not be applicable to FSGS in general. The latter 
conclusion may not come as a surprise in view of the large clinical variability of patients with 
FSGS. Thus far, most studies have been done in rat models with evidence of glomerular or 
systemic hypertension. Most notably is the observation that in the reported studies there was 
always evidence of capillary ballooning and glomerular hypertrophy. It is tempting to 
speculate that the proposed pathway toward FSGS based upon the rat models is relevant for 
the process of secondary FSGS that is observed in patients with reduced renal mass or 
longstanding hypertension. 
In our mouse model we did not observe dilatation of the glomerular capillaries or 
glomerular hypertrophy. Rather, we observed segmental collapse of the tuft with prominent 
extracapillary proliferation and frequent formation of adhesions. Therefore, from a 




variant of human FSGS 2;27, although the segmental rather than global nature of the process 
and the frequent formation of adhesions are more typical for other variants of human FSGS. 
Collapsing FSGS is a recently recognized entity, predominantly seen in Afro-Americans, also 
associated with HIV infection, and with a poor prognosis and rapid progression toward end 
stage renal disease (ESRD). Collapsing FSGS in humans is associated with higher initial 
proteinuria and by some authors considered to be early and/or active lesions 29-33. To what 
extent is our model representative of human collapsing FSGS? Kriz et al. consider collapsing 
FSGS to be distinct from the classical form, with a different underlying pathogenetic 
mechanism 14;15. It has been proposed that the cellular lesions that are prominently present in 
collapsing FSGS consist of podocytes that are dysregulated and are dedifferentiated with loss 
of all podocyte specific markers 34-37 and increased expression of desmin 28. These podocytes 
are apparently no longer growth restricted and have regained the ability to proliferate. 
Normal podocytes are considered post-mitotic cells, unable to proliferate due to high level 
expression of cyclin-dependent kinase inhibitors (CKIs) p27 and p5734. In our mouse model, we 
also observed podocyte hypertrophy and loss of podocyte specific markers, synaptopodin and 
ASD33, and an increased expression of desmin, consistent with dedifferentiation. However, 
because of the continued expression of podocyte specific markers WT-1 and Thy-1.1, we were 
able to show that podocytes in our model do not proliferate. Conversely, the orientation of 
the proliferating epithelial cells relative to Bowman's capsule and Bowman’s space, the strong 
expression of CD10 and the composition of the ECM that is produced by these cells strongly 
argue that the proliferating cells are PECs. PECs have low level expression of CKIs and are 
known to proliferate in response to different stimuli 38. A typical example of PEC proliferation 
is seen in the formation of crescents 39;40. Taken together, our data argue against a 
dedifferentiated and dysregulated podocyte being responsible for the formation of FSGS 
lesions in our model. 
How should earlier data be interpreted? In the studies that have assessed podocyte 
dedifferentiation it is noteworthy that these "dedifferentiated podocytes" had lost expression 
of WT-1, GLEPP, synaptopodin and podocalyxin. Some cells were seen that had detached from 
the GBM, and these cells did not express podocyte markers but rather demonstrated 
characteristic features of macrophages 41;42. Thus, it can not be excluded that some of the 
cells, present in cellular lesions in human collapsing FSGS, originate from proliferating PECs. 
Contribution of PECs to cellular lesions in human collapsing FSGS has been previously 
proposed by other authors on the basis of positive staining for cytokeratin 38. We also need to 
consider the possibility that FSGS lesions may develop differently in mouse as compared with 
humans. In mouse glomeruli, proximal tubular epithelial cells are present within the 
glomerulus close to the urinary pole. It can not be excluded that proximal tubular epithelial 
cells proliferate and influence FSGS development. The fact that in our mice FSGS lesions 
develop not only close to the urinary pole, but also in the perihilar region argues against this 
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possibility. Nevertheless, the existence of proximal tubular epithelial cells within Bowman's 
capsule in mice complicates any analysis of glomerular cell changes. 
The finding that cellular lesions in our model are of PEC origin does not preclude an 
important role for the podocyte in the development of FSGS lesions. The initial bridge 
consists of a hypertrophic podocyte that attaches to PECs or comes into contact with 
Bowman’s capsule. Attachment of a hypertrophic podocyte to PEC or appositioning to 
denuded Bowman’s capsule may be the critical event that leads to an FSGS lesion. In this 
respect, our findings partly resemble crescent formation in a mouse model of crescentic 
glomerulonephritis 39. These authors observed that podocyte bridges between the capillary 
tuft and Bowman's capsule precede the development of crescents. Of note, in this model PEC 
injury with gaps between the PECs and areas of denuded Bowman's capsule was not observed. 
The authors suggest that the bridging podocyte is critically involved in regulating proliferation 
of PECs. In our model a similar effect may then be responsible for the proliferation of the 
PECs that we observed. Le Hir et al. suggested that the podocyte produced basement 
membrane-like material that formed in continuity with the Bowman's capsule. However, this 
conclusion was based on staining for collagen IV with a polyclonal antibody, which does not 
allow to differentiate between different α-chains. Our findings clearly prove that the 
adhesion is made up of Bowman's capsule like material. In Figure 7 we have proposed a 
scheme for the sequence of events that ultimately lead to FSGS in our model.  





Figure 7. Hypothetical sequence of events leading to cellular FSGS lesions in the Thy1.1 tg mice, illustrated in
schematic drawings. (A) (day 1-7) Injury of the glomerular epithelial cells. Podocytes (green) show foot process
effacement and microvillous transformation (not illustrated). There is no podocyte detachment. PECs (blue) show
vacuolisation and detachment leading to “bare” segments of Bowman's capsule (Bowman's capsule is drawn as a gray
line). (B) (days 3-7) Podocytes become hypertrophic (with activated nuclei, resorption droplets and pseudocysts) and
form bridges between the glomerular tuft and Bowman's capsule. (C) (days 6 and 7) Proliferation of PECs adjacent to
the bridging podocytes, filling up Bowman's space, giving the appearance of a cellular FSGS lesion. (D) The proliferating





How to reconcile both models with human data? As mentioned above, the classical 
pathway of FSGS as described by Kriz and coworkers in rat models of hypertrophy and 
hypertension may best fit with secondary FSGS. Our model may bear more resemblance to 
primary FSGS. This needs to be further investigated using human renal biopsy material. 
Notably, PEC damage in biopsies from patients with FSGS is frequently observed 43-45 and 
possibly caused by protein overload.  
 In conclusion, PECs play an important role in the formation of cellular FSGS lesions in 
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Glomerular diseases are caused by multiple mechanisms. Progressive glomerular 
injury is characterized by the development of segmental or global glomerulosclerosis 
independent of the nature of the underlying renal disease. Most studies on glomerular disease 
focus on the constituents of the filtration barrier (podocytes, GBM, endothelial cells) or the 
mesangial cells. Little attention is given to the epithelial cells lining Bowman’s capsule the so 
called parietal epithelial cells (PECs). This “lack of attention” is partly explained by the 
presumed “passive” function of PECs in normal glomerular physiology. PECs are large, 
flattened cells, which cover Bowman’s capsule in a single cell layer and form a barrier 
between the ultrafiltrate and the periglomerular interstitium. A more important reason has 
been the lack of an established primary role for the parietal epithelium in glomerular 
diseases. However, in recent years, several studies have demonstrated that PECs are involved 
in extracapillary proliferation. In addition, PECs can become highly active, proliferating cells 
expressing many growth factors, chemokines, cytokines and their receptors. It was recently 
demonstrated that PECs are also involved in the development of focal segmental 
glomerulosclerosis (FSGS).  
In this review we summarize the current state of knowledge on the parietal epithelial 
cell, with emphasis on the role of PECs in the development of FSGS. 
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The PEC in nephrogenesis 
 
Progressive glomerular injury is characterized by the development of segmental or 
global glomerulosclerosis independent of the nature of the underlying renal disease 1. Most 
studies on glomerular disease focus on the constituents of the filtration barrier (podocytes, 
GBM, endothelial cells) or the mesangial cells. Less attention is given to the epithelial cells 
lining Bowman’s capsule the so called parietal epithelial cells (PECs). The parietal epithelial 
cells are flattened inconspicuous cells that appear ”pressed against” Bowman’s capsule and 
were for the first time described by Sir William Bowman (1812-1891) in 1842 2. PECs emerge 
during nephrogenesis as the result of a remarkable transitional process in which mesenchymal 
cells of the blastema become polarized to form the nephric epithelium. The differentional 
process of renal epithelial cells is extremely complex and involves interplay of various 
extracellular matrix (ECM) glycoproteins, ECM degrading enzymes and their inhibitors, cell 
adhesion molecules, growth factors and their receptors, and proto-oncogenes. The key 
molecular events that direct differentiation of stromal cells towards one of the highly 
specialized epithelial cells of the nephron are still poorly defined.  
The PEC is one of approximately 15 epithelial cell types derived from the metanephric 
mesenchyme 3;4. In nephrogenesis, after mesenchymal to epithelial differentiation, 
presumptive PECs and podocytes share a common phenotype until the S-shaped body stage. In 
between the late S-shaped body stage and the capillary loop stage, when endothelial and 
mesangium cells also start to differentiate, PEC and podocyte phenotype diverges. Podocytes 
continue to express WT-1 and begin to express vimentin instead of cytokeratin. In contrast 
PECs lose WT-1 and continue to express cytokeratin. This divergence of the phenotype is also 
reflected by the fact that CD10 is not expressed until the capillary loop stage, when PECs 
become CD10 positive and podocytes remain negative (Figure 1). In addition, podocytes no 
longer express proliferation markers (eg. proliferating cell nuclear antigen) whereas PECs do 
5-7. The common embryonic origin of PECs and podocyte complicates the clear-cut 

































Figure 1. Expression of WT-1 and CD10 in developing mouse glomeruli. 
WT-1 can already be detected in the earliest histologically definable glomerular stage of development, the comma-
shaped body (WT-1; asterisks). In the S-shaped body stage WT-1 staining can be observed in both the developing
podocytes (arrowhead) and PECs (arrow). In the capillary stage and in mature glomeruli PECs have lost WT-1
expression (arrows), whereas podocytes continue to express WT-1 (arrowheads). CD10 expression cannot be detected
in the comma-shaped and s-shaped body stage. CD10 expression commences in the capillary stage and is restricted to
PECs (arrows). For color figure see appendix. 
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PECs and glomerular disease 
 
One of the earliest reports on involvement of PECs in glomerular disease came from 
Gaffney and Panner 8;9 who noted abnormal appearance (prominence) of PECs as defined by 
cuboidal appearance, enlarged nuclei and vacuolation, in a number of different glomerular 
conditions. For membranous glomerulopathy they could show an association between 
prominent PECs and poor prognosis. They invariably found prominent PECs in biopsy 
specimens containing cellular crescents, which suggested that prominent PECs and crescents 





Involvement of PECs in glomerular disease is best established in crescentic 
glomerulonephritis. Crescent formation is a highly predictive parameter of adverse renal 
prognosis, irrespectively of the underlying kidney disease 10;11. A cellular crescent consists of 
a multilayered accumulation of cells in Bowman’s space and is usually the result of an 
inflammatory process.  The cellular composition of crescents has been a matter of debate and 
views have changed over time. Initially, it was postulated on the basis of the ultrastructure 
that crescents originate from proliferation of glomerular parietal epithelial cells 12-14. Later, 
studies demonstrated the presence of macrophages in crescents. Nonetheless, the majority of 
cells in crescents have been shown to stain for epithelial markers (eg. cytokeratin, PGP9.5, 
pan-cadherin), indicating that PECs are the predominant cell type in crescents 15-18. The 
cellular composition of crescents appears to change over time, with predominantly 
proliferating glomerular epithelial cells in early stages of crescent formation 19. In later stages 
infiltrating macrophages, lymphocytes and myofibroblasts are numerous, especially when 
Bowman’s capsule is ruptured 20-22.  PECs play an active role in the progression from cellular- 
to late fibrous- crescents. PECs produce C-C chemokines, monocyte chemoattractant protein-
1 (MCP-1) and macrophage inflammatory protein-1α and β (MIP-1α and MIP-1β), which are 
major chemoattractants for monocytes and the CXC-chemokine interleukin 8 (IL8) a 
chemokine that directs neutrophil infiltration and transmigration into peri-glomerular and 
intraglomerular spaces 23;24. In addition, PECs in crescents up-regulate expression of the 
adhesion molecules ICAM, VCAM and CD44, ligands of the leukocyte selectins and integrins, 
which may also contribute to the recruitment and adhesion of monocytes and macrophages 
into the urinary space 25-27.  
PECs also play an important role in the scarring of crescents. PECs produce 
extracellular matrix molecules like fibronectin and collagen I, III and IV 28-31. In addition PECs 




macrophages and myofibroblasts and presumably also on the PECs themself, in an autocrine 
fashion. PECs produce and express the receptors for platelet-derived growth factor (PDGF)-
BB, basic fibroblast growth factor (FGF)-2, transforming growth factor (TGF)-β and connective 
tissue growth factor (CTGF) 30;32-38.  
Taken together, studies on glomerular crescents have shown that the PEC can become 
a highly activated cell that proliferates and plays an active role in the formation and 
progression of crescents.  
Despite the numerous studies showing PEC involvement in inflammatory glomerular 
diseases, in non-inflammatory glomerular disease PECs have generally been considered to be 
“innocent bystanders“. Nevertheless, epithelial hyperplasia and sometimes pseudo-crescent 
formation can be observed in a number of non-inflammatory conditions and most notably in 
FSGS. In fact, lesions in FSGS with prominent epithelial hyperplasia may resemble cellular 




Focal segmental glomerulosclerosis 
 
FSGS is one of the most common glomerular diseases 39. FSGS is characterized by the 
focal and segmental occurrence of lesions with mesangial sclerosis, obliteration of glomerular 
capillaries with hyalinosis and intracapillary foam cells, adhesions between the glomerular 
tuft and Bowman’s capsule, and podocyte hypertrophy 40. FSGS is not a disease entity, but 
rather a pattern of injury with quite diverse clinical behavior, morphology, and possibly also 
pathogenesis 1. Morphology of FSGS lesions is diverse. Recently, various morphological 
variants have been defined and a classification has been proposed to better address this 
diversity 41. Five light microscopic variants of FSGS were defined: the perihilar variant (lesions 
predominantly located at the vascular pole), the tip variant (the presence of lesions located 
at the urinary pole), the cellular variant (characterized by endocapillary hypercellularity), 
the collapsing variant (collapse of the glomerular tuft associated with epithelial cell 
hypertrophy and hyperplasia), and finally FSGS not otherwise specified (NOS) if lesions do not 
fit into one of the above mentioned categories. All morphological variants are accompanied 
by some degree of epithelial hyperplasia, being minimal or absent in the perihilar variant and 
sometimes very prominent in the cellular and collapsing variant.  
The pathogenesis of FSGS has been the subject of many studies. Initially, FSGS was 
considered to be the consequence of mesangial cell injury due to mesangial overload, 
followed by mesangial cell proliferation and increased production of extracellular matrix 42-45. 
More recently, focus has turned strongly toward the podocyte46-48. This switch has mainly 
been brought about by the discovery of mutations in podocyte proteins, such as nephrin, 
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podocin and α-actinin-4 in familial FSGS 49-52. Since segmental scarring of glomeruli can be 
observed in many glomerular diseases it was initially postulated that the pathogenesis of FSGS 
follows one common pathway. Numerous studies in various rat models of FSGS have addressed 
the pathogenesis of FSGS 53-59. These studies resulted in the proposal of the following 
sequence of events that ultimately leads to FSGS: 1) podocyte injury resulting in podocyte 
loss with denudation of the GBM, 2) adherence of the parietal epithelial cell (PEC) to the 
naked GBM, 3) formation of an adhesion between the GBM and Bowman's capsule, and 4) 
misdirected filtration of proteins into the periglomerular and peritubular space 46;60;61. 
However, all these studies by Kriz and co-workers were performed in animal models in which 
a common feature was glomerular hypertension with capillary ballooning and the 
development of hypo-cellular FSGS lesions. Therefore, the above mentioned 
pathophysiological mechanism may not apply to FSGS in general. Currently, it is believed that 
epithelial cell hyperplasia in glomeruli is an alternative mechanism leading to 
glomerulosclerosis, as recently reviewed by Kriz and Le Hir 62. Studies on the pathogenesis of 
FSGS lesions with prominent epithelial hyperplasia in humans have mainly focused on 
idiopathic or HIV-associated collapsing FSGS. In collapsing FSGS the proliferating epithelial 
cells are considered to be of podocyte origin as they cover the glomerular tuft and 
connections to Bowman’s capsule appear to be lacking. This led to the concept of the 
dysregulated podocyte 63. Dysregulated podocytes are characterized by loss of all podocyte 
markers, including the transcription factor WT-1, which is expressed very early on in 
embryonic glomerular development. In addition, podocytes start to express markers that are 
not normally seen in podocytes, such as cytokeratin 64, PAX2 65 and CD68 66;67. Podocyte 
dysregulation was also observed in a transgenic mouse (Tg26), in which several genes of the 
HIV genome are ectopically expressed in tubular and glomerular epithelial cells. Therefore, it 
was proposed that in HIVAN the expression of HIV genes leads to dedifferentiation and 
dysregulation of podocytes. It was also proposed that dysregulated podocytes are no longer 
growth restricted and have regained the ability to proliferate, causing epithelial hyperplasia. 
The observation that podocytes transfected with specific HIV genes (Tat or Nef-1) proliferate 
in vitro, supports this 68;69.  
Based on these findings, epithelial hyperplasia, which is also commonly observed in 
FSGS other than the collapsing variant, is generally considered to be the result of 
proliferation of dedifferentiated podocytes. However, data from the literature is conflicting. 
As described above, in vitro studies showed that incorporation of HIV–1 Nef induces 
proliferation of podocytes. In contrast, podocyte specific expression of HIV-1 Nef in mice did 
cause podocytes to enter the cell cycle, but mitosis was not completed, hence there was no 
proliferation 70. Podocytes entering the cell cycle without completion of mitosis is also 
observed in rats with experimental membranous nephropathy and may therefore be a rather 




that the epithelial cells that proliferate in collapsing FSGS are not podocytes but PECs. We 
have studied the development of FSGS in Thy-1.1 transgenic mice. Thy-1.1 transgenic mice 
carry a mouse-human chimaeric transgene that causes ectopic expression of the mouse Thy-
1.1 antigen on podocytes 72;73. Injection of mAb directed against the Thy-1.1 antigen induces 
FSGS lesions with prominent epithelial cell hyperplasia that resemble human collapsing FSGS 
74. As the Thy-1.1 transgene was relatively stably expressed in these mice the involvement of 
the podocytes in lesions with epithelial hyperplasia could be studied. Dedifferentiation of 
podocytes occurred, as shown by the loss of synaptopodin and ASD33 (an unidentified cell 
membrane antigen strongly expressed on mouse podocytes). The proliferating epithelial cells 
in Bowman space were negative for all tested podocyte markers, including Thy-1.1 and 
stained positive for CD10, which in mouse is a PEC marker expressed from the precapillary 
stage onwards (Figure 1). The extracellular matrix (ECM) produced by the proliferating 
epithelial cells stained identical to Bowman’s capsule in stainings for different heparan 
sulfate species and for collagen (IV) α2 (Figure 2).  
From these findings we concluded that PECs rather than podocytes proliferate. A 
recent study by Asano and co-workers confirmed these findings75. These authors generated 
transgenic mice with podocyte specific expression of CD25 and LacZ, driven by the Nphs-1 
promotor. Injection of LMB2, an immunotoxin against the podocytic CD25 antigen caused 
podocyte injury characterized by vacuolar degeneration of podocytes, hyalinosis and 




Figure 2. Phenotype of proliferating cells in experimental FSGS Thy-1.1 mouse model.  
In panel A and B a collapsing FSGS lesion with prominent epithelial proliferation is shown. Panel A shows staining for
Thy-1.1 (green) and anti heparan sulfate antibody HS4E4 (red). Nuclei are stained with TO-PRO-3 (blue staining). Panel
B shows staining for CD10. Accumulating cells in Bowman’s space are negative for Thy-1.1(panel A, asterisks) and stain
strongly positive for CD10 (arrow, panel B). The newly deposited ECM by the cells in Bowman’s space (arrows, panel A)
stains positive for HS4E4 as does Bowman’s capsule. For color figure see appendix. 
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found no evidence for proliferation or transdifferentiation of podocyte-derived cells but did 
find proliferating PECs migrating onto the glomerular tuft. A third study by Zhong et al 
reached similar conclusions 76. In this study in HIV13FBV mice, which express HIV-1 genes in 
podocytes, prominent cell proliferation was observed in Bowman's space. The extracapillary 
proliferating cells were adjacent to the parietal epithelial epithelium lining Bowman's capsule 
and were often positive for Ki-67 and cytokeratin. In contrast, the cells adjacent to the GBM 
were rarely positive for Ki-67 and no cells were found doubly positive for synaptopodin and 
Ki-67. From their observations the authors concluded that most proliferating cells in 





From the above cited experimental data the question arises whether in human FSGS 
the proliferating epithelial cells, considered to be dysregulated podocytes, may also be 
derived from the parietal epithelium. We conducted phenotypic analysis of the proliferating 
epithelial cells in a nephrectomy specimen with recurrence of idiopathic FSGS after 
transplantation 77. In this patient the proliferating epithelial cells in Bowman’s space stained 
positively for all PEC markers, did not express podocyte markers and deposited ECM that 
stained as Bowman’s capsule, arguing that they derive from the parietal epithelium (Figure 
3). Obviously, the validity of marker analysis to determine cell origin can be questioned in 
view of possible de-differentiation accompanied by neo-expression by podocytes of antigens 
commonly found on PECs, especially since PECs and podocytes share a common embryonic 
origin. However, in the latter study an extra argument was provided by 3-Dimensional analysis 
of the glomeruli. It was shown that, in the absence of cell-bridges between Bowman’s capsule 
and the glomerular tuft, PECs covering Bowman’s capsule acquired the CK8 positive 
phenotype prior to proliferation. In addition, in glomeruli with epithelial proliferation CK8 
positive cells on the tuft were always in continuity with CK8 positive cell lining Bowman’s 
capsule 77 (Figure 4). These data are in agreement with the findings in studies by Nagata et 
al. and Kihara et al. In these studies it was suggested that PECs identified by their cytokeratin 
expression, contribute to the hypercellular lesions in patients with idiopathic FSGS 78-80. On 
basis of these studies it can be concluded that PECs proliferate and play a role in the 













Figure 3. Phenotype of the epithelial cells in Bowman’s space in human FSGS.  
Panel A shows a series of consecutive sections of a glomerulus with collapsed capillaries, pronounced epithelial 
hyperplasia and endocapillary foam cells. The sections are stained for synaptopodin, CK8 and PAX-2. The epithelial 
cells in Bowman’s space are positive for CK8 and PAX-2, but negative for synaptopodin. In affected segments 
synaptopodin is lost. 
Panel B shows immunofluorescence staining on sections of glomeruli with glomerular tuft adhesions (arrowheads).
The sections are stained for specific heparan sulfates species recognized by the single chain antibodies HS4C3 and 
HS4E4. The glomerular tuft adhesions are negative for HS4C3, which stains the mesangial ECM and the GBM. In









Figure 4. Parietal epithelial cells (PECs) “invade” the glomerular tuft. 
Panel A shows five of the sections used for the 3-Dimensional reconstruction in panel B. CK8-positive cells, whether 
positioned at the outer aspect of the tuft or more centrally in the glomerulus (arrowheads), are always in continuity with 
the CK8-positive layer of PECs lining Bowman’s capsule (arrow).  
Panels B and C show three-dimensional reconstructions of two glomeruli illustrating that CK8-positive cells (red) are in 
continuity with CK8-positive cells lining Bowman’s capsule (green). Note that not all PECs lining Bowman’s capsule are







Collapsing glomerulopathy (CG) is described as a clinically and pathologically distinct 
variant of FSGS characterized by black racial predominance, massive proteinuria, and 
relatively rapid progressive renal insufficiency 81;82. CG is pathologically characterized by 
segmental to global collapse of the capillary tuft, and pronounced epithelial cell hyperplasia. 
This pattern has been described in HIV-associated nephropathy 83, parvovirus B19 infection 84, 
pamidronate toxicity 85;86 and also in some patients with idiopathic FSGS 81;87;88.  
As discussed earlier the concept of the dysregulated podocyte was proposed by 
Barisoni et al in a study on collapsing idiopathic FSGS and HIV-associated nephropathy 63. In 
the absence of expression of podocyte markers, the authors identified the proliferating cells 
as podocytes based on their localization on top of the tuft, without an apparent connection to 
Bowman’s capsule. However, in a recent review it was clearly pointed out that the absence of 
cell bridges between the glomerular tuft and Bowman’s capsule is not a very good criterion 
without proper three dimensional analysis 89. The question arises whether in collapsing FSGS 
dysregulated podocytes proliferate or PECs proliferate, as in non-collapsing FSGS. 
We addressed this question in a study examining the phenotype of the proliferating 
epithelial cells in two renal biopsies from patients with HIV associated collapsing FSGS 90. We 
did observe dedifferentiation of the podocytes as illustrated by the loss of podocyte markers 
synaptopodin and CD10. However the majority of the proliferating epithelial cells in 
Bowman’s space were positive for CK8. Furthermore, cell bridges were found in serial 
sections and double stainings for CD10/CK8 and synaptopodin/CK8 demonstrated residual 
podocytes among CK8 positive cells but no co-expression of a podocyte markers and CK8. 
Based on these findings it was concluded that the proliferating cells in HIV associated 
collapsing FSGS were PECs (Figure 5). In summary, the proliferating cells in Bowman’s space 
in human idiopathic FSGS and HIV associated collapsing FSGS appear to be derived from the 
parietal epithelium. Since the proliferating PECs produce and deposit the newly formed 
extracellular matrix that leads to scarring, it can be concluded that PECs play an important 
role in the progression of human FSGS. It is important to emphasize that these studies do not 
dispute the fact that in the chain of events that leads to FSGS it is the podocyte that is 
initially injured, causing proteinuria. In addition, this data does not exclude the possibility 
that PEC proliferation is a secondary phenomenon aiming at replacing damaged or injured 
podocytes. However, the data challenges the concept that epithelial proliferation subsequent 











Figure 5. Phenotype of proliferating epithelial cells in HIV associated nephropathy. 
Panels A to F show consecutive sections of two glomeruli with collapse of the glomerular tuft and epithelial cell
hyperplasia (asterisks). Panel B shows CK8 immunostaining. CK8 positive cells cover segments of Bowman’s
capsule (arrow) and the capillary tuft in areas of epithelial cell hyperplasia (arrowheads). Panel C shows prominent
cell proliferation as confirmed by Ki-67 (D, arrow). These proliferating cells and the cell lining Bowman’s capsule
stain positive for PAX-2 (E, arrows). Affected glomeruli showed segmental to global loss of synaptopodin (F). For







It has become clear that despite its histological diversity FSGS begins as a podocyte 
disease and that in the disease process FSGS lesions can evolve from cellular to scar lesions 
74;91-93. In view of this potential progression of FSGS lesions over time it can be questioned if 
the different morphological variants of FSGS are pathogenetically different (different 
cellular/molecular mechanism and/or different underlying cause) or a reflection of activity 
and chronicity of the disease process. By serial sectioning of involved glomeruli in a 
nephrectomy specimen of a patient with a recurrence of idiopathic FSGS it was shown that 
collapsing lesions, lesions with prominent epithelial hyperplasia, and sclerosing lesions co-
occur. Moreover, within a single glomerulus both collapsing and sclerosing areas could be 
seen 77. In addition, Howie and coworkers, demonstrated that FSGS (NOS) can evolve from a 
tip lesion 94. These findings show that the morphologic appearance of an FSGS lesion can be a 
reflection of developmental stage rather than underlying cause.  On the other hand, we know 
there are associations between underlying cause and morphological appearance of FSGS as for 
instance the perihilar variant of FSGS is often seen secondary to glomerular hyperfiltration 
and collapsing FSGS is associated with HIV infection. This leaves us with the complex situation 
in which morphological appearance of FSGS lesions in a biopsy can be a reflection of both 
activity/developmental stage of the disease and underlying cause. This raises the issue of 
clinical relevance of identifying FSGS variants. So far, only two studies have investigated a 
possible relation between morphology of FSGS lesions and outcome. Chun and co-workers 
evaluated differences in presentation, response to therapy, and clinical outcomes in a 
retrospective analysis of 87 nephrotic adult patients with biopsy-proven primary FSGS. 
Patients were categorized on basis of histological criteria, and patients with either classical 
scars, cellular/collapsing lesions, or tip lesions were compared.  The authors observed that 
patients with collapsing FSGS had more severe proteinuria. The conclusions with respect to 
outcome were influenced by treatment bias. In fact, when only considering treated patients 
they showed that the remission rate after treatment was similar among patients with the 
different histologic variants. Thus Chun et al concluded that the response to therapy could 
not be predicted on the basis of histology alone and that in nephrotic adults with primary 
FSGS, the response to therapy remains the best prognostic indicator of outcome irrespective 
of the histologic subclassification 95. A somewhat different conclusion was reached by Thomas 
et al who studied 197 patients with biopsy-proven FSGS. They observed significant differences 
in patient demographics, clinical features at the time of biopsy, and renal outcomes. 
Specifically, patients with collapsing FSGS (predominantly black patients) and patients with 
the tip variant (mainly Caucasian) had higher proteinuria and lower serum albumin than 
patients with the perihilar and NOS variants. Prognosis was poor in patients with collapsing 
FSGS 96. These findings and the absence of a difference in chronicity in the initial renal 
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biopsies led these authors to conclude that the various histological subclasses represent 





This review illustrates that PECs are not innocent bystanders in experimental and human 
FSGS, but play an important role in both development and progression. This conclusion is 
based on findings that are largely descriptive, and underlying cellular and molecular 
mechanisms are unknown. Cell biological studies on PECs and their interplay with neighboring 
cell types under both normal and pathophysiological conditions are needed. This knowledge 
will provide a better understanding of critical events in development of FSGS and may result 
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Thy-1.1 tg mice develop hypercellular FSGS lesions that mimic human collapsing FSGS, 
in 7 days after injection with anti-Thy-1.1 antibodies. These lesions consist of proliferating 
parietal epithelial cells (PECs). We questioned if the ACE-inhibitor captopril could prevent the 
development of FSGS and if protection is related to the timing of drug administration. 
First, we compared the effect of captopril treatment to angiotensin II (ANGII) 
independent antihypertensive therapy (triple therapy). Secondly, we tested the effects of 
captopril administered over 4 different time intervals: day -7-0 (Ca-7>0), day -7-7 (Ca-7>7), day 
0-7 (Ca0>7) and day 3-7 (Ca3>7) (day 0 being the day of injection of the antibody).  
In anti-Thy-1.1 injected control mice (C) we observed dedifferentiation and activation 
of podocytes, reflected by loss of ASD33 and increased expression of desmin, followed by a 
marked accumulation of PECs forming hypercellular lesions. PEC’s showed an increased 
expression of CTGF. Triple therapy or captorpil pre-treatment (Ca-7>0) had no significant 
effect on albuminuria or FSGS. In contrast, Ca0>7 and Ca3>7 treatment significantly lowered 
albuminuria and attenuated development of FSGS. Latter two treatments attenuated loss of 
ASD33 expression by podocytes but could not prevent increased desmin expression. In 
addition, these treatments reduced CTGF expression by PECs and prevented PEC 
proliferation. 
In conclusion, ACE inhibition but not triple therapy prevents the development of 
FSGS, suggesting an important role for ANGII. ACE inhibition has a protective effect even 
when started 3 days after the initial podocyte insult, which is probably related to the ability 




Focal and segmental glomerulosclerosis (FSGS) has become one of the most common 
patterns of glomerular injury encountered in human renal biopsies. According to the first 
descriptions FSGS was characterized by the focal and segmental occurrence of lesions that 
consisted of (combinations of) mesangial sclerosis, obliteration of glomerular capillaries with 
hyalinosis and intracapillary foam cells, formation of adhesions between the glomerular tuft 
and Bowman’s capsule, and podocyte hypertrophy. FSGS is not a disease entity, but rather a 
pattern of injury with quite diverse clinical presentation, morphology, pathogenesis and 
response to treatment 1.  
During the last two decades, the renoprotective effects of angiotensin converting 
enzyme inhibitors (ACEi) in the treatment of glomerular disease have been extensively 
studied and are increasingly appreciated in the treatment of progressive and chronic 
nephropathies including secondary forms of FSGS associated with hypertension and structural 
adaptive changes of the glomerulus. Although studied to a lesser extent, the salutary effects 
of ACEi have also been shown in patients with primary FSGS. Guidelines for the treatment of 
nephrotic and non-nephrotic patients with primary FSGS include good blood pressure control 
and the use of ACEi (and/or angiotensin II type I receptor antagonists) 2.  
These effects are attributed to the reduction in angiotensin II (ANGII) formation. 
Recent studies have provided evidence that the effects of ACE inhibitors cannot simply be 
explained by their effects on systemic blood pressure, since other antihypertensive drugs 
have not been equally effective 3. It has been suggested that the superiority of ACE-inhibitors 
may be explained by their specific effects on intraglomerular pressure, and subsequent 
reduction of proteinuria. In addition many studies have shown that angiotensin II (ANGII) is 
not merely a vasoactive agent but also is a true profibrotic cytokine capable of inducing 
extracellular matrix (ECM) production, inhibition of ECM degradation and induction of cellular 
growth by either proliferation or hypertrophy 4. The profibrotic effects of ANGII are 
predominantly mediated by induction of other cytokines or growth factors, like Platelet 
Derived Growth Factor (PDGF), Transforming Growth Factor (TGF-β) and Connective Tissue 
Growth Factor (CTGF). CTGF is a down-stream mediator of TGF-β, of which the latter is 
considered to be the most potent profibrotic cytokine in the kidney 4. Unfortunately, the 
possibility to study the mechanisms by which ACEi provide renoprotection is limited due to 
lack of good animal models for primary FSGS.  
Recently, we have described a mouse model of FSGS that resembles primary FSGS. We 
have used Thy-1.1 transgenic (tg) mice 5. These mice ectopically express the Thy-1.1 antigen 
on podocytes and develop massive albuminuria after injection of anti-Thy-1.1 antibodies. The 
albuminuria peaks at 4 to 8 hrs after antibody injection and persists for weeks 6. The 




have described the development of FSGS in this mouse model in detail 5. In brief, affected 
glomeruli initially show segmental to global collapse of the capillary tuft followed by a 
marked increase of epithelial cells in Bowman’s space at day 3-7. The first FSGS lesions with 
tuft adhesions to Bowman’s capsule are seen at day 6-7. Early lesions resemble the collapsing 
variant of human FSGS. Previously, we showed that the hypercellular lesions originate from 
proliferating parietal epithelial cells (PECs) and we concluded that PECs play a crucial role in 
the development of these lesions 5. Involvement of PECs in the development of hypercellular 
FSGS lesions was recently confirmed in two other mouse models of collapsing FSGS 7;8, in a 
study on a nephrectomy specimen of a patient with recurrence of idiopathic FSGS 9 and in two 
renal biopsies from patients with HIVAN 10.    
 In the present study we examined whether ACE inhibition by captopril is more 
effective than ANGII independent anti-hypertensive treatment in preventing the development 
of collapsing FSGS. Furthermore, we questioned whether protection was related to the timing 
of drug administration, and evaluated the role of PECs and podocytes by analyzing their 








Heterozygous Thy-1.1 transgenic mice (T6, T-construct mice were generated by 
injecting a hybrid human-mouse Thy-1.1 gene into pronuclei of zygotes of Thy-1.2 CBA x 
C57BL/10 mice 11. These mice express the Thy-1.1 gene abnormally in podocytes, resulting in 






For in vivo experiments a mouse anti-mouse Thy-1.1 mAb (19XE5: subclass IgG3) was 
used. 19XE5 was generated in vitro, by hollow fibre culture, purified by protein-A column 
affinity chromatography and concentrated (Nematology Department, Agriculture University 





Five-week old Thy-1.1 transgenic mice received an intravenous injection with 1 mg 
anti-Thy-1.1 mAb (19XE5) in 0.1 ml 0.9% saline solution. Transgenic mice injected with 0.1 ml 
0.9% saline solution alone were used as controls. Mice of different groups received treatment 
as depicted in the experimental designs (Figures 1 and 2). The Ca-7>0 and Ca-7>7 mice were 
sacrificed at day 8. Urine of these mice was sampled at day 7. The saline, C, Ca0>7 and Ca3>7 
mice were devided in three groups. The first group was sacrificed at day 6 to examine the 
effect of captopril treatment on PEC proliferation (Figure 6). Groups 2 and 3 were sacrificed 
at day 8 or day 22, respectively. Latter groups were used to study the albuminuria and FSGS 
score in either the first week or the following two weeks. The 18 hrs urine samples were 
collected at days 7, 14 and 21 after the anti-Thy-1.1 mAb injection. Tissues were collected at 
day 8 or day 22. The captopril treated mice received captopril via drinking water (400 mg/L 
Capoten® 50, Bristol Myers Squibb b.v. Woerden, The Netherlands). Triple therapy was also 
administered via drinking water (25 mg/L atenolol, 25 mg/L hydrochlorothiazide and 80 mg/L 
hydralazine, Sigma-Aldrich, St. Louis, MO, USA). The different treatment groups (Figure 1A, 
2A) consisted of comparable numbers of female and male mice. There were no differences in 
albuminuria and FSGS scores between male and female mice within the groups. Throughout 




(drug containing) drinking water. Urine albumin in 18 hrs urine was measured by radial 
immunodiffusion using a goat antiserum against mouse albumin. The 18 hrs urine samples 
were collected by placing the animals individually in metabolic cages. During their 
confinement in the metabolic cages the mice had only access to tap water. To prevent 
dehydration during their confinement in the metabolic cages, the mice received 1 ml 0.9% 
saline by an intra-peritoneal injection.  
 
 
Systemic blood pressure measurements 
 
The effect of treatment on blood pressure was evaluated in separate experiments. 
For systemic blood pressure measurements mice were anaesthetized with a mixture of 
isofluorane and oxygen. After anaesthetization, the abdomen was opened. A 19 mm 24 gauge 
NeoflonTM catheter (Becton Dickinson, Helsingborg, Sweden) was inserted in the aorta just 
above the aortic bifurcation. The catheter was connected to a pressure transducer (Hewlet 
Packard, Palo Alto, CA, USA) and after a 3-5 min stabilization period the mean arterial 
pressure was monitored during a 5 min period in which the mice was just reactive on 
stimulation of the foot reflex. After the measurement the mice were killed by cervical 
dislocation. 
The committee of animal experiments of the Radboud University Nijmegen approved 
all conducted animal experiments. 
 
 
Light microscopy  
 
For light microscopy, kidney fragments were fixed in Bouin’s solution, dehydrated, 
and embedded in paraplast (Amstelstad, Amsterdam, The Netherlands). 4 µm sections were 
stained with periodic acid-Schiff (PAS), and 2 µm sections with silver methenamine. To obtain 
the FSGS-score at least 60 glomeruli per mouse were evaluated. Only lesions with an adhesion 





Immunohistochemical staining was performed on kidneys, fixed in 4% buffered 
formaldehyde for 24 hrs and embedded in paraffin. Before every immunolabeling with 
biotinylated secondary antibodies, the tissue sections were treated with an avidin / biotin 
blocking reagent (Vector Laboratories, Burlingame, CA, USA) to block endogenous biotin. 4 
 101
µm sections were incubated with rabbit anti-mouse Ki-67 (Dianova Immundiagnostic, 
Hamburg, Germany), goat anti-CD10 (Vector laboratories Inc., Burlingame, CA, USA). As 
secondary antibodies we used a biotinylated goat anti-rabbit antibody for Ki-67, a horse anti-
goat for CD10 (Vector laboratories Inc., Burlingame, CA, USA). Detection of Ki-67 and CD10 
was carried out using the vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA), 
according to manufacturer’s protocol and by using diaminobenzidine as substrate. For 
quantification of Ki-67 positive cells, the sections were counterstained with Schiff’s reagent 
to stain the glycoproteins in the basal membranes. Positive nuclei within Bowman’s space 
were counted. Per mouse approximately 50 (at least 40) glomeruli were counted in one cross-
section. All quantifications were performed by an investigator who was unaware of 
treatment. To minimize cross-reactivity of the secondary antibodies with endogenous 
immunoglobulins, preabsorption was performed by adding 4% normal mouse serum to the 





Kidney fragments were snap-frozen in liquid nitrogen, and 2 µm acetone fixed serial 
cryostat sections were used. A double-immunolabeling technique was performed to determine 
the co-localization of Thy-1.1 and desmin. Thy-1.1 was detected using a rat polyclonal anti-
Thy-1 antibody (59AD2.2; IgG2a). As secondary antibody we used a FITC labeled sheep anti-
rat antibody (Serotec, Oxford, UK). After washing with PBS, the sections were incubated with 
rabbit anti-desmin12, and detected with a goat anti-rabbit AlexaTM 568 antibody (Molecular 
probes Inc, Leiden, The Netherlands). For detection of the podocyte we also have used 
ASD33, a rat monoclonal antibody, generated in our laboratory, which only reacts with the 
podocyte cell membrane 13. The identity of the antigen is unknown. For the detection of 
ASD33 we have used a FITC-labeled rabbit anti-rat antibody (Dako A/S, Glostrup, Denmark). 
To minimize cross-reactivity of the secondary antibodies with endogenous immunoglobulins, 
preabsorption was performed by adding 4% normal mouse serum to the secondary antibodies. 
In control sections, primary antibodies were omitted. 
 
 
In situ hybridisation 
 
The in situ hybridisation was performed on 4µm paraffin section of kidneys fixed in 4% 
buffered formaldehyde for 24 hrs. A 542 bp cDNA fragment of rat CTGF (Genbank gi5070343 
496-1037) was amplified by PCR and cloned in the PCR2.1-TOPO vector (Invitrogen, breda, the 




RNA polymerases and digoxigenin (DIG)-conjugated UTP (Roche, Almere, The Netherlands) to 
produce DIG-labeled sense or antisense riboprobes, respectively. Hybridisation of the probe 
was detected by an alkaline phosphatase-labeled sheep anti-DIG antibody and visualized with 
nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP). The 
prevalence of PECs and podocytes expressing CTGF mRNA was assessed in a semi-quantitative 
way. For each mouse a single cross section of both kidneys was judged for the presence of 
CTGF expressing PECs and podocytes by an investigator who was unaware of treatment, and a 
score was assigned. The following scale was used: 1 = low, 2 = moderate, 3 = high prevalence 





For multiple comparisons, ANOVA was used and post hoc analyses were done with 
Tukey’s test. Significance of differences between the mean values of the semi-quantitative 
CTGF scores was evaluated using the non-parametric Kruskal-wallis test. A value of P < 0.05 





Animal data  
 
We have assessed the antihypertensive effects of captopril and triple therapy by 
measuring blood pressures in a separate set of anti-Thy-1.1 injected tg mice after 3, 4 and 7 
days of treatment. In control mice mean blood pressure (MBP) was 97 ± 2 mm Hg at day 7 
after the anti-Thy-1.1 mAb injection. This value was not different from blood pressures in 
saline injected Thy-1.1 tg mice (data not shown). The MBP was 89 ± 1 mm Hg (p < 0.01 v C), 
82 ± 1 mm Hg and 73 ± 2 mm Hg (p < 0.001 v control), at day 3, 4 and 7 after start of 
captopril, respectively. Triple therapy resulted in even lower blood pressures with a MBP of 
69 ± 1, 61 ± 3 and 63 ± 5 mm Hg (all days: p < 0.001 v C) at days 3, 4 and 7, respectively 
(Figure 1B).  As expected, injection of anti-Thy-1.1 mAb induced a substantial albuminuria. 
FSGS lesions were observed in 24% of the glomeruli at day 8 (Figure 1C). Almost complete 
protection was observed in mice treated with captopril throughout the study period (day 0 till 
day 7, Ca0>7) (Figure 1C). These effects of captopril cannot be explained merely by the 
reduction of the systemic blood pressure, since triple therapy was less effective and did not 
result in a statistically significant reduction in albuminuria and FSGS (Figure 1C).  
In view of the efficacy of captopril in preventing the development of FSGS we 
questioned if protection was dependent on the timing of drug administration. Therefore we 
tested the effect of captopril administered at different time intervals during the development 
of FSGS lesions, as depicted in figure 2A. Results are depicted in Figures 2B and 2C. Captopril 
pre-treatment from day –7 till the day of injection of the anti-Thy-1.1 mAb (Ca-7>0) had no 
effect on the level of albuminuria nor on the number of glomeruli with FSGS lesions (Figure 
2B). In contrast, if treatment was continued for an additional 7 days (Ca-7>7), albuminuria and 
FSGS were markedly and significantly reduced. A similar effect was obtained with captopril 
treatment from 4 hrs after the anti-Thy-1.1 mAb injection till day 7 (Ca0>7). Remarkably, even 
a delayed start of captopril treatment, resulting in a short period of treatment, from day 3 to 
7 (Ca3>7), significantly reduced albuminuria and FSGS. We have further evaluated the 
persistence of the protective effects of captopril by studying additional groups of mice, 
treated with captopril from day 0-7 or from day 3-7, and sacrificed at day 22.  In these mice 
albuminuria was measured at days 7, 14 and 21 and FSGS lesions were scored at day 22. As 
illustrated in Figure 3, albuminuria gradually decreased in control mice, without further 
increase of FSGS score. In captopril treated mice albuminuria remained unchanged. Notably, 
in these mice there was no progression of FSGS after stopping captopril treatment (Figure 3). 
Thus, the temporary treatment with captopril in the active phase of FSGS development 
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Figure 1. (A) Experimental design I. Captopril treatment (Ca0>7), (400 mg/L captopril in drinking water). Triple
therapy (Tr0>7) consisted of atenolol (25 mg/L), hydrochlorothiazide (25 mg/L) and hydralazine (80 mg/L) in drinking
water. Mice were treated for 7 days from 4 hrs after the anti-Thy-1.1 mAb injection. A third group (C) received the anti-
Thy-1.1 mAb but no treatment. At day 7 the mice were placed in a metabolic cage to collect the urine and at day 8 the
kidneys and blood were collected for further experiments. (B) Mean blood pressure (MBP) at baseline and at days 3,
4 and 7 after start of treatment with captopril or triple therapy. MBP was significantly lower on triple therapy compared
to captopril treatment (a = P < 0.001, b = P < 0.01 compared to captopril treatment). (C) Effect of captopril treatment
and triple therapy on albuminuria and the development of FSGS in anti-Thy-1.1 mAb injected tg mice. Captopril
treatment (Ca0>7) significantly decreased albuminuria and FSGS compared to the non-treated mice (C), P < 0.001.
Triple therapy (Tr0>7) was not able to effectively decrease albuminuria and FSGS compared to non-treated mice (C),
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Figure 2. (A) Experimental design II: Mice received captopril treatment during different time intervals. The saline, C,
Ca0>7 and Ca3>7 mice were divided in three groups. The first group was sacrificed at day 6 to examine the effect of
captopril treatment on PEC proliferation (Figure 6). Group 2 and 3 were sacrificed at day 8 and 22, respectively. Latter
groups were used to study the albuminuria and FSGS score in either the first week (Figure 2B) or the following two
weeks (Figure 3).  
(B) Effect of the different captopril treatment protocols on albuminuria and the development of FSGS in anti-Thy-1.1
mAb injected tg mice. Captopril treatment over the whole period  (Ca-7>7) or starting after the antibody injection (Ca0>7
and Ca3>7) significantly decreased albuminuria and FSGS, a: P < 0.001 compared to non-treated mice (C). Pre-







Affected glomeruli in kidneys of control mice showed segmental or global collapse of 
the capillary tuft and a marked increase of epithelial cells in Bowman’s space (Figure 4). 
Adhesions (continuity of ECM between the capillary tuft and Bowman’s capsule) were formed 
by thin strands of ECM that were located in between the epithelial cells in Bowman’s space. 
Captopril treatment (either from day 0 or day 3 onwards) markedly reduced the severity of 
the lesions, with fewer ECM adhesions and only minor collapse of the glomerular tuft (Figure 
4, Ca3>7). In particular the hypercellular lesions, characteristically observed in Bowman’s 
space of affected glomeruli in C mice, were virtually absent after captopril treatment (Figure 
4, Ca3>7). The few affected glomeruli in the captopril treated mice were primarily situated in 
the juxtamedullary segment of the kidney. The lesions observed in mice sacrificed at day 22 
were more advanced, with a high degree of extracellular matrix accumulation, and the 
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Figure 3. Progression of albuminuria and FSGS: Mice received captopril treatment till day 7. Albuminuria was
measured at day 7, 14 and 21. FSGS was scored at day 8 and 22. Captopril treatment stabilized proteinuria (A) and the
FSGS score (B). a: P < 0,001 vs C, b:  P < 0.05  vs C. 
(A) Day 7: saline n=8, C, Ca0>7 and Ca3>7 n=18. Days 14 and 21: saline n=4, C n=10, Ca0>7 and Ca3>7 n=9. 





In our model albuminuria is induced by injection of mAbs directed against the Thy-1.1 
antigen present on podocytes. We therefore questioned if the initial podocyte injury could be 
the decisive step toward development of FSGS. Pre-treatment with captopril might then be 
protective. However, this approach failed. We next have evaluated the changes in podocyte 
phenotype during development of FSGS in control mice and in mice treated with captopril 
from day 0 or day 3. To this end we have studied the expression of desmin (associated with 
podocyte dedifferentiation or injury) and the podocyte specific marker ASD33 (an 
unidentified cell membrane antigen, strongly expressed on mouse podocytes in Thy-1.1 mice 
and a sensitive marker of podocyte dediffrentiation) at days 3 and 8 after the Thy-1.1 mAb 








Figure 4. Renal histology at day 8. Affected glomeruli in anti-Thy-1.1 injected mice (C) showed segmental or global
collapse of the capillary tuft and, glomerular tuft adhesions (C, arrow) and a marked increase of epithelial cells in
Bowman’s space (C, asterisks). The hypercellular FSGS lesions were virtually absent after captopril treatment.




activated or injured podocytes had lost expression of ASD33 and synaptopodin but could still 
be identified by their expression of WT-1 and the Thy-1.1 antigen 5.   
In C mice we observed increased desmin staining at day 3 after mAb injection, 
compatible with podocyte activation or injury (Figure 5). Captopril treatment started at day 0 
or 3 did not decrease desmin staining (Figure 5). The desmin staining was not exclusively 
present in glomeruli showing collapsed segments or adhesions but was also observed in 
morphologically normal glomeruli.  In C mice we observed a decreased staining of ASD33 at 
day 8, in particular in glomerular segments that contained a tuft adhesion or tuft collapse. 
The percentage of glomeruli with segmental loss of ASD33 staining was equal to the 
percentage of FSGS lesions. In both captopril treated groups we observed significantly less 
glomeruli with decreased ASD33 expression, in agreement with the reduced number of 
glomeruli with FSGS lesions (data not shown). 
 






Figure 5. desmin expression: In saline injected mice there is a faint staining for desmin within the mesangium of the
glomerulus (saline). Anti-Thy-1.1 mAb injected mice showed already at day 3 after the anti-Thy-1.1 mAb injection an
increased desmin staining within the glomerulus but also in peritubular capillaries (C day 3). At day 8 there was a
comparable desmin expression in the glomerular tuft. But in affected glomeruli there was also desmin expression
surrounding Bowman’s capsule (C day 8). Ca0>7 and Ca3>7 mice showed no decrease in desmin expression
compared to the non-treated anti-Thy-1.1 mAb injected mice (Ca0>7, Ca3>7) Original magnification: 200x. To examine
the podocyte specific desmin expression the desmin staining (red) was merged with the Thy-1.1 transgene expression
(green), co-expression results in yellow staining (merge) Original magnification: 400x. For color figure see appendix. 
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Evaluation of proliferation  
 
We have examined the expression of the proliferation marker Ki-67 and the PEC 
marker CD10 in kidneys of mature control and captopril treated mice at day 6 after anti-Thy-
1.1 mAb injection. In the control mice (C) we observed the anticipated increase of Ki-67 cells 
in Bowman’s space, which was absent in the captopril treated mice (Figure 6A, 6B). Of note, 
even captopril started at day 3 resulted in reduced proliferation. We previously demonstrated 
that in our model the proliferating epithelial cells in Bowman’s space are PECs and CD10 
positive (Figure 6C) 5. In C mice we observed accumulation of CD10 positive cells in Bowman’s 
space (Figure 6D), whereas in the captopril treated mice we could no longer detect CD10 





















































Figure 6. (A) Effect of captopril treatment on PEC proliferation. Only Ki-67 positive cells positioned in Bowman’s
space (area depicted by dotted line) were counted. Original magnification: 400x. (B) The number of Ki-67 positive
cells in Bowman’s space was increased at day 6 after the anti-Thy-1.1 mAb injection. This increase was absent in
the captopril treated mice. a: P < 0.01  v saline, b: P < 0.02  v C. 
Panel C - D shows immunohistochemistry for CD10. Immunoreactive cells stain brown. In control mice CD10 is
strongly expressed on PECs (C, arrowhead). In a hypercellular lesion (day 7) epithelial cells in Bowman’s space






We have analysed the effect of captopril treatment on expression of CTGF during 
development of FSGS (Figure 7). Studying of the expression of CTGF mRNA, instead of the 
(secreted) protein, allows us to identify the cell type producing CTGF. In all groups we 
observed a comparable prevalence of podocytes expressing CTGF. CTGF expression by PECs 
was neglectable in the saline treated mice. In contrast, in C mice we observed an increased 
number of PECs expressing CTGF. The expression of CTGF by PECs in these mice was observed 
in glomeruli with FSGS lesions as well as in morphologically normal glomeruli. In the Ca0>7 
mice the number of PECs expressing CTGF was reduced. In the group Ca3>7 the majority of the 
mice showed a moderate reduction in PECs expressing CTGF compared to the C mice.  


































































Figure 7. (A-D) In situ hybridization (ISH) for CTGF mRNA. (A) CTGF mRNA is expressed mainly by podocytes in saline
injected Thy-1.1 transgenic mice. (B arrows) At day 8 after anti-Thy-1.1 injection (C mice) an increased CTGF mRNA
expression by PECs was observed in morphological normal glomeruli. (C) In FSGS lesions we observed a high number of
cells expressing CTGF. Note also a marked CTGF mRNA expression by periglomerular cells surrounding the affected
glomeruli. (D) Captopril treatment reduced the number of CTGF expressing PECs and CTGF mRNA expression was
mainly observed for the podocytes. Original magnification: 400x.  
Panel E shows the CTGF mRNA score (a semi-quantitative assesment of the prevelance of positive PECs). All C mice
show an increased CTGF score. Captopril treatment significantly reduced the CTGF score P<0.005. There was no





The ACE inhibitor captopril reduced albuminuria and almost completely prevented the 
development of FSGS in our anti-Thy-1.1 mouse model. Evidently, captopril was more 
effective than triple therapy. Of note, triple therapy did not lower albuminuria, despite a 
considerable reduction of the systemic blood pressure. This finding, may be explained by the 
possibility that lowering of the systemic blood pressure by triple therapy does not result in an 
equivalent reduction of the intraglomerular blood pressure. Our data, add more evidence to 
the observations in animal models and humans that the beneficial effects of ACEi cannot be 
explained merely by a decrease in systemic blood pressure 3.  
The present data also provide additional evidence for the role of the parietal 
epithelial cells (PECs) in FSGS. In our previous study, we have discussed the role of podocytes 
and PECs in the development of FSGS. In our Thy-1.1 mouse model, we have shown that 
administration of anti Thy-1.1 antibody caused podocyte activation with increased expression 
of desmin; activated podocytes interacted with PECs; PECs started to proliferate from day 3 
onwards and proliferation peaked at day 7. The PECs produced extracellular matrix that leads 
to scarring; podocytes did not proliferate and from day 3 onwards lost podocyte specific 
markers such as ASD33 and synaptopodin but remained WT-1 and Thy-1.1 positive; in 
advanced sclerotic glomeruli WT-1 positive cells were lost 5. In the present study, we 
observed that captopril prevented development of FSGS, despite identical initial podocyte 
activation and desmin staining, which is a marker of podocyte injury or activation 15;16. Thus, 
these findings indicate that captopril does not offer protection thru interference with the 
initial activation of podocytes. This conclusion is particularly strengthened by the observation 
that captopril administered from day 3 onwards, also afforded protection. Renoprotection 
was associated with inhibition of PEC proliferation and reduced loss of ASD33, which is 
indicative of maintenance of podocyte integrity. Both mechanisms may be relevant in the 
renoprotective effects of captopril. Since the proliferative, hypercellular variants of FSGS are 
the most aggressive, we feel that inhibition of PEC proliferation may be most important.  
It remains to be established how ACEi prevents PEC proliferation, either indirectly via 
lowering of intraglomerular blood pressure, reduction of proteinuria and maintenance of 
podocyte differentiation or directly by blocking ANGII mediated cellular proliferation. It is 
well known that ANGII has proliferative and profibrotic effects, likely mediated by growth 
factors such as platelet-derived growth factor (PDGF), plasminogen activator inhibitor type 1 
(PAI-1), transforming growth factor-β (TGF-β) 4 and connective tissue growth factor (CTGF) 17 
In our model, induction of proteinuria was followed by an increased expression of CTGF mRNA 
in PECs, which was largely diminished by captopril treatment. Thus, PECs may be important in 
the process of fibrosis via the production of CTGF. Recent studies have indeed shown that 




vitro. In addition, studies have proposed that CTGF expressing proliferating PECs participate 
in glomerular scarring in human and experimental crescentic glomerulonephritis 14;18. 
Admittedly, it remains to be elucidated whether the increased CTGF production observed in 
the present study induces PEC proliferation, migration and/or ECM production, and if the 
effect of captopril on CTGF expression is mediated via the depletion of ANGII.  
As discussed previously, our mouse model of FSGS resembles human primary FSGS 5. 
The early phase is characterized by collapse and proliferation of epithelial cells and 
resembles collapsing FSGS, whereas the late phase is characterized by the development of 
segmental scars 5. Thus far, the salutary effects of ACEi and/or ANG II antagonism has been 
established mostly in experimental models of secondary FSGS, in which FSGS lesions develop 
secondary to glomerular hyperfiltration and/or increased glomerular pressure. The present 
study suggests that the efficacy of ACEi is not limited to secondary forms of FSGS. ACEi may 
even be beneficial in collapsing FSGS, the most severe form of primary FSGS.  
How to reconcile our findings with clinical data? Up till now, few studies in humans 
have evaluated ACEi in patients with primary FSGS. Some authors have suggested that ACEi 
may slow deterioration of renal function, however efficacy seems limited compared to the 
success of ACEi in secondary forms of FSGS 2. The unimpressive results of ACEi in human 
primary FSGS may be explained by the fact that ACEi are often administered long after onset 
of the disease. Many patients are diagnosed with FSGS long after the first symptoms. Renal 
biopsy seldom discloses active hypercellular lesions. Administration of ACEi in advanced 
disease may indeed be too late. In animal studies Yoshida et al showed that ACEi prevented 
progression of disease when glomeruli were in the early stages of sclerosis but were unable to 
halt progression in glomeruli with advanced sclerosis 19. Our finding, suggests that the 
efficacy of ACEi is strikingly high in early FSGS lesions with prominent proliferation. 
Treatment with captopril from day 0 till day 7 attenuated the proliferation of the epithelial 
cells and prevented the development of segmental scars at day 8 and 22. Since the FSGS 
lesions in our mouse model resemble those seen in human collapsing FSGS, we would predict 
ACEi to be beneficial in human collapsing FSGS. Indeed, several cohort studies have 
demonstrated significant benefits of ACEi, with a three to five fold longer renal survival, in 
HIV nephropathy, the best known example of the collapsing variant of FSGS in humans 20. 
In conclusion, captopril prevented the development of FSGS in a mouse model of FSGS 
that closely resembles human collapsing FSGS. A similar effect was not observed with ANGII 
independent antihypertensive treatment, pointing to a specific role of ANGII. Our data 
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Thy-1.1 transgenic (tg) mice are characterized by the ectopic expression of the Thy-
1.1 antigen on podocytes. Thy-1.1 transgenic mice spontaneously develop podocyte injury and 
associated proteinuria and eventually develop focal and segmental glomerulosclerosis (FSGS). 
Injection of a monoclonal antibody (mAb) directed against the Thy-1.1 protein in Thy-1.1 tg 
mice induces acute massive albuminuria that is followed by accelerated development of 
FSGS.  
Podocyte injury is associated with retraction of podocyte foot processes (foot process 
effacement; FPE). FPE is highly reversible. Loss of the podocyte plasticity, resulting in 
persistent FPE is associated with proteinuria and may predispose for development of FSGS. In 
the present study we examined whether Thy-1.1 tg mice are characterized by loss of 
podocyte plasticity. In addition we questioned whether binding of the anti-Thy-1.1 mAb, in 
the absence of proteinuria, induces FPE.  
We assessed the dynamics of the podocyte actin cytoskeleton of wild-type and Thy-
1.1 tg mice using the protamine sulfate (PS) model of acute FPE. Impairment of podocyte 
plasticity would attenuate the reorganization of the actin skeleton induced by heparin, which 
neutralizes the PS. To examine the effects of anti-Thy-1.1 mAb binding we perfused the 
kidneys with saline prior to perfusion of the anti-Thy-1.1 mAb. Podocyte architecture was 
examined by electron microscopy. 
PS perfusion induced podocyte FPE. Subsequent reperfusion with heparin resulted in a 
full recovery of the podocyte foot process structures in both wild-type and tg mice. Perfusion 
with the anti-Thy-1.1 mAb antibody resulted in FPE. 
In conclusion, the development of proteinuria and FSGS in the Thy-1.1 mice cannot be 
explained by an impaired plasticity of the podocyte. FPE induced by the anti-Thy-1.1 mAb is 




Proteinuria is a hallmark of glomerular renal diseases and an important predictor of 
progressive renal failure1. Proteinuria is generally attributed to defects in the permselectivity 
of the filtration barrier. The discovery of several podocytic proteins and disease causing 
mutations have emphasized the importance of the podocyte for the maintenance of the 
filtration barrier 2. Podocytes are terminally differentiated, specialized epithelial cells that 
are anchored to, and cover the glomerular basement membrane (GBM). Podocytes have a 
characteristic architecture with interdigitating foot processes, which are bridged by several 
proteins (e.g. nephrin) that form the slit diaphragm. The slit diaphragm is believed to be a 
key structure of the filtration barrier.  
The integrity and the structure of the podocytes is affected in most glomerular 
diseases characterized by proteinuria, reflected by a uniform process of simplification and 
retraction of the podocyte foot processes, so-called foot process effacement (FPE). Although 
more than 40 years have past since the first description of these spectacular changes in the 
organization of the podocytic foot processes in nephrotic syndrome 3;4, the molecular 
mechanisms involved in FPE and the causative factors are largely unknown. FPE and 
proteinuria always co-exist in nephrotic syndrome. Nonetheless, a cause-effect relation 
between FPE and albuminuria remains to be proved. FPE is either a response to proteinuria or 
directly associated with podocyte injury.  
FPE is a dynamic process. This has been shown in studies demonstrating that 
protamine sulfate induced FPE is rapidly restored after infusion of heparin 5-7. Recent studies 
have shown that this podocyte plasticity is actually dependent on synaptopodin. Impaired 
podocyte plasticity, as observed in synaptopodin knock-out mice, predispose to increased and 
prolonged proteinuria after injection of LPS 8. 
We have used the Thy-1.1 transgenic mouse model to study the development of FSGS. 
Thy-1.1 transgenic mice spontaneously develop proteinuria within the first 8 to 10 weeks 
after birth and display FSGS lesion in approximately 20% of the glomeruli at 6 months after 
birth. Injection of anti-Thy-1.1 mAb accelerates this process and induces acute massive 
proteinuria with development of FSGS lesions within 7 days 9-11. The molecular mechanisms 
leading to the podocyte injury and subsequent FSGS are unknown. We hypothesized that the 
development of FSGS may be the consequence of altered podocyte function in the Thy-1.1 
transgenic mice, characterized by loss of podocyte plasticity of the podocyte. 
In the present study we questioned if Thy-1.1 mice have an impaired plasticity. In 











Heterozygous Thy-1.1 transgenic mice were kindly provided by Dr. D.J. Evans (T6, T-
construct mice 12). These mice were generated by injecting a hybrid human-mouse Thy-1.1 
gene into pronuclei of zygotes of Thy-1.2 CBA x C57BL/10 mice 12. These mice express the 
Thy-1.1 gene abnormally in podocytes, resulting in the presence of the Thy-1.1 antigen on the 
podocytes. All mice were bred in our animal facility. Breading pairs consisted of a 





For in vivo experiments a mouse anti-mouse Thy-1.1 mAb (19XE5: subclass IgG3) was 
used. 19XE5 was generated in vitro, by hollow fibre culture, purified by protein A column 
affinity chromatography and concentrated (Nematology Department, Agriculture University 
Wageningen, The Netherlands). The mAb was decomplemented at 56°C for 45 min and 





To study the placticity of the podocytes Thy-1.1 transgenic mice (n=3) and wild-type 
littermates (n=3) were anaesthetized with a mixture of isofluorane and oxygen. After 
anaesthetization, the abdomen was opened. A 19 mm 24 gauge NeoflonTM catheter (Becton 
Dickinson, Helsingborg, Sweden) was inserted in the aorta just above the aortic bifurcation. 
After removal of the inner needle the cannula was connected to an infusion system placed 1.2 
m above working level and an incision was made in the vena cava. Subsequently, both kidneys 
were perfused for 2 min with a buffered 0.9% NaCl solution (B.Braun, Melsungen, Germany) 
(saline). Successively, the kidneys were perfused for 15 min with protamine sulfate (PS) 
solution (2mg/ml PS in saline) (Sigma Aldrich, St. Louis MO, USA). PS perfusion was followed 
by a perfusion with saline for 2 min. The right kidney was clamped and removed for light and 
ultrastructural microscopy. The left kidney was perfused for 10 min with heparin (Sigma 
Aldrich, St. Louis MO, USA) (1mg/ml heparin in saline), rinsed for 2 min with saline and 
subsequently removed for microscopy. All solutions were pre-heated to 37°C.  
To establish whether the anti-Thy-1.1 mAb binding can induce FPE in the absence of 
albuminuria, kidneys of Thy-1.1 transgenic mice (n=3) were rinsed for 5 min with saline after 
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cannulation of the aorta, as described above. When the kidneys were completely blanched 
and free of blood the right kidney was clamped and the left kidney was perfused for 15 min 
with the anti-Thy-1.1 mAb (0.2mg/ml 19XE5 in saline), followed by a 2 min perfusion with 
saline alone. Subsequently both kidneys were removed for microscopic analysis.    
 
 
Immunofluorescence and Electron microscopy 
 
For immunofluorescence (IF) kidney fragments were snap-frozen in liquid nitrogen, 
and 2 µm acetone fixed cryostat sections were used. The binding of the anti-Thy-1.1 mAb was 
studied using a goat anti-mouse IgG3-FITC (Nordic, Tilburg, The Netherlands). The slides were 
examined with a confocal microscope (Leica lasertechnik GmbH, Heidelberg, Germany). 
For electron microscopy small fragments of the kidney were fixed in 2.5% 
glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer, pH 7.4 overnight at 4°C and 
washed in the same buffer. The tissue fragments were postfixed in cacodylate-buffered 1% 
OsO4 for 2 hrs, dehydrated, and embedded in Epon812 (Merck, Darmstadt, Germany). 
Ultrathin sections were used and contrasted with 4% uranyl acetate for 45 min and 
subsequently with lead citrate for 4 min at room temperature. Sections were examined in a 








Perfusion of both the wild-type and transgenic mice with PS for 15 min resulted in 
marked effacement of the podocyte foot processes as can be appreciated from Figure 1A and 
1C. Subsequent reperfusion of the kidneys with the heparin solution resulted in full recovery 







































Figure 1. Transmission electron microscopy images of kidneys subjected to protamine sulfate (PS) and to PS followed by
heparin (PSH). (A,C) In both the wild-type and transgenic Thy-1.1 mice almost complete foot process effacement was
observed in de PS kidneys. (B, D) Subsequent heparin perfusion resulted in an almost complete recovery of the foot
process structures. The recovery was comparable between the wild-type and transgenic mice, arguing against an
impaired plasticity due to ectopic expression of Thy-1.1. 
(E) High magnification electron micrograph illustrating the recovery of the foot process integrity after heparin perfusion.
The protamine sulfate is neutralized by the formation of protamine sulfate heparin complexes seen as dense granules
(arrowhead). This neutralization results in the reappearance of the typical foot process architecture and slit diaphragms
(arrow). 
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Anti-Thy-1.1 mAb mediated foot process effacement 
 
The control kidney, which was perfused for 5 min with saline and clamped for the 
duration of the experiment showed no sign of podocyte injury or ischemia (normal sized 
mitochondria and no vacuolization of the tubular and glomerular epithelial cells). The Thy-1.1 
mAb perfused kidneys showed partial FPE (Figure 2, A and B). 
Immunofluorescence showed that the perfused anti-Thy-1.1 mAb bound in a 
homogenous pattern to apical and basolateral cell membranes of the podocytes. There was no 






Figure 2. Transmission electron microscopy images of kidneys blanched by saline perfusion followed by anti-Thy-1.1 
perfusion. (A) In the saline treated kidneys anti-Thy-1.1 perfusion induces partial foot process effacement. (B) The 
clamped kidney, which did not receive anti-Thy-1.1 mAb showed normal foot process morphology. (C)
Immunofluorescence staining of the perfused anti-Thy-1.1 mAb results in a homogenous staining of the podocytes. (D)





The Thy-1.1 transgenic mouse is a model of FSGS. These mice spontaneously develop 
proteinuria and FSGS. Injection of a monoclonal antibody directed against the Thy-1.1 antigen 
acutely increases proteinuria and causes accelerated FSGS. The mechanisms of proteinuria 
and FSGS remain unknown.  
In this study we demonstrate that podocyte plasticity is normal in Thy-1.1 transgenic 
mice. In addition, we showed that binding of the anti-Thy-1.1 mAb induces foot process 
effacement in the absence of proteinuria.  
A recent study suggested that a decreased plasticity of the podocytes may be involved 
in increased and prolonged proteinuria 8. Podocyte plasticity was tested using the protamine 
heparin model. Perfusion of isolated rat kidneys with the polycationic compound PS was found 
to induce rapid (i.e. within 15 min) flattening of foot processes in an energy- and actin-
dependent fashion. Interestingly, subsequent perfusion with heparin resulted in a full 
recovery of the foot process structures, illustrating that FPE is highly reversible 5-7. Podocyte 
plasticity is impaired in the synaptopodin knock-out mice (synpo-/-). These mice lack 
expression of synaptopodin, an actin-associated protein of differentiated podocytes, where it 
is involved in the organization of the podocyte actin-cytoskeleton. Synpo-/- mice display 
normal podocyte morphology. However in the protamine sulfate model synpo-/- mice show no 
recovery of FPE after heparin infusion. Injection of LPS in the synpo-/- mice causes increased 
and prolonged proteinuria 8. We have studied podocyte plasticity in Thy-1.1 tg mice using the 
protamine sulfate model. We did not observe any impairment of podocyte plasticity, thus 
excluding that such mechanism may be involved in the development of proteinuria and FSGS 
in our mouse model. 
Severe proteinuria is almost invariably associated with podocyte FPE. It is unknown if 
proteinuria is the cause or consequence of FPE. Exposure of podocytes to high amount of 
protein causes FPE 13. We show that injection of the anti-Thy-1.1 antibody causes FPE in the 
absence of proteinuria. 
 What could be the mechanism of this antibody mediated FPE? In previous studies we 
did not find evidence for interference with the GBM negative charge or podocyte GBM 
interaction 10. We have also been unable to demonstrate changes in the expression pattern of 
α3 integrin, a molecule involved in podocyte-GBM adhesion 14. Hence, other possibilities 
remain such as regulation of the cytoskeleton 15, interference with the negative charge of 
podocytes or the function of the slit diaphragm 6;16-18. 
In conclusion, the development of proteinuria and FSGS in the Thy-1.1 mice cannot be 
explained by an impaired plasticity of the podocyte. FPE induced by anti-Thy-1.1 mAb binding 
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In this thesis the Thy-1.1 transgenic mouse model was used for the identification of 
mechanisms involved in the development of acute albuminuria and accelerated FSGS upon 
injection of monoclonal anti-Thy-1.1 antibodies. In Chapter 2 we describe the phenotype of 
this relatively new model for nephropathological research with emphasis on the time course 
of proteinuria, the dose-dependency of FSGS, and the pathogenesis of the acute proteinuria. 
We showed that a single injection of anti-Thy-1.1 antibody induced an acute proteinuria 
(within 10 min) followed by rapid development of FSGS within 3 weeks. There was no 
correlation between the dose of the anti-Thy-1.1 mAb and the magnitude of the initial 
albuminuria at day 1. In contrast, the persistence of proteinuria, calculated as the time-
averaged albuminuria over 3 weeks, was dose dependent. In addition, only the time-averaged 
albuminuria showed a significant correlation with the development of FSGS. These data 
suggest that the persistence of albuminuria reflects the severity of podocyte injury induced 
by the anti-Thy-1.1 antibody. Furthermore, it is suggested that the extent of FSGS is 
dependent on the extent of podocyte injury. Nevertheless, the data leave open the possibility 
that albuminuria itself is harmful for the podocyte and contributes to FSGS development. The 
acute albuminuria and the associated foot process effacement could not be related to 
alterations in the expression pattern of cytoskeleton and slit diaphragm associated proteins, 
the GBM adhesion molecule α3-integrin or heparan sulfate in the GBM. The protein expression 
and localization of the examined proteins was assessed by immunofluorescence. Using this 
technique we cannot exclude that structural changes within these proteins might have 
occurred. The immediate onset of albuminuria after anti-Thy-1.1 mAb injection, argues in 
favor of pivotal structural alterations of proteins due to post translational modifications, 
since changes due to gene regulation including the molecular processes of transcription, 
translation of the transcripts and targeting of the newly made proteins, are believed to 
require more time.  
To be able to study differential expression of glomerular proteins important in the 
processes of proteinuria and development of FSGS, we optimized the application of 2D 
electrophoresis (2DE) as described in Chapter 3. 2DE has been the main technique used in 
most proteomic studies where different samples are compared with respect to the relative 
quantities of the different proteins and/or post translational modifications. Additionally, by 
using 2DE one is able to examine a large number of proteins isolated from a particular tissue 
sample in a single analysis. We optimized the isolation of glomeruli and the sample 
preparation to develop reproducible glomerular protein profiles. To test the application of 
2DE we compared protein profiles of saline injected Thy-1.1 tg mice and profiles of Thy-1.1 tg 
mice at day 6 after anti-Thy-1.1 mAb injection. 2DE resulted in reproducible glomerular 
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profiles consisting of approximately 600 protein spots of which 47 spots could be identified. 
All identified proteins were abundantly expressed “house keeping” proteins, which are 
generally believed to have a relatively invariable expression pattern under normal and 
pathological conditions. We were unable to increase the sensitivity of the technique to allow 
detection of proteins that are less abundantly expressed. We feel that if proteome analysis is 
to provide truly meaningful information about regulatory processes, it must also be able to 
detect and to identify regulatory proteins (e.g. growth factors) that are typically present in 
low quantities. Therefore, we concluded that the technology that we have used cannot 
detect and identify decisive molecular processes that are involved in the pathogenesis of 
proteinuria and FSGS. We next focussed on histological studies of the development of FSGS as 
described in Chapter 4. We particularly evaluated the specific roles of podocytes and PECs. 
We showed that the scar lesions, which are typically observed in the Thy-1.1 model at 3 
weeks after antibody injection, were preceded by cellular FSGS lesions that resemble human 
collapsing FSGS. Characterization of the cellular components of these lesions, by 
immunostaining with specific markers, revealed that the lesions consisted primarily of 
proliferating PECs. Evaluation of the composition of the deposited extracellular matrix 
demonstrated that the composition resembled that of Bowman’s capsule and therefore was 
produced by the PECs. We concluded that PECs play an important role in the development 
and progression of FSGS in the Thy-1.1 transgenic mouse.  
Obviously, these observations in the mouse model prompted the question if PECs are 
also involved in human FSGS. Thusfar, most studies in patients with collapsing FSGS have 
attributed the epithelial hyperplasia to dysregulation of podocytes and ensuing proliferation. 
Therefore, we studied the cellular origin of the proliferating epithelial cells in human FSGS. 
We have analyzed a nephrectomy specimen of a patient with recurrent FSGS after 
transplantation and biopsies of patients with collapsing FSGS associated with HIV and 
pamidronate toxicity. Our findings are summarized and discussed in Chapter 5. Phenotypic 
characterization of the proliferating epithelial cells in these human renal tissues showed that 
the proliferating epithelial cells in Bowman’s space stained positively for all PEC markers and 
did not express podocyte markers and deposited ECM that stained as Bowman’s capsule. From 
these studies we concluded that the proliferating cells in Bowman’s space in human 
idiopathic FSGS and HIV associated collapsing FSGS must be derived from the parietal 
epithelium. Since the proliferating PECs produce and deposit the newly formed extracellular 
matrix that leads to scarring, it can be concluded that PECs play an important role in the 
progression of human FSGS.  
The early FSGS lesions in the Thy-1.1 transgenic mice bear much resemblance to FSGS 
lesions in human collapsing FSGS. Hence, this mouse model may be relevant to evaluate 




ACE inhibitors and/or AT1 receptor antagonists are considered standard treatment for 
patients with proteinuric renal diseases. The agents are effective in reducing the progression 
rate of renal failure.  It has been suggested that the renoprotective effects of drugs that 
interfere with the renin angiotensin system cannot merely be attributed to the lowering of 
blood pressure or the reduction of hyperfiltration. The beneficial effects of ACE inhibitors and 
AT1 receptor antagonists may depend on the reduction of angiotensin II mediated fibrosis and 
cell proliferation. The role of ACE inhibition or AT1 receptor blockade in human collapsing 
FSGS is unknown. Therefore, we studied if the ACE inhibitor captopril could prevent the 
development of FSGS in the Thy-1.1 transgenic mouse. Additionally, we questioned whether 
protection was related to the timing of drug administration, and evaluated the role of PECs 
and podocytes by analyzing their phenotype. The data presented in Chapter 6 clearly 
indicated that captopril reduced albuminuria and almost completely prevented the 
development of FSGS in our anti-Thy-1.1 mouse model, even when started 3 days after the 
initial podocyte insult. In addition, captopril reduced CTGF expression by PECs and prevented 
PEC proliferation. Evidently, captopril was more effective than ANGII independent anti-
hypertensive therapy, pointing to a specific role of ANGII. Our data thus add more evidence 
to the observations in animal models and humans that the beneficial effects of ACEi cannot 
be explained merely by a decrease in systemic blood pressure. Moreover, our study suggests 
that the efficacy of ACEi is not limited to secondary forms of FSGS. ACEi may even be 
beneficial in collapsing FSGS. Based on our observations we assume that the beneficial effects 
of ACEi are related to the ability of ACEi to block PEC activation and proliferation. It remains 
to be established how ACEi prevents PEC proliferation, either indirectly by reducing 
proteinuria and maintaining podocyte integrity, or directly by blocking ANGII mediated 
cellular proliferation. 
We tested podocyte plasticity in Thy-1.1 transgenic mice (Chapter 7). Loss of 
podocyte plasticity may attenuate the recovery of the podocyte after injury. Podocyte 
plasticity was tested using the protamine sulfate model, in which FPE is induced by protamine 
sulfate. Subsequent heparin perfusion neutralizes the polycation allowing podocytes to 
recover. We observed normal recovery of podocytes of Thy-1.1 transgenic mice and thus 
concluded that podocyte plasticity is not impaired in Thy-1.1 transgenic mice.  
We have used perfusion experiments to determine if FPE, observed in our mouse 
model, depends on proteinuria. We could demonstrate that injection of the anti-Thy-1.1 
antibody caused FPE in the absence of proteinuria. Thus these experiments prove that FPE is 
not merely a response to or a consequence of proteinuria. These data are in agreement with 
the results of other experiments where we observed a discrepancy between the onset of FPE 
and albuminuria. Thus, both foot process effacement and albuminuria may be consequences 






Proteïnurie is een van de eerste kenmerken van beschadiging van de filtratiebarriëre 
van de glomerulus. Bij aanhoudende beschadiging van de glomerulus ontstaat focale 
segmentale glomerulosclerose (FSGS). FSGS is geen ziekte-entiteit maar een glomerulair 
beschadigingpatroon dat wordt gekenmerkt door podocyt schade met verlies van de 
podocytvoetjes, toename van extracellulaire matrix (sclerose), vorming van adhesies tussen 
de glomerulaire capillaire lissen en het kapsel van Bowman, en ophoping van schuimcellen en 
afzetting van hyaliene materiaal in de capillairen. FSGS gaat gepaard met progressief 
nierfunctieverlies en/of een nefrotisch syndroom. Het beloop is variabel en een aanzienlijk 
deel van de patiënten met FSGS zal uiteindelijk een terminale nierinsufficiëntie ontwikkelen. 
FSGS kan onderverdeeld worden in primaire FSGS en secundaire FSGS. Bij primaire 
(idiopathische) FSGS is de oorzaak niet bekend. Bij secundaire FSGS is de oorzaak bekend, 
zoals bv. hypertensie, tubulo-interstitiële nefritis, obesitas, HIV infectie, mutaties in 
podocytaire eiwitten.  
De pathogenese van FSGS is in vele studies onderzocht. Lange tijd is gedacht dat FSGS 
het gevolg was van beschadiging of activatie van de mesangiumcel. FSGS zou dan het gevolg 
zijn van activatie of proliferatie van de mesangiumcel met toegenomen productie van 
mesangiale matrix. De laatste jaren staat de podocyt in het centrum van de belangstelling. 
De podocyt, en dan met name het “slit-diafragma” tussen de podocytvoetjes, speelt een 
belangrijke rol bij het handhaven van de permselectiviteit van de filtratiebarriëre. 
Beschadigingen van het slit-diafragma leiden tot proteïnurie. Het besef dat proteïnurie met 
name het gevolg is van podocyt disfunctie kwam voort uit de ontdekking dat aan het 
congenitale nefrotische syndroom van het Finse type een mutatie in het slit-pore eiwit 
nefrine ten grondslag ligt. Later is gebleken dat mutaties in eiwitten die voor het normaal 
functioneren van podocyten van belang zijn (podocine, α-actinine 4, CD2AP, mitochondriële 
eiwitten), aanleiding kunnen geven tot familiaire FSGS, hetgeen bewijst dat podocyt 
disfunctie de eerste stap kan zijn in de ontwikkeling van FSGS. Echter de mechanismen 
betrokken bij de ontwikkeling FSGS lesies zijn nog niet opgehelderd.  
In dit proefschrift gebruiken we de Thy-1.1 transgene muis als een model voor met 
podocyt beschadiging geassocieerde proteinuria. Wij gebruiken dit model voor onderzoek naar 
de pathogenese van proteïnurie en FSGS. 
De Thy-1.1 transgene muis wordt gekenmerkt door expressie van het Thy-1.1 antigeen 
op de podocyt. Injectie van antilichamen tegen het Thy-1.1 antigeen leidt tot acute 
proteïnurie en ontwikkeling van FSGS. In hoofdstuk 2 is het fenotype van het muismodel 
beschreven waarin we de nadruk hebben gelegd op dosis-respons relatie tussen het 




relatie tussen proteïnurie en FSGS en de mogelijke pathogenese van de acute proteïnurie 
bestudeerd. Injectie van het anti-Thy-1.1 antilichaam induceerde een acute proteïnurie 
(binnen 10 min) welk piekte rond dag 1 en gevolgd werd door de ontwikkeling van FSGS 
binnen 3 weken. We hebben geen relatie gevonden tussen de dosis van het antilichaam en de 
mate van proteïnurie op dag 1. Ook de ontwikkeling van FSGS correleerde niet met de 
proteïnurie op dag 1. De mate van persisteren van de proteïnurie was wel gerelateerd aan de 
hoeveelheid ingespoten antilichaam. Een lage dosis resulteerde in een kortdurende transiënte 
proteïnurie terwijl bij hogere doseringen de proteïnurie bleef bestaan. Daarnaast vonden we 
een significante correlatie tussen de mate van FSGS (FSGS score) en de gemiddelde 
proteïnurie in de studie periode. Deze bevindingen suggereren dat de gemiddelde proteïnurie 
over een bepaalde periode goed de mate van podocytschade reflecteert en dat de FSGS score 
afhankelijk is van de mate van podocyt schade. Echter een directe rol voor de proteïnurie in 
de vorming van de FSGS lesies kunnen we op basis van deze bevindingen niet uitsluiten.  
De ontwikkeling van de proteïnurie ging gepaard met partieel verlies van de podocyt 
voet structuren en vernauwing van de zgn “slit pores” tussen de overgebleven 
podocytvoetjes. Deze ultrastructurele verandering van de podocyt konden niet gerelateerd 
worden aan veranderingen in het expressiepatroon van cytoskelet- en slitdiafragma- 
geassocieerde eiwitten, het GBM adhesiemolecuul α3 integrine, en van heparansulfaten in het 
GBM. Ondanks dat het expressiepatroon van deze eiwitten onveranderd was gebleven kunnen 
we structurele veranderingen van deze eiwitten als gevolg van post translationele 
modificaties niet uitsluiten. Omdat proteïnurie direct optreedt (<10 min), zijn de 
veranderingen in podocyt functie waarschijnlijk een gevolg van eiwit modificaties onder 
invloed van een snelle signaaltransductie. Veranderingen in gen regulatie met transcriptie, 
translatie van het transcript en “targeting” van de gevormde eiwitten zijn onwaarschijnlijk.  
Om de veranderingen in het expressiepatroon en de structuur van eiwitten, betrokken 
bij de pathogenese van proteïnurie en FSGS, te kunnen bestuderen hebben we de toepassing 
van 2D gel-electroforese (2DE) in ons onderzoek onderzocht. 2DE is een techniek waarbij 
eiwitten gescheiden worden op basis van hun iso-electrisch punt en molecuulgewicht. Met 
behulp van 2DE is het mogelijk om in één analyse een groot aantal eiwitten kwantitatief en 
kwalitatief te bestuderen. In hoofdstuk 3 beschrijven we de optimalisatie en evaluatie van 
deze techniek voor de identificatie van eiwitten betrokken bij de pathogenese van 
proteïnurie en FSGS. Door optimalisatie van de monsterbereiding waren we in staat 
reproduceerbare profielen van glomerulaire eiwitten te produceren. Om de toepassing van 
2DE voor onze onderzoeksvraagstelling te evalueren hebben we glomerulaire eiwitprofielen 
van “gezonde” muizen vergeleken met profielen van muizen met vroege FSGS lesies. De 
verkregen eiwitprofielen bestonden uit ongeveer 600 “spots”. In totaal hebben we 47 “spots” 
kunnen identificeren met behulp van matrix-assisted laser desorption ionization-time of flight 
(MALDI-TOFF) massa spectrometrie. Bijna alle geïdentificeerde “spots” betroffen eiwitten die 
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betrokken zijn bij het celmetabolisme of bij het cytoskelet. Van dergelijke eiwitten wordt 
over het algemeen gedacht dat ze een hoge en relatief stabiele expressie hebben. We hebben 
geen eiwitten kunnen identificeren die laag tot expressie komen en/of eiwitten die volgens 
de literatuur een rol in de ontwikkeling van FSGS hebben (bijv. groeifactoren / cytokines). Op 
basis van deze bevindingen hebben wij geconcludeerd dat de techniek zoals die door ons 
geoptimaliseerd en gebruikt is, niet toepasbaar is voor de identificatie van moleculaire 
processen die een fundamentele rol spelen in de pathogenese van proteïnurie en FSGS.  
Vervolgens hebben we ons geconcentreerd op histopathologische studies naar de 
pathogenese van FSGS zoals beschreven in hoofdstuk 4. In deze studie onderzochte we met 
name de rol van respectievelijk de podocyt en pariëtale epitheelcel (PEC). We hebben 
aangetoond dat de relatief “inactieve” hypocellulaire FSGS lesies die worden waargenomen in 
week 3 na het inspuiten van het anti-Thy-1.1 antilichaam ontwikkelen uit “actieve” cellulaire 
FSGS lesies. Deze vroege lesies in de Thy-1.1 transgene muis komen morfologische sterk 
overeen met de cellulaire lesies die voorkomen bij patiënten met “collapsing FSGS”. Door 
middel van immunokleuringen voor specifieke markers hebben we aangetoond dat de 
prolifererende cellen in de cellulaire FSGS lesie voornamelijk PECs zijn. Daarnaast hebben we 
laten zien dat de compositie van de nieuw gevormde extracellulaire matrix (ECM) 
overeenkomt met die van het kapsel van Bowman, waaruit we geconcludeerd hebben dat 
deze ECM geproduceerd wordt door PECs. Deze bevindingen suggereren een belangrijke rol 
voor PECs in de ontwikkeling en progressie van FSGS in de Thy-1.1 transgene muis.  
Vanzelfsprekend rijst de vraag of de PEC ook een rol speelt in FSGS bij de mens. Tot 
op heden wordt aangenomen dat de cellulaire lesies bij patiënten met collapsing FSGS het 
gevolg zijn van disregulatie en proliferatie van de podocyt. Om een eventuele rol voor PECs 
te bestuderen in humane FSGS hebben we de herkomst van de prolifererende epitheelcellen 
onderzocht. Hiervoor hebben we een nefrectomie preparaat van een patiënt met een recidief 
FSGS na transplantatie en biopten van patiënten met HIV- en pamidronaat toxiciteit- 
geassocieerde collapsing FSGS onderzocht. De resultaten hiervan worden samengevat en 
bediscussieerd in hoofdstuk 5. Fenotypische analyse van de prolifererende epitheelcellen in 
deze humane nierweefsels heeft aangetoond dat deze epitheelcellen in de ruimte van 
Bowman positief kleurden voor alle PEC markers en geen podocyt markers tot expressie 
brachten. Daarnaast was de compositie van de nieuw gevormde ECM gelijk aan die van het 
kapsel van Bowman. Op basis van deze bevindingen hebben we geconcludeerd dat de 
prolifererende cellen in de ruimte van Bowman in idiopatische en HIV-geassocieerde 
collapsing FSGS afkomstig zijn van het pariëtaal epitheel. Ook bij de mens spelt de PEC dus 
een belangrijke rol bij de ontwikkeling en progressie van FSGS. 
Zoals eerder beschreven komen de vroege FSGS lesies in de Thy-1.1 transgene muis 




verkregen met behulp van dit model, omtrent bijvoorbeeld behandelingsmethoden van dit 
soort lesies, relevant zijn voor patiënten met collapsing FSGS.  
Behandeling van proteïnurie en de bloeddruk kan bij patiënten progressieve 
nierschade voorkomen. ACE remmers en/of AT1 receptor antagonisten zijn hiervoor het 
meest effectief en worden standaard gebruikt bij de behandeling van patiënten met 
proteïnurie. Het beschermende effect van deze medicijnen, welke interfereren in het renine 
angiotensine systeem, kan niet volledig toegeschreven worden aan de verlaging van de 
bloeddruk en vermindering van de hyperfiltratie. Andere mogelijke factoren zijn 
vermindering van de angiotensine II (ANGII) gemedieerde fibrose en celpoliferatie.  
De effecten van ACE inhibitie en/of AT1 receptor blokkers zijn tot dusver 
onvoldoende onderzocht bij patiënten met collapsing FSGS. Daarom hebben we onderzocht of 
de ACE remmer captopril de ontwikkeling van FSGS lesies in de Thy-1.1 transgene muis kan 
voorkomen. Daarnaast hebben we bestudeerd of het beschermend effect gerelateerd is aan 
het moment en de duur van de behandeling. De resultaten van deze studie, zoals beschreven 
in hoofdstuk 6, hebben duidelijk laten zien dat captopril behandeling de proteïnurie 
verminderd en de ontwikkeling van FSGS bijna geheel voorkomt. Daarnaast verminderde 
captopril de expressie van connective tissue growth factor (CTGF) door PECs en de mate van 
PEC proliferatie. Het feit dat captopril effectiever was dan een combinatie van drie ANGII 
onafhankelijke bloeddrukverlagende middelen (“triple therapie”), wijst op een specifieke rol 
voor ANGII in de ontwikkeling van FSGS in de Thy-1.1 transgene muis. Onze bevindingen geven 
nog eens aan dat het beschermende effect van ACE remming niet volledig verklaard kan 
worden door een verlaging van de systemische bloeddruk en dat de beschermende effecten 
van ACE inhibitie, zoals beschreven voor secundaire vormen van FSGS, ook een rol kunnen 
spelen bij collapsing FSGS. 
Wij veronderstellen dat het beschermend effect van ACE-remming berust op 
vermindering van PEC activatie en proliferatie door verlaging van ANGII spiegels. Er moet nog 
aangetoond worden hoe ACE remming PEC activatie en proliferatie vermindert. Dit kan een 
indirect effect zijn als gevolg van een verminderde proteïnurie en podocyt schade, óf een 
direct effect door remming van ANGII gemedieerde celproliferatie. 
Podocyten zijn zeer dynamisch en kunnen herstellen van een beschadiging.  Dit is 
aangetoond in experimentele studies met behulp van het protamine sulfaat model. Perfusie 
van de nier met protamine sulfaat induceert podocyt schade met als gevolg verlies van de 
podocytvoetjes (foot process effacement, FPE). Een hierop volgende perfusie met heparine 
neutraliseert het protamine sulfaat waardoor de podocyt kan herstellen. Wanneer de 
plasticiteit van de podocyt is verminderd kan dit leiden tot een vertraagd of niet volledig 
herstel van de podocyt wat resulteert in een aanhoudende proteïnurie en mogelijk FSGS. We 
hebben de plasticiteit van de podocyten in de Thy-1.1 transgene muis onderzocht (hoofdstuk 
7). We hebben aangetoond dat in de Thy-1.1 transgene muis het herstel van de podocyten na 
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perfusie met heparine normaal is en hebben hieruit geconcludeerd dat de podocytplasticiteit 
niet verminderd is. 
Daarnaast hebben we perfusie experimenten uitgevoerd om te bepalen of de FPE, 
geïnduceerd door het anti-Thy-1.1 antilichaam, afhankelijk is van proteïnurie. Voor dit 
doeleinde hebben we niertjes, kort met fysiologisch zout gespoeld en vervolgens 
geperfundeerd met het anti-Thy-1.1 antilichaam in fysiologisch zout. We hebben aangetoond 
dat FPE als gevolg van binding van het antilichaam aan de podocyt onafhankelijk is van 
proteïnurie. Deze bevindingen zijn in overeenstemming met de resultaten van andere 
experimenten waarin we een loskoppeling hebben waargenomen tussen initiële FPE en 
proteïnurie. Dus FPE en proteïnurie hoeven niet causaal gerelateerd te zijn maar zijn 
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ruim 7 jaar geleden mijn werknemersbestaan begon als analist op de afdeling celbiologie, had 
ik misschien wel de stille wens, maar nooit verwacht dat ik zou gaan promoveren. Dit was dan 
ook nooit gebeurd zonder de steun en hulp van collega’s, familie en vrienden. Ik wil daarom 
ook iedereen bedanken voor zijn of haar betrokkenheid. Het is ondoenlijk op deze plaats 
iedereen persoonlijk te bedanken, maar een aantal mensen wil ik toch in het bijzonder 
vermelden. 
Allereerst ben ik veel dank verschuldigd aan mijn promotor, prof. dr. Jack Wetzels. 
Beste Jack, veel dank voor jouw begeleiding. Jouw gedrevenheid en passie voor je werk, 
zowel in de kliniek als in het nefro(patho)logisch onderzoek, zijn een enorme inspiratie voor 
mij en hebben ten grondslag gelegen aan de behaalde resultaten, o.a. beschreven in dit 
proefschrift. 
Daarnaast wil ik mijn co-promotor, dr. Eric Steenbergen bedanken. Eric, bedankt voor 
de vele discussies tijdens de microscopie sessies of tijdens de diners in Amerika. Jouw 
kritische analyses van de door mij geschreven teksten heb ik altijd zeer gewaardeerd. 
 Het leeuwendeel van het werk in dit proefschrift is afkomstig uit de vakkundige 
handen van Nathalie en Mark, de paranimfen. Nathalie, terugbladerend in je labjournaals valt 
op hoeveel verschillende vraagstukken en hypotheses wij getest hebben. Je hebt enorm veel 
werk verricht. Je nuchtere houding en je gezelligheid zorgden ervoor dat al dat werk en de 
tijd voorbij vlogen. Mark, jouw enorme hoeveelheid energie (zelfs vóór het eerste kopje 
koffie) was bewonderenswaardig. Verder heeft je neiging tot structuur en orde ertoe geleid 
dat met de tijd zelfs in mijn administratie voorzichtig wat structuur kwam (ik gebruik nog 
altijd je databases). Ik denk met plezier terug aan de samenwerking met jullie en vind het 
geweldig dat jullie mijn paranimfen willen zijn.  
De collega’s van de nefropathologiegroep, Fieke, Kiek en Henry. Fieke, je bent op het 
vervolg project van het promotieonderzoek komen werken. Maar dankzij jouw bekwaamheid 
heb ik zaken, zoals het reilen en zeilen van de werkzaamheden op het dierenlab, begeleiding 
van stagiaires, en experimenten volledig aan je over kunnen laten zodat ik o.a. dit 
proefschrift heb kunnen schrijven. Kiek, zeer recentelijk heb jij onze groep weer verlaten 
maar ik ben ook jou veel dank verschuldigd voor de gezelligheid en het werk dat je verricht 
hebt. Henry, wij kennen elkaar van het begin van mijn promotieonderzoek maar de 
samenwerking werd een stuk intensiever toen we in dezelfde schoenen kwamen te staan. 
Deze samenwerking heeft veel vruchten afgeworpen en mooi werk opgeleverd en ik hoop dat 
wij dat in de toekomst kunnen voortzetten.  
De (ex)collega’s van de afdeling pathologie, allemaal bedankt voor de plezierige 
werksfeer die op de afdeling pathologie heerst. Patricia, het was dankzij jou dat ik als OIO 
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kon beginnen waarmee de eerder beschreven stille wens in vervulling ging. Ik wil je bedanken 
voor het vertrouwen en voor de begeleiding in de eerste periode van het promotieonderzoek. 
Micha, we ronden tegelijk ons promotieonderzoek af. Ik heb veel steun gevonden in ons 
gezamenlijke leed van de zogenaamde. “laatste loodjes” wat jij als “hobby-pessimist” enorm 
hebt kunnen uitbuiten. Jack, de sfeer op de afdeling is de laatste jaren toch wat verandert. 
Komt het door de nieuwbouw? Of is het een gevolg van jouw vertrek? Velen zullen het met 
mij eens zijn dat met jouw vertrek de afdeling pathologie een groot gangmaker, en een zeer 
dierbare collega is kwijtgeraakt. Irene en Jacco, jullie ervaring en expertises op het lab 
waren zeer belangrijk voor mij. Mijn kamergenoten: Ruud, Margit, Max en Marieke en de 
overige leden van de barak. Bedankt voor de gezellige lunches, gesprekken, en café 
bezoekjes. Dit alles maakte de werkomstandigheden in de barak acceptabel. Margit, jammer 
dat je niet bij de promotie aanwezig kan zijn maar het feest halen we tijdens het carnaval 
wel in. De stagiaires, Mark, Roy, Nick en Hanie bedankt voor jullie inzet en het werk wat 
jullie verzet hebben. De collega’s van de histologie wil ik bedanken voor de snelle en hoog 
kwalitatieve verwerking van alle muizenweefsels.  
Daarnaast wil ik de collega’s van het dierenlaboratorium (CDL) bedanken voor de 
prettige samenwerking.  
Voor het onderzoek beschreven in dit proefschrift waren de samenwerkingen met de 
afdelingen nefrologie en biochemie onontbeerlijk. Hiervoor wil ik vooral bedanken dr. Johan 
van der Vlag, prof. dr. Jo Berden, dr. Toin van Kuppevelt, Angelique Rops en Joost Lensen. 
Verder wil ik dr. Jan Aten van de afdeling pathologie van het AMC Amsterdam bedanken voor 
de plezierige samenwerking op het gebied van CTGF. Ik hoop dat wij deze werkzaamheden in 
de toekomst kunnen continueren. 
Tenslotte wil ik mijn familie en schoonfamilie bedanken. Serge en Nicolle en Esther 
en Norbert bedankt voor de belangstelling en steun die ik van jullie heb gekregen. Serge veel 
succes met je onderzoek en ik hoop dat ik snel jouw proefschrift mag ontvangen. Frans en Jo, 
bedankt voor de nimmer aflatende steun en de goede zorgen voor Hugo! Arcen voelt als een 
tweede thuishaven. 
Lieve pap en mam, bedankt voor een zorgeloze jeugd waarin jullie mij hebben 
grootgebracht en het vertrouwen en de mogelijkheden die jullie mij hebben gegeven. Zonder 
dit warme thuisfront en deze solide basis was ik nooit zo ver gekomen. 
Lieve Tanja, al meer dan twaalf jaar geniet ik van jouw aanwezigheid. Je hebt mij 
altijd volledig gesteund in de keuzes die ik maakte, ook al betekende dat in het geval van het 
promotieonderzoek, wat minder tijd voor elkaar. Ons leven samen kent bijna alleen maar 
mooie momenten met als hoogtepunt de geboorte van Hugo. Ik hoop nog lang van jou en Hugo 
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Appendix: List of abbreviations 
 
2DE  2-dimensional electrophoresis 
3' UTR  3' untranslated region 
ACE  angiotensin converting enzyme 
ACEi  ACE inhibitor 
ANGII  angiotensin II 
APA  aminopeptidase A 
AT1  angiotensin II type 1 receptor  
BSA  bovine serum albumin 
CBB  colloidal coomassie brilliant blue 
CD2AP  CD2-associated protein 
CG  collapsing glomerulopathy 
CK8  cytokeratin 8 
CTGF  connective tissue growth factor 
DAB  diaminobenzidine 
DIG  digoxigenin 
DNA  deoxyribonucleic acid 
ECM  extracellular matrix 
EM  electron microscopy 
FGF-2  fibroblast growth factor 2 
FITC  fluorescein isothiocyanate 
FPE  foot process effacement 
FSGS  focal segmental glomerulosclerosis 
GBM  glomerular basement membrane 
GLEPP  glomerular epithelial protein 1 
GPI  glycophosphatidylinositol 
HIV  human immunodeficiency virus 
HIVAN  human immunodeficiency virus associated nephropathy 
ICAM  Intercellular adhesion molecule  
IEF  isoelectric focussing 
IEM  immunoelectron microscopy 
IF  immunofluorescence 
IHC  immunohistochemistry 
IL8  interleukin 8 
ISH  in situ hybridisation 
LC  liquid chromatography 
LPS  lipopolysaccharide  
mAb  monoclonal antibody 
MALDI-TOF matrix-assisted laser desorption/ionisation time-of-flight 
MBP  mean blood pressure 
MCP-1  monocyte chemoattractant protein-1 
MIP-1  macrophage inflammatory protein-1 
mRNA  messenger RNA 
MS  mass spectrometry 
NBT/BCIP  4-nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate
NOS  not otherwise specified  






PAF  platelet-activating factor  
PAI-1  plasminogen activator inhibitor-1 
PAX-2  paired box gene 2 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PDGF  platelet-derived growth factor  
PEC  parietal epithelial cell 
PLP  paraformaldehyde/lysine/periodate 
PS  protamine sulfate 
RNA  ribonucleic acid 
TFA  trifluoroacetic acid  
TGF-β  transforming growth factor beta 
TNF-α  tumor necrosis factor alpha 
UTP  uridine 5'-triphosphate  
VCAM  vascular cell adhesion molecule 1 
VEGF  vascular endothelial growth factor  
WT-1  Wilms tumor 1 

















Chapter 2: Figure 3. (A) Light microscopy of Thy-1.1 mice kidney sections at 10 min and 8hrs after mAb injection.
Deposits of proteins (asterisks) are already observed 10 min after mAb injection. (B) At 8hrs after mAb injection
massive deposits (dense casts) are observed. There is a high rate of protein resorption in proximal tubuli (arrow).








Chapter 2: Figure 4. (A) Indirect immunoelectron microscopy of a Thy-1.1 transgenic mouse kidney incubated with
the anti-Thy-1.1 mAb. Linear staining of the Thy-1.1 protein along the apical and basal cell membrane of the
podocyte (Insert) Closer view on the foot-processes. (P) podocyte cell body, (CL) capillary lumen, (US) urinary
space. Bar = 2µm.  (B) Immunofluorescence pictures of kidneys of Thy-1.1 transgenic mice injected with 1000 µg of
anti-Thy-1.1 mAb. Strong homogeneous binding of the injected anti-Thy-1.1 mAb to podocytes, already at 10 min





































Chapter 2: Figure 6. The immunologic localization of the slit diaphragm associated protein podocin in (A) saline
injected mouse and at 10 min, 1 hr, and 24 hrs after injection of the anti-Thy-1.1 mAb in Thy-1.1 transgenic mice
(B,C,D, respectively). The prominent homogeneous staining for podocin along the capillary wall (A, B) gradually




                 




Chapter 3: Figure 2. To visualize the reproducibility of the sample preparation two separate samples were
prepared from the same mouse kidneys. Two segments of the obtained silver-stained protein profiles were digitally
converted to green (sample 1) and red (sample 2) signals and merged (merge) (RGB signals were converted in
Adobe® Photoshop® 7.0). The two samples have an almost identical protein profile resulting in a yellow signal for

































Chapter 3: Figure 3. (A) For the detection of differentially expressed proteins in total six gel were compared (n=3
per sample). One of the differentially expressed protein spots (encircled) showed an elevated staining in the gels of
the glomerular lysate obtained from the anti-Thy-1.1 injected mice. This protein was identified as β-actin (Figure 4
and Tabel 1). 
(B) In situ hybridization analysis showed an elevated signal for β-actin mRNA in glomeruli of the anti-Thy-1.1
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Chapter 4: Figure 1. Histology of kidney sections of Thy-1.1 transgenic mice, at days 1, 3, 6, 7 and 21 after
anti-Thy-1.1 mAb injection, (A-E, respectively). (A) At day 1, light microscopy revealed vacuolization and
detachment of PECs (arrow). In proximal tubules many protein resorption droplets were observed (*). (B) At day
3, a pronounced hypertrophy of glomerular epithelial cells was observed (*). (C,D) At days 6 and 7, tuft
adhesions were observed (arrows). Glomeruli showed segmental collapse of capillaries and an increased
number of epithelial cells in Bowman’s space (*). (E) At day 21, glomeruli showed accumulation of ECM in
Bowman's space, with formation of segmental scars (arrow) Unaffected glomerulus (*). Methenamine silver
staining. Original magnification: X400. (F) Occasionally, mild hyalinosis (arrow) and a mitotic endocapillary cell
(arrowhead) was observed. PAS staining. Original magnification X400.  The percentage of glomeruli with FSGS














































Chapter 4: Figure 3. Podocyte phenotype.  
(A) IF for podocyte markers and an anti-heparan sulfate single chain antibody (HS4C3). Serial sections, from
control- and anti-Thy-1.1 mAb injected- mice (day 7). HS4C3 stains GBM and mesangium, showing a normal tuft
architecture in the control and a segmental lesion in thy-1.1 injected mice (day 7, *). In control mice, ASD33,
synaptopodin, and Thy-1.1 showed a homogeneous staining pattern along the GBM. There is a decrease in
expression of ASD33 and synaptopodin in areas with a segmental lesion. There is still high expression of the Thy-
1.1 antigen surrounding the collapsed segment (arrow). 
(B) IF for desmin and Thy-1.1. Section from an anti-Thy-1.1 mAb injected- mouse (day 7). Thy-1.1 shows a normal
podocyte staining in the unaffected glomerulus (arrowhead) but an irregular pattern in an affected glomerulus (*).


















Chapter 4: Figure 5: Phenotype of proliferating cells.  
(A) shows immunofluorescence in an anti-Thy-1.1 mAb injected mouse (day 7), for Thy-1.1 (green) and HS4E4, an
anti-heparan sulfate antibody (red). Nuclei are stained with TO-PRO-3 (blue staining). Shown is a FSGS lesion with
accumulation of cells in Bowman’s space (A, arrowhead). Thy-1.1 is present along the glomerular tuft, but there is
no staining for Thy-1.1 within the lesion. HS4E4 stains Bowman's capsule and tuft adhesions (A, arrow). (B) shows
immunofluorescence for collagen α2 (IV) (red) and Ki-67 (green). Collagen α2 (IV) is present in Bowman's capsule,
mesangium and tuft adhesions (B, arrow) Ki-67 positive cells are located adjacent to tuft adhesions. Magnifications:
X500 in A and X600 in B. Panels C and D shows immunohistochemistry for CD10. Immunoreactive cells stain
brown. In control mice CD10 is, within the glomerulus, strongly expressed on PECs (C). In a FSGS lesion (day 7)
epithelial cells in Bowman’s space strongly express CD10 (D). Original magnification: X400. 
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Chapter 4: Figure 6. Assessment of the composition of the ECM.  
Immunofluorescence for collagen IV α2 and α4 (green) and HS4E4 (red), in serial sections of a glomerulus with
adhesions (day 7). (A) Within the glomerulus, collagen α4 (IV) is expressed specifically in the GBM. (B) Collagen α2
(IV) is expressed in Bowman's capsule, mesangium and in the tuft adhesions. (C,D) HS4E4 stains Bowman's
capsule and the accumulations of ECM, which form the tuft adhesions (arrows). (E) There was no co-localisation of
collagen α4 (IV) and heparan sulfate identified by HS4E4. (F) Collagen α2 (IV) shows co-localisation with the
























Chapter 4: Figure 7. Hypothetical sequence of events leading to cellular FSGS lesions in the Thy1.1 tg mice,
illustrated in schematic drawings. (A) (day 1-7) Injury of the glomerular epithelial cells. Podocytes (green) show foot
process effacement and microvillous transformation (not illustrated). There is no podocyte detachment. PECs (blue)
show vacuolisation and detachment leading to “bare” segments of Bowman's capsule (Bowman's capsule is drawn
as a gray line). (B) (days 3-7) Podocytes become hypertrophic (with activated nuclei, resorption droplets and
pseudocysts) and form bridges between the glomerular tuft and Bowman's capsule. (C) (days 6 and 7) Proliferation
of PECs adjacent to the bridging podocytes, filling up Bowman's space, giving the appearance of a cellular FSGS































Chapter 5: Figure 1. Expression of WT–1 and CD10 in developing mouse glomeruli. 
WT-1 can already be detected in the earliest histologically definable glomerular stage of development, the comma-
shaped body (WT-1; asterisks). In the S-shaped body stage WT-1 staining can be observed in both the developing
podocytes (arrowhead) and PECs (arrow). In the capillary stage and in mature glomeruli PECs have lost WT-1
expression (arrows), whereas podocytes continue to express WT-1 (arrowheads). CD10 expression cannot be
detected in the comma-shaped and s-shaped body stage. CD10 expression commences in the capillary stage and

































Chapter 5: Figure 2. Phenotype of proliferating cells in experimental FSGS Thy-1.1 mouse model.  
In A and B a collapsing FSGS lesion with prominent epithelial proliferation is shown. Panel A shows staining for
Thy-1.1 (green) and anti heparan sulfate antibody HS4E4 (red). Nuclei are stained with TO-PRO-3 (blue staining).
Panel B shows staining for CD10. Accumulating cells in Bowman’s space are negative for Thy-1.1 (A, asterisks)
and stain strongly positive for CD10 (B, arrow). The newly deposited ECM by the cells in Bowman’s space (A,













Chapter 5: Figure 3. Phenotype of the epithelial cells in Bowman’s space in human FSGS.  
Panel A shows a series of consecutive sections of a glomerulus with collapsed capillaries, pronounced epithelial
hyperplasia and endocapillary foam cells. The sections are stained for synaptopodin, CK8 and PAX-2. The epithelial
cells in Bowman’s space are positive for CK8 and PAX-2, but negative for synaptopodin. In affected segments
synaptopodin is lost. 
Panel B shows immunofluorescence staining on sections of glomeruli with glomerular tuft adhesions (arrowheads).
The sections are stained for specific heparan sulfates species recognized by the single chain antibodies HS4C3 and
HS4E4. The glomerular tuft adhesions are negative for HS4C3, which stains the mesangial ECM and the GBM. In



















Chapter 5: Figure 4. Parietal epithelial cells (PECs) “invade” the glomerular tuft. 
Panel A shows five of the sections used for the 3-Dimensional reconstruction in panel B. CK8-positive cells,
whether positioned at the outer aspect of the tuft or more centrally in the glomerulus (arrowheads), are always in
continuity with the CK8-positive layer of PECs lining Bowman’s capsule (arrow).  
Panel B and C show three-dimensional reconstructions of two glomeruli illustrating that CK8-positive cells (red) are
in continuity with CK8-positive cells lining Bowman’s capsule (green). Note that not all PECs lining Bowman’s












Chapter 5: Figure 5. Phenotype of proliferating epithelial cells in HIV associated nephropathy. 
Panels A to F shows consecutive section of two glomeruli with collapse of the glomerular tuft and epithelial cell
hyperplasia (asterisks). Panel B shows CK8 immunostaining. CK8 positive cells cover segments of Bowman’s
capsule (arrow) and the capillary tuft in areas of epithelial cell hyperplasia (arrowheads). Panel C shows prominent
cell proliferation as confirmed by Ki-67 (D, arrow). These proliferating cells and the cell lining Bowman’s capsule


























Chapter 6: Figure 5. Desmin expression: In saline injected mice there is a faint staining for desmin within the
mesangium of the glomerulus (saline). Anti-Thy-1.1 mAb injected mice showed already at day 3 after the anti-Thy-
1.1 mAb injection an increased desmin staining within the glomerulus but also in peritubular capillaries (C day 3). At
day 8 there was a comparable desmin expression in the glomerular tuft. But in affected glomeruli there was also
desmin expression surrounding Bowman’s capsule (C day 8). Ca0>7 and Ca3>7 mice showed no decrease in
desmin expression compared to the non-treated anti-Thy-1.1 mAb injected mice (Ca0>7, Ca3>7) Original
magnification: 200x. To examine the podocyte specific desmin expression the desmin staining (red) was merged








































































Chapter 6: Figure 6. (A) Effect of captopril treatment on PEC proliferation. Only Ki-67 positive cells positioned in 
Bowman’s space (area depicted by dotted line) were counted. Original magnification: 400x. (B) The number of Ki-67 
positive cells in Bowman’s space was increased at day 6 after the anti-Thy-1.1 mAb injection. This increase was 
absent in the captopril treated mice. a: P < 0.01  v saline, b: P < 0.02  v C. 
Panels C - D shows immunohistochemistry for CD10. Immunoreactive cells stain brown. In control mice CD10 is
strongly expressed on PECs (C, arrowhead). In a hypercellular lesion (day 7) epithelial cells in Bowman’s space 






































































Chapter 6: Figure 7. (A-D) In situ hybridization (ISH) for CTGF mRNA. CTGF mRNA is expressed mainly by
podocytes in saline injected Thy-1.1 transgenic mice (A). At day 8 after anti-Thy-1.1 injection (C mice) an increase
in CTGF mRNA expression by PECs was observed in morphological normal glomeruli (B arrows). In FSGS lesions
we observed a high number of cells expressing CTGF. Note also a marked CTGF mRNA expression by
periglomerular cells surrounding the affected glomeruli (C). Captopril treatment reduced the number of CTGF
expressing PECs and CTGF mRNA expression was mainly observed for the podocytes (D) Original magnification:
400x.  
Panel E shows the CTGF mRNA score (a semi-quantitative assesment of the prevelance of positive PECs). All C
mice show an increased CTGF score. Captopril treatment significantly reduced the CTGF score P<0.005. There
was no difference in mean values of the CTGF scores for podocytes between the groups (P = 0.45). 
